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The differential emission of left- or right-handed circularly polarised light is termed circularly polarised 
luminescence (CPL).1,2 CPL emission has promising applications in a wide range of fields, such as the 
development of CPL microscopes.3,4 Commonly chiral lanthanide complexes are employed in CPL-
related studies, due to their high luminescence dissymmetry factors (glum).5–7 However these systems 
are limited by their typically low fluorescence quantum yields (φF), leading to low overall CPL 
efficiencies (|glum|·φF). Therefore there is considerable interest in the development of small organic 
molecules capable of CPL emission (CPL-SOMs). 
The 4,4′-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) dyes are a class of organic fluorophores 
which have desirable photophysical properties, including typically high fluorescence quantum yields. 
Furthermore BODIPYs have highly tuneable absorption and emission bands which can be modulated 
through varied and robust synthetic transformations. In this work, we have focused on the 
development of helically chiral BODIPY dyes for use as CPL-SOMs. 
Herein we describe the synthesis and chiroptical characterisation of a novel, helically chiral N,N,O,C-
BODIPY, which we have shown is capable of CPL emission upon irradiation in solution (glum = 3.7×10-3, 
figure A.1).8 Subsequent mechanistic investigation has allowed us to identify an improved synthetic 
route to the N,N,O,C-BODIPYs, and thus the expansion of the N,N,O,C-BODIPY series. Study of the 
chiroptical properties of the N,N,O,C-BODIPYs has revealed that this architecture is amenable to the 
addition of functional groups, without detriment to CPL-emission. This opens up the possibility of 
introducing more complex functionality to this architecture, whilst retaining the desired chiroptical 
activity. 
 
Figure A.1: Schematic representation of CPL emission from an N,N,O,C-BODIPY. 
Furthermore our investigations into the fundamental molecular properties of the N,N,O,C-BODIPY 
system has given us insight into design strategies towards development of BODIPY CPL-SOMs with 
increased glum. We describe our attempts towards the synthesis of helically chiral BODIPYs containing 
sulfur atoms, and the synthesis of a π-extended helically chiral N,N,O,O-BODIPY system. Through these 
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Chapter 1. Introduction 
This thesis describes investigations into the synthesis of novel, chiral fluorophores which are capable 
of circularly polarised light emission upon irradiation with visible light in solution. In particular this 
work was focused on the synthesis of chiral 4,4′-difluoro-4-bora-3a,4a-diaza-s-indacene (hereafter 
referred to as BODIPY) dyes. This chapter discusses some of the underlying theory behind 
luminescence (i.e. fluorescence, section 1.1.1), circularly polarised light and solution phase circularly 
polarised luminescence (section 1.1.2) and finally the synthesis and modification of BODIPY 
architectures, with a focus on the synthesis of chiral BODIPYs including those known to exhibit CPL 
(sections 1.2 and 1.3). 
1.1 Fluorescence and Circularly Polarised Light 
1.1.1 Fluorescence 
The photophysics of organic molecules is often visualised using a molecular energy level (or Jablonski) 
diagram (figure 1.1). Here the singlet excited states (S0, S1, etc.) and vibrational energy levels (v1, v2, 
etc.) are visually represented, as well as the changes in energy levels resulting from or in a photon 
(solid lines) and those resulting from changes in vibrational energy (wavy lines). In the absence of 
external stimuli, molecules exist in the S0 or ground state. Upon the absorption of a photon (1) the 
molecule transitions from the ground state to the singlet excited states. Then through vibrational 
relaxation and internal conversion (2) the molecule relaxes to the lowest energy level of the S1 excited 
state. From here, there are two main pathways which can be taken: internal conversion (2), whereby 
the molecule undergoes non-radiative relaxation to return to the ground state, and fluorescence (3), 
whereby the molecule emits a photon and returns to the ground state.9 




Figure 1.1: A Jablonski diagram showing the light-induced transitions between the electronic (black) 
and vibrational (grey) energy levels of an organic molecule: (1) absorption of a photon, (2) internal 
conversion, (3) fluorescence. 
It should be noted that although emission typically occurs from the lowest energy level of the S1 
excited state, it can result in the population of any of the vibrational energy levels of the S0 state. 
Similarly the excitation of an organic molecule can result in the population of any vibrational energy 
level of the singlet excited states. 
The population of these vibrational energy levels is dictated by the Franck-Codon principle, and is 
visually represented in figure 1.2. The Franck-Codon principle states that because nuclei are much 
larger than electrons, electronic transitions occur much faster than the motion of the nuclei. Thus 
upon absorption or emission of a photon from a molecule, the nuclear separation (Q) of the molecule 
does not change considerably. In terms of absorption, this results in the highest population of the 
excited state vibrational energy level which has the largest overlap with the lowest vibrational energy 
level of the ground state. In terms of emission, the same is true: the most populated ground state 
energy level is that which has the largest overlap with the lowest vibrational energy level of the excited 
state. Other transitions between vibrational energy levels of the ground and excited states are still 
possible, but will be less intense. 




Figure 1.2: Franck-Codon energy principle diagram showing the highest probability absorptive 
transition (blue arrow), highest probability emissive transition (green arrow) and internal conversion 
(wavy arrow). 
1.1.2 Circularly Polarised Light 
We will discuss in this section two polarisation states of an electromagnetic wave: linear and circular. 
Our interest is in the circular polarisation of light, which occurs when the electric field of light has a 
constant magnitude but the direction rotates at a steady rate in a plane which is perpendicular to the 
direction of the light wave.10 Both a ‘packet’ of photons and an individual photon can be circularly 
polarised. Circular polarisation of individual photons arises because the spin of an individual photon 
can be either +1 or -1. The spin angular momentum of a photon is the coefficient of h, therefore the 
spin angular momentum of a photon is ±1h (where h is Planck’s constant).11 Linear polarisation is the 
result of a superposition of equal amounts of left-handed (-1h) and right-handed (+1h) photons. 
Conversely circular polarisation is the result of a superposition of an unequal amount of left-handed 
and right-handed photons. 
The circular polarisation of an individual photon can be visualised by representing the electrical field 
of a photon as two perpendicular sine waves. If these sine waves are in phase (i.e. the maxima and 
minima occur at the same point along the axis of time) then the resultant wave is described as linearly 
polarised (figure 1.3a). However if these sine waves are out of phase by π/2 (or a quarter-wave) then 
the resulting wave is described as circularly polarised (figure 1.3b). Right-handed circularly polarised 
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light forms a clockwise helix, and left-handed circularly polarised light forms an anti-clockwise helix. 
Thus circular polarisation infers chirality to a beam of light, which is the basis of chiral photonics or 
chiroptics.1,2,11 
 
Figure 1.3: (a) two sine waves which represent the z and y components of the electrical field of a 
photon (green and blue respectively) and the resultant linearly polarised wave (red); (b) two sine 
waves representing the z and y components of the electrical field of a photon which are a quarter 
wave out of phase (green and blue respectively) and the resultant circularly polarised wave (red, 
left-handed CPL shown). 
1.1.2.1 Circularly Polarised Luminescence 
The differential emission of right- or left-handed circularly polarised light from chiral, non-racemic 
luminescent systems is known as circularly polarised luminescence (hereafter referred to as CPL).1,2 
The study of CPL provides valuable information about the structures of the involved excited states. 
Interest in CPL-active luminescent systems has grown significantly in recent years due to the promising 
applications of CPL in the improvement and development of chiroptical technologies. Some 
applications of CPL include: 3D optical displays,12 enantioselective CPL sensors,13 biological 
probes3,5,14,15 and CPL lasers.16 Moreover the overwhelming presence of chirality in the natural world 
makes CPL an indispensable tool in the study of biological systems, such as in the development of CPL 
microscopes.3,4 
For example Zhu, Cheng et al. have disclosed a Eu(III)-containing polymer which, in the presence of 
either D- or L-proline, displayed induced CPL emission of opposite signs (dependant on the enantiomer 
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of proline used) upon irradiation in solution, thus providing an example of an enantioselective CPL 
sensor.13 The use of CPL as a tool to probe biological systems has been explored by Kawai et al. through 
their synthesis and chiroptical characterisation of proteins (namely Staphylococcus aureus nuclease, 
bovine serum albumin and insulin) covalently bonded to Eu(III) chelates.15 
In order to make these technologies workable, the efficiency of CPL emission must be high. The extent 
of asymmetry in fluorescence is quantified using the luminescence dissymmetry factor (glum). 







Where IL is the intensity of left-handed circularly polarised light and IR is the intensity of right-handed 
circularly polarised light. Thus CPL spectroscopy is the measurement of the differential emission of 
circularly polarised light. The theoretical equation which defines glum is as follows: 
𝑔𝑙𝑢𝑚 =
4(𝝁 ∙ 𝒎 ∙ 𝑐𝑜𝑠𝜏)
(𝝁2 + 𝒎2)
 
Where m and µ are the magnetic and electric transition dipole moment vectors and τ is the angle 
between them. It should be noted here that CPL spectroscopy is the emission analogue of electronic 
circular dichroism (ECD) spectroscopy. Whereas CPL reflects the structure of the excited state of the 
involved fluorophore, ECD reflects the structure of the ground state. In ECD spectroscopy the 







Where εL(λ) and εR(λ) are the molar extinction coefficients of left- and right-handed circularly polarised 
light at a particular wavelength (λ). 
Commonly chiral lanthanide complexes are employed in studies of CPL emission. This is due to their 
high luminescence dissymmetry factors, which stem from their electric dipole forbidden, magnetic 
dipole allowed f → f transitions. Typical glum values from chiral lanthanides are in the range 0.1-0.5, 
and the largest glum value measured from a chiral lanthanide complex has been reported by the group 
of Kaizaki and Muller (|glum| = 1.38).7 However the overall brightness of chiral lanthanide complexes 
is sub-optimal, due to the typically low fluorescence quantum yields (φF) of these systems. 
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Thus there is considerable interest in the development of small organic molecules as CPL-emitters 
(CPL-SOMs).17,18 The photonic properties of organic molecules make CPL-SOMs one of the most 
promising alternatives to chiral lanthanide complexes. These desirable properties include: 
• ability to display high fluorescence quantum yields, 
• facile modulation of the photonic properties through simple structural modifications, and 
• low toxicity, allowing for potential live cell imaging. 
The first example of CPL emission from a small organic molecule was described by Emeis and 
Oosterhoff, where they showed that chiral cyclic ketone 1.1 was capable of CPL emission upon 
irradiation in solution (glum = 3.5×10-3). Later other systems have been examined as CPL-SOMs, 
including other chiral cyclic ketones,19–21 helicenes,22–25 cyclophanes26–28 and biaryls29–31 (figure 1.4). 
For example the two binapthyl systems 1.9 and 1.10 were described by Imai, Fujiki et al., wherein they 
found that the sign of CPL could be controlled by the choice of either ‘open’ ((S)-1.9, positive CPL) or 
‘closed’ ((S)-1.10, negative CPL) type binapthyls exhibiting the same axial chirality. 
 




Figure 1.4: A selection of CPL-SOMs: chiral cyclic ketones (1.1-1.3), helicenes (1.4-1.6), cyclophanes 
(1.7 and 1.8) and biaryls (1.9-1.11). 
1.2 General Introduction to BODIPYs 
In this work, we have focused on the development of chiral 4,4′-difluoro-4-bora-3a,4a-diaza-s-
indacene (BODIPY) fluorophores as CPL-SOMs. 
The BODIPY dyes are a class of fluorophores whose core structure consists of two methylene-bridged 
pyrrole moieties chelated by a central boron atom (figure 1.5). In recent years BODIPY dyes have 
become a ubiquitous class of fluorophores, finding use in a wide range of applications including live 
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cell bioimaging,32 fluorescent sensing,33 photodynamic therapy,34 and dye sensitised solar cells.35 The 
success of BODIPY dyes for use in a wide range of applications can be attributed to both their desirable 
photophysical properties (high fluorescence quantum yields, high molar extinction coefficients and 
sharp absorption and emission bands), and their relative insensitivity to their chemical environments 
(such as pH and polarity). Furthermore, simple synthetic modifications to the BODIPY core (section 
1.2.2) can be performed in order to fine-tune the photophysical properties of the BODIPY. 
 
Figure 1.5: The core structure of a BODIPY dye, and of two key synthetic precursors dipyrromethene 
and dipyrromethane. Two numbering systems are shown, the IUPAC numbering (left) and common 
numbering system (right). 
1.2.1 General Synthetic Strategies towards BODIPYs 
We will now discuss general methods to synthesise BODIPYs (section 1.2.1), and common synthetic 
modifications which can be used to introduce functionality to the BODIPY system (section 1.2.2). These 
sections are adapted from a recent book chapter entitled ‘Recent developments in the synthesis of 
BODIPYs’ written by R. G. Clarke and M. J. Hall and published in Advances in Heterocyclic Chemistry, 
Volume 128.36 
1.2.1.1 Synthesis of Symmetrical BODIPYs 
The first BODIPY dye was disclosed by Triebs and Kreuzer in 1968.37 Their synthetic approach involved 
a one-pot procedure, in which two equivalents of 2,4-dimethylpyrrole 1.12 undergo a Lewis acid 
catalysed condensation with one equivalent of acetic anhydride. Subsequent chelation of the nitrogen 
atoms by boron was achieved through treatment with boron trifluoride diethyl etherate to form the 
BODIPY core. The presence of an excess of acetic anhydride resulted in a subsequent in situ 
electrophilic aromatic (SEAr) acetylation of the 2- or 2,6-positions, leading to the formation of BODIPYs 
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1.13 and 1.14. This approach (i.e. the condensation of pyrrole with acid anhydride) is commonly 
employed in the synthesis of C2-symmetric BODIPYs.38,39 
 
Scheme 1.1: Reagents and conditions: (i) Ac2O, BF3.Et2O. 
Another frequently utilised approach is the condensation of two equivalents of pyrrole with one 
equivalent of an activated ester (or equivalent). The resulting dipyrromethenes are chemically 
unstable, and so are typically not isolated. In this case chelation with boron trifluoride diethyletherate 
in the presence of a suitable amine base is performed in situ to give the desired BODIPY. For example 
Tour et al. have employed this approach, wherein reaction between 2,4-dimethyl pyrrole 1.12 and 
acid chloride 1.15 is used to form BODIPY 1.16.40 BODIPY 1.16 was then used in the synthesis of a light 
driven nanocar 1.17, which features two BODIPY axles. 
 
Scheme 1.2: Reagents and conditions: (i) 1,2-dichloroethane, reflux, 13 h then BF3⋅OEt2, Et3N, reflux, 
2 h (24%). 
A further strategy used to synthesise C2-symmetric BODIPYs involves the use of an orthoester as the 
electrophilic component of the initial condensation reaction, rather than an acyl chloride or acetic 
anhydride. This is followed by boron chelation under standard conditions to form the BODIPY core 
structure. Whilst allowing access to BODIPYs with meso-alkyl substituents and meso-unsubstituted 
BODIPYs (through the use of an orthoformate), one drawback of this approach is that it is limited by 
the availability of commercial orthoesters. The condensation of pyrroles with orthoesters was first 
reported by Reese and Yan, in their synthesis of tri-(pyrrol-2-yl)alkanes.41 This condensation reaction 
was first applied to the synthesis of BODIPYs by Suzuki et al. in their synthesis of BODIPY 1.18, which 
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was synthesised via an acid catalysed condensation between 2,4-dimethylpyrrole 1.12 and 
triethylorthoformate. Boron chelation under standard conditions then lead to the synthesis of BODIPY 
1.18, which is a key intermediate in the synthesis of a BODIPY-based chemiluminescent probe 1.19.42 
 
Scheme 1.3: Reagents and conditions: (i) CH(OEt)3, TFA, CH2Cl2, R.T., 2 h; (ii) BF3⋅OEt2, Et3N, toluene, 
R.T. 30 min (57%). 
One of the most popular methods to synthesise BODIPYs was developed by Lindsey et al., wherein an 
aldehyde (typically an arylaldehyde, such as 1.20) undergoes acid catalysed condensation with two 
equivalents of α-substituted pyrrole (such as 2-methylpyrrole 1.21). The resultant symmetrical 
dipyrromethane 1.22 is then oxidised using DDQ or p-chloranil to form the corresponding 
dipyrromethene 1.23. A final boron chelation step under standard conditions affords the desired 3,5-
methyl-8-aryl substituted BODIPY (for example, BODIPY 1.24, scheme 1.4). The use of α-substituted 
pyrrole is key to this method, as the substituent at the α-position prevents further condensation 
reactions and thus the formation of porphyrins. 
 
Scheme 1.4: Reagents and conditions: (i) CH2Cl2, TFA(cat.), R.T., 1.5 h (95%); (ii) p-chloranil, toluene, 
R.T., 5 min, then Et3N, BF3⋅OEt2, R.T., 1 h (15%). 
However this method may only be used to synthesise α-substituted BODIPYs. If instead α-
unsubstituted BODIPYs are required, an alternative strategy must be used. Lindsey et al. have 
developed a ‘solventless’ approach in which pyrrole is used in a large excess as both reagent and 
solvent.43 Here the use of a large excess of pyrrole prevents the occurrence of over condensation, and 
thus the formation of porphyrins and other higher order condensates is suppressed. The acid catalysed 
condensation between 1H-pyrrole and an aryl aldehyde thus gives the corresponding dipyrromethane. 
Following oxidation and chelation under standard conditions, the desired BODIPY can be isolated. 
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An alternative method towards the synthesis of α-unsubstituted BODIPYs was described by Dehaen 
et al., in which near stoichiometric amounts of α-unsubstituted pyrroles are condensed with 
arylaldehydes under aqueous acidic conditions.44 The success of this approach stems from the 
comparative solubility of the reagent arylaldehyde and the product dipyrromethane, the latter of 
which precipitates from solution during the course of the reaction. Not only does this prevent 
porphyrin formation (as there is little dipyrromethane available in solution to undergo further 
condensation processes) but also allows for purification by simple filtration. 
1.2.1.2 Synthesis of Unsymmetrical BODIPYs 
The synthetic strategies we have so far discussed involve the condensation of two equivalents of 
pyrrole with an electrophilic centre, resulting in the synthesis of C2-symmetric BODIPYs. In order to 
break this symmetry and produce unsymmetrical dyes, an alternative approach must be used. Mély, 
Bonnet et al. described the step-wise formation of BODIPY dyes via keto-pyrrole intermediates.45 The 
2-ketopyrrole 1.25 was synthesised through the Grignard addition of 2,4-dimethyl pyrrole 1.12 to 4-
iodobenzoyl chloride. This was followed by the addition of a second equivalent of 2,4-dimethyl pyrrole 
to 2-ketopyrrole 1.25 in the presence of phosphorous oxychloride to form dipyrromethene 1.26. 
Subsequent oxidation and boron chelation under standard conditions afforded BODIPY 1.16. Although 
in this work this approach was used to synthesise symmetrical BODIPY 1.16, it can be imagined that 
this approach could be employed to form unsymmetrical BODIPYs.  
 
Scheme 1.5: Reagents and conditions: (i) CH3MgBr, Et2O, reflux, 30 min then IC6H4COCl, R.T., 12 h 
(81%); (ii) 2,4-dimethylpyrrole, POCl3, CH2Cl2, pentane, 0 °C then R.T., 24 h (46%); (iii) BF3·Et2O, NEt3, 
toluene 80 oC, 30 min (80%). 
This approach was used by Hall et al. in the synthesis of an unsymmetrical BODIPY displaying axial 
chirality.46 Bromination of 2-ketopyrrole 1.27 was followed by condensation with 2,4-dimethyl-3-ethyl 
pyrrole to give dipyrromethene 1.28. Chelation by boron under standard conditions was followed by 
a Mizoroki-Heck coupling with ethyl acrylate to give BODIPY 1.29. The restricted rotation around the 
meso-aryl bond of BODIPY 1.29 (due to the steric clash between the ortho-methyl group of the meso-
aryl ring and the 1,7-methyl substituents of the BODIPY core) combined with the unsymmetrical 
BODIPY core result in axial chirality (sections 1.3.1.3 and 1.3.2.2). 




Scheme 1.6: Reagents and conditions: (i) Br2, CH2Cl2, R.T., 24 h (100%); (ii) (a) 2,4-dimethyl-3-
ethylpyrrole, TFA, CH2Cl2, R.T., 18 h (47%). 
1.2.2 Modifications to the BODIPY core 
Modifications to the BODIPY core are commonly used to fine tune the photophysical properties of the 
dye. For example the extension of the π-system of the BODIPY core results in a bathochromic shift of 
the absorption and emission bands of the BODIPY. Additionally modifications to the BODIPY core can 
be used to introduce functionality to the BODIPY system. There are many synthetic methodologies to 
introduce functionality to the BODIPY core, which are summarised in figure 1.6. In this section we will 
discuss only the modifications which are highlighted in red. 




Figure 1.6: Reported modifications which can be made to the BODIPY core, with those discussed in 
this section highlighted in red. 
1.2.2.1 Electrophilic Aromatic Substitutions (SEAr) 
BODIPY dyes are intrinsically electron rich heteroaromatics. As such they are susceptible to 
electrophilic aromatic substitution (SEAr) chemistry. The electrophilic aromatic substitution of 
BODIPYs is highly regioselective for the 2- and 6-positions, as these are the positions which bear the 
largest negative charge. Examples of SEAr nitration,47 sulfonation48–50 and halogenation49,51 are 
commonly found throughout BODIPY literature. 
Halogenation of the 2,6-positions BODIPYs using reagents such as liquid bromine49 or iodic acid51 can 
result in over-halogenation. Once reaction at the 2,6-positions is complete, further unwanted 
halogenation can then occur at any unsubstituted positions of the BODIPY. Milder halogenation 
methodologies are therefore attractive, since they provide greater regioselectivity and reduce the 
occurrence of over-halogenation by-products. The relatively mild N-halosuccinimide (NXS) reagents 
(NCS, NBS and NIS) are therefore commonly employed to halogenate BODIPYs. 
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Ortiz, García-Moreno, Chiara et al. have examined the stepwise chlorination of BODIPY 1.30, allowing 
the selective synthesis of a series of chlorinated BODIPYs 1.31-1.34.52 Reaction between BODIPY 1.30 
and two equivalents of NCS gave 2-chloro-BODIPY 1.31. By increasing the equivalents of NCS used 2,6-
chloro-BODIPY 1.32 (3 eq.), 2,3,5-chloro-BODIPY 1.33 (4 eq.) and 2,3,5,6-chloro-BODIPY 1.34 (10 eq.) 
were selectively synthesised. 
 
Scheme 1.7: Reagents and conditions: (i) NCS, THF, R.T., 12-72 h. 
One limitation which is implied by the high regioselectivity of the SEAr chemistry of BODIPYs is that 
the substitution of the 3,5-positions is not possible unless the 2,6-positions are sterically blocked. 
However the 3,5-positions are the most spectroscopically interesting positions to decorate,53,54 and so 
there is interest in methodologies to substitute the 3,5-positions. 
Dipyrromethanes, commonly used BODIPY precursors, display complimentary regioselectivity to the 
corresponding BODIPYs. Dipyrromethanes are more pyrrole-like in their chemistry, and so SEAr 
substitution occurs preferentially at the α- or 1,9-positions (corresponding to the 3,5-positions of the 
subsequently formed BODIPY). Thus the SEAr α-functionalisation of dipyrromethenes serves as a route 
to 3- or 3,5-substituted BODIPYs. 
For example Dehaen et al. have described the highly regioselective SEAr reaction between 
dipyrromethane 1.35 and NCS to give 3,5-dichlorinated dipyrromethane 1.36. Following oxidation and 
boron chelation under standard conditions, 3,5-dichloro-BODIPY 1.37 was synthesised.55,56 A similar 
methodology can be used to synthesise 3,5-dibromo-BODIPYs, through the reaction of 
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dipyrromethanes with NBS at low temperatures to form α,α-dibrominated dipyrromethanes. After 
oxidation and boron chelation under standard conditions, 3,5-dibromo-BODIPYs may be isolated.57,58 
 
Scheme 1.8: Reagents and conditions: (i) NCS, THF, -78 °C for 2h, then -20 °C overnight; (ii) p-
chloranil, CH2Cl2, 1 h; (iii) BF3·Et2O, NEt3, toluene, reflux, 2.5 h (47%). 
1.2.2.2 Nucleophilic Aromatic Substitutions (SNAr) 
BODIPYs which contain leaving groups in the 3- or 3,5-positions are susceptible to nucleophilic 
aromatic substitution (SNAr) chemistry. Commonly SNAr chemistry is performed on 3,5-dichloro-
BODIPYs, since the electron withdrawing nature and good leaving group ability of the chloride 
substituents result in typically facile, high yielding substitutions. 
Dehaen et al. first reported the application of SNAr chemistry to BODIPYs,55,59 wherein oxygen, nitrogen 
and sulfur centred nucleophiles were shown to react with 3,5-dichloro-BODIPY 1.37 to produce 3- and 
3,5-substituted BODIPYs. Control over mono- versus di-substitution was easily achieved through 
control of the reaction temperature. 
 
Scheme 1.9: Reagents and conditions: (i) Nucleophile (2 eq.), MeCN, R.T. (1.38 74%; 1.39 69%; 1.40 
65%; 1.41 67%); (ii) Nucleophile (4 eq.), MeCN, reflux (1.42 78%; 1.43 64%; 1.44 70%; 1.45 71%). 
This chemistry was further expanded by Dehaen et al., wherein the substitution of 3,5-dichloro-
BODIPY 1.37 with 2-bromophenol was described.60 It was then shown that the resulting BODIPY 1.46 
was susceptible to a palladium catalysed, intramolecular benzofuran formation to produce ring-fused, 
bathochromically shifted BODIPY 1.47. 




Scheme 1.10: Reagents and conditions: (i) 2-bromophenol (2 eq.), Na2CO3 (2 eq.), MeCN, reflux, 1 h 
(94%); (ii) Pd(OAc)2, PPh3 (10 mol%), K2CO3 (3 eq.), toluene, reflux, 48 h (69%). 
Nitrogen-centred nucleophiles undergo SNAr chemistry with 3,5-dichloro-BODIPYs at relatively fast 
rates, even at room temperature. For example, Zhao et al. have reported the SNAr reaction of 3,5-
dichloro-BODIPYs with a range of N-heteroaromatic molecules.61 Matano et al. later described a 
further improvement to the substitution of 3,5-dichloro-BODIPYs with N-heteroaromatics.62 Initial 
experiments by Matano et al. showed that the SNAr addition of pyrazole to 3,5-dichloro-BODIPY 1.48 
was slow and selective for mono-addition, even after extended reaction times. However the addition 
of two equivalents of sodium hydride to the reaction conditions resulted in the formation of 3,5-
disubstituted BODIPY 1.49 after a dramatically shortened reaction time. 
 
Scheme 1.11: Reagents and conditions: (i) pyrazole (10 eq.), THF, reflux, 22 h (61%); (ii) pyrazole (2 
eq.), NaH (2 eq.), THF, R.T., 1 h (87%). 
The use of sodium hydride as a base to activate the N-heteroaromatic nucleophile allowed for the 
addition of a wide range of N-heteroaromatics to 3,5-dichloro-BODIPY 1.48 (scheme 1.12). 




Scheme 1.12: Reagents and conditions: (i) N-heteroaromatic, NaH, THF, R.T. 
As previously discussed, Dehaen et al. showed that carbon centred nucleophiles undergo SNAr 
chemistry with 3,5-dichloro-BODIPY 1.48 to produce 3- and 3,5-substituted BODIPYs.55 An expansion 
of this work was reported by Hao et al., in which electron rich heteroaromatics are used as carbon-
centred nucleophiles in the SNAr reaction of BODIPYs. Thus 2,3,4,6-tetrachloro-BODIPY 1.50 was 
reacted with pyrrole to produce either mono- or di-pyrrolyl-BODIPYs 1.51 or 1.52, dependant on the 
reaction time and temperature. 
 
Scheme 1.13: Reagents and conditions: (i) pyrrole (neat), 60 °C, 24 h (78%); (ii) pyrrole (neat), 120 °C, 
72 h (52%). 
The drawback of this approach is that relatively forcing conditions are used, for example the use of 
pyrrole as the reaction solvent and high temperatures are required. If a more electron rich pyrrole, 
such as 2,4-dimethylpyrrole, is used then lower reaction temperatures can be employed to synthesise 
3- and 3,5-dipyrrolyl-BODIPYs 1.53 and 1.54. Furthermore the use of electron rich pyrroles allows for 
the use of a reaction solvent instead of an excess of pyrrole (in this case, toluene). 
 




Scheme 1.14: Reagents and conditions: (i) 2,4-dimethylpyrrole (19 eq.), toluene, 60 °C, 24 h (44%); 
(ii) 2,4-dimethyl-3-ethylpyrrole (19 eq.), toluene, 60 °C, 24 h (67%). 
Aryl and alkyl chalcogens are good nucleophiles, and as such we would expect that they would 
undergo SNAr chemistry with suitably functionalised BODIPYs. The synthesis of a series of 3,5-
dichalcogen substituted BODIPYs was described by Vosch et al., synthesised through the SNAr addition 
of a range of aryl chalcogens to 3,5-dichloro-BODIPY 1.37. Thus 3,5-dithiophenol-BODIPY 1.55 was 
formed through reaction of 3,5-dichloro-BODIPY 1.37 and thiophenol, in the presence of sodium 
carbonate. In the case of the more easily oxidisable fourth and fifth row chalcogens, selenium and 
tellurium, the corresponding nucleophile was first formed through reductive cleavage of 1,2-
diphenyldiselane or 1,2-diphenylditellane using sodium borohydride. The resulting aryl chalcogen 
then underwent SNAr chemistry with 3,5-dichloro-BODIPY 1.37 to give 3,5-diselenophenolyl-BODIPY 
1.56a and 3,5-ditellurphenolyl-BODIPY 1.56b. 
 
Scheme 1.15: Reagents and conditions: (i) thiophenol (10 eq.), K2CO3 (10 eq.), DMF, 50 °C, 12 h 
(87%); (ii) NaBH4 (2.4 eq.), Ph2Y2 (2.1 eq.), EtOH, THF, R.T., 12 h (1.56a: Y = Se (96%), 1.56b: Y = Te 
(91%)). 
It should be noted here that SNAr chemistry is also possible from 1,7-dichloro-BODIPYs63 and 8-halo-
BODIPYs,64–67 provided there is not significant steric bulk in either the 8- (for 1,7-substitutions) or 1,7-
positions (for 8-substitutions) to block the incoming nucleophile. 
1.2.2.3 Substitutions at Boron 
The 4-position (i.e. the boron atom) of the BODIPY framework can also be functionalised, where the 
BF2 chelating group is replaced by a BX2 group.68 Stable chelates can be formed when X is C, O or N, 
and useful synthetic intermediates can be formed when X is Cl. Typically exchange of the fluorine 
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atoms (to form a BX2 BODIPY complex) is achieved using a nucleophilic aromatic substitution 
approach, usually (but not always) in the presence of a suitable Lewis acid catalyst. Another route to 
BX2 complexed BODIPYs is the chelation of the precursor dipyrromethene with a boron reagent 
already bearing the desired X groups. 
The replacement of the fluorine atoms with carbon based ligands through reaction with a suitable 
organometallic reagent is one of the most commonly used approaches to BX2-BODIPYs.69–72 The first 
report of this type of transformation was described by Ziessel et al., in which ethynylpyrene and 
ethynyltoluene functionalised BODIPYs 1.58 and 1.59 were formed through reaction between BODIPY 
1.57 and the corresponding lithium acteylides.73 This approach can also be applied to aryl or alkyl 
lithium reagents, to produce 4-arylated- or 4-alkylated-BODIPYs, respectively. 
 
Scheme 1.16: Reagents and conditions: (i) 1-ethynylpyrene or 1-ethynyltoluene (2 eq.), n-
butyllithium (2.5 eq.), THF, -78 °C for 1 h, then R.T. for 30 min (1.58 62%, 1.59 30%). 
Alternatively other organometallic reagents can be employed, such as Grignard reagents, in place of 
organolithiums. This strategy was first described by Ziessel et al., wherein BODIPY 1.57 was diarylated 
at boron through reaction with arylmagnesium bromides to produce BODIPYs 1.60 and 1.61.74 
Substitutions with alkynyl and alkyl Grignard reagents have been shown to produce the corresponding 
4-alkynyl- and 4-alkyl-BODIPYs.75–78 
 
Scheme 1.17: Reagents and conditions: (i) phenylmagnesium bromide or 2-napthylmagnesium 
bromide (2 eq.), diethyl ether, R.T., 1 h (1.60 25%, 1.61 35%). 
The replacement of the fluorine atoms of a BODIPY with oxygen atoms has been achieved through 
both intramolecular and intermolecular substitutions with appropriate oxygen centred nucleophiles. 
Burgess et al. reported the first example of a tetradentate dipyrromethene ligand, N,N,O,O-BODIPY 
1.64, which contains a central boron atom directly bonded to the oxygen atoms of the 3,5-phenolic 
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substituents.79 The synthesis of N,N,O,O-BODIPY 1.64 involved the formation of dipyrromethene 1.62, 
followed by chelation under standard conditions to form BODIPY 1.63. A subsequent double 
demethylation of the phenolic oxygens using boron tribromide was followed by an in situ double B-O 
bond formation to form N,N,O,O-BODIPY 1.64. The tetradentate N,N,O,O-chelation motif of 1.64 was 
shown to induce bathochromically shifted absorption and emission bands, as a result of the highly 
conjugated and constrained ring system. 
 
Scheme 1.18: Reagents and conditions: (i) Et3N, BF3·Et2O, toluene, 80 °C, 20 min; (ii) BBr3, 0 to 25 °C, 
5 h (93%). 
Since this initial report, there have been further examples of using this demethylation, in situ boron 
chelation approach to produce highly constrained, bathochromically shifted BODIPYs.80–84 These 
reactions are driven in part by the entropically favourable formation of a tetra- or tri-dentate 
coordination geometries around the central boron atom. 
Intermolecular substitutions at boron are also possible for oxygen centred nucleophiles, if a suitable 
base or Lewis acid is used to mediate the process. The first instance of this type of substitution at 
boron was described by Nagano et al., in which BODIPY 1.65 was reacted with sodium methoxide 
(methanol, reflux) to form the mono- and di-methoxy BODIPYs 1.66 and 1.67.85 
 
Scheme 1.19: Reagents and conditions: (i) MeONa, MeOH, reflux, 14 h (1.66 37%, 1.67 52%). 
Another strategy reported by Mély, Bonnet et al. described the nucleophilic substitution of the 
fluorine atoms of boron with alcohols under Lewis acidic conditions.45 Activation of BODIPY 1.65 by 
treatment with aluminium trichloride was followed by the addition of methanol, to give dimethoxy-
BODIPY 1.67 in a quantitative yield. This methodology was subsequently extended to include a wider 
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range of alcohols, including pyrocatechol and 1,1’-bi-2-napthol (BINOL). This approach has since been 
widely used to access N,N,O,O-BODIPYs.86–91 
 
Scheme 1.20: Reagents and conditions: (i) AlCl3, CH2Cl2, reflux, 5 min; (ii) MeOH, R.T., 5 min 
(quantitative). 
A similar approach involves the activation of the fluorine atoms of the BODIPY through treatment with 
trimethylsilyl trifluoromethanesulfonate (TMSOTf). Mazitschek et al. have examined the substitution 
of one fluorine atom of the BODIPY boron with alkoxy groups.92 BODIPY 1.68 was reacted with TMSOTf 
(10 equivalents) before the rapid addition of methanol (100 equivalents) gave the N,N,O,F-BODIPY 
1.69. This approach was shown by Mazitschek et al. to be a general route to 4-monoalkoxy-BODIPYs 
through the introduction of a wide range of alcohols. This approach has since been applied to the 
synthesis of 4,4-dialkoxy-BODIPYs.93 Furthermore the generation of TMSOR from TMSCl and the 
appropriate carboxylic acid ROOH has allowed for the incorporation of more complex alkoxy 
substituents.94,95 
 
Scheme 1.21: Reagents and conditions: (i) 5 eq. TMSOTf, CH2Cl2, 0 oC, 2.5 min, then 100 eq. MeOH, 
iPr2NEt (46%). 
The replacement of the fluorine atoms of BODIPYs with chlorine atoms results in the formation of 
more easily substitutable boron centres. This is because B-Cl bonds are significantly weaker than B-F 
bonds, resulting in facile substitutions from BCl2-BODIPYs. Lundrigan and Thompson have reported 
the conversion of BF2-BODIPY 1.70 to BCl2-BODIPY 1.71 through treatment of 1.70 with boron 
trichloride.96 The BCl2-BODIPY 1.71 can be isolated, or alternatively can be reacted directly with, for 
example, sodium methoxide or ethylmagnesium bromide to give N,N,O,O-BODIPY 1.72 or N,N,C,C-
BODIPY 1.73. 




Scheme 1.22: Reagents and conditions: (i) BCl3 (1 eq.), CH2Cl2, 22 °C, 1 h; (ii) NaOMe, CH2Cl2, 22 °C, 1 
h (98%); (iii) EtMgBr, CH2Cl2, 22 °C, 1 h (98%). 
Thompson et al. have also reported the formation of BBr2-BODIPY 1.74, which was formed through 
reaction of BODIPY 1.70 with boron tribromide.97 BBr2-BODIPY 1.74 was isolated by removal of the 
reaction solvent, however the reaction chemistry of BBr2-BODIPY 1.74 has yet to be reported. 
 
Scheme 1.23: Reagents and conditions: (i) BBr3 (1 eq.), CCl4, R.T. (quantitative). 
Another strategy towards the synthesis of BODIPYs with functionality at the boron atom (or 4-position) 
is the chelation of dipyrromethenes with boron species containing the desired functionality. For 
example Ikeda and Nabeshima have reported the synthesis of a series of head-to-tail cyclic BODIPY 
oligomers 1.76a-1.76c. These were formed through reaction of dipyrromethene 1.75 with boron 
trichloride to form a more reactive BCl2-BODIPY intermediate, followed by self-condensation to form 
the supramolecular N,N,O,O-BODIPYs 1.76a-1.76c.98 
 
 




Scheme 1.24: Reagents and conditions: (i) BCl3, iPr2NEt, toluene, reflux, 16 h (1.76a 2%, 1.76b 5%, 
1.76c 0.3%). 
A further example of this methodology was described by Holten et al.,99 wherein chelation of a 
dipyrromethene with three dialkylboranes resulted in the synthesis of a series of 4-functionalised 
BODIPYs. The scope of this methodology was subsequently extended by Thompson et al.,100 in which 
monofluoroaryl N,N,F,C-BODIPY 1.78a and N,N,C,C-BODIPYs 1.78b and 1.78c were produced through 
treatment of the HBr salt of dipyrromethene 1.77 with C6F5BF2 (1.78a), (C6F5)2BCl (1.78b) or 
perfluorinated 9-bromoborafluorene (1.78c). 
 
Scheme 1.25: Reagents and conditions: (i) NEt3, CH2Cl2, 15 min, then C6F5BF2, (C6F5)2BCl or 
perfluorinated 9-bromoborafluorene, 15 min (1.78a 48%, 1.78b 89%, 1.78c 62%). 
Nabeshima et al. have described an alternative strategy which does not involve the use of reactive 
boranes as chelating reagents. Instead dipyrromethenes have been shown to chelate a range of 
boronic acids. For example reaction between dipyrromethene 1.79 and phenylboronic acid gave 
N,N,O,C-BODIPY 1.80 following chelation and intramolecular B-O bond formation.101 




Scheme 1.26: Reagents and conditions: (i) phenyl boronic acid, CHCl3, reflux, 3 h (quant.). 
This approach has been employed by Nabeshima et al. to synthesise a number of N,N,O,C-BODIPY 
systems.102,103 A further development was described by Jiao et al. through their ‘one-pot’ synthesis of 
N,N,O,C-BODIPYs through reaction between pyrrole and a 2-ketopyrrole, followed by an in situ 
chelation of the dipyrromethene formed with a boronic acid.104 
1.2.2.4 Cross-Coupling Reactions of BODIPYs 
Palladium catalysed cross-coupling reactions to make carbon-carbon bonds are widely used in organic 
chemistry, and have unsurprisingly found significant use in the synthesis of BODIPYs. Suitably 
halogenated BODIPYs have been shown to undergo Suzuki-Miyaura, Migita-Kosugi-Stille, Mizoroki-
Heck and Sonogashira cross-coupling reactions, with many of these examples coming from Dehaen 
and coworkers.105 Palladium cross-couplings in all positions (3,5-positions,84,105–108 2,6-
positions,103,106,107,109–111 1,7-positions63,112–114 and 8-position64,113,115–119) of the BODIPY framework 
have been reported. 
Jiao, Hao et al. have examined the regioselectivity of palladium cross-couplings, including Suzuki-
Miyaura, Migita-Kosugi-Stille, Mizoroki-Heck and Sonogashira cross-couplings. It was found that when 
2,3,5,6-tetrabromo-BODIPY 1.81 was reacted under a variety of palladium cross-coupling conditions, 
there was always a strong preference for 3,5-addition. The tetra-substituted BODIPYs were accessible 
when an excess of the coupling reagent was used, along with more forcing reaction conditions. 
 
Scheme 1.27: Regiochemistry of palladium cross-coupling reactions with 2,3,5,6-tetrabromo-BODIPY 
1.81. 
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In their seminal work, Ortiz et al. have shown that Negishi cross-coupling reactions can be performed 
on 3,5-dihalo-BODIPYs. Reaction of 3,5-dichloro-BODIPY 1.37 or 3,5-dibromo-BODIPY 1.82 under 
Negishi cross-coupling conditions resulted in the formation of 3- and 3,5-substituted BODIPYs 
containing alkyl, aryl and alkynyl substituents.120 The Negishi cross-coupling of 1,7- and 8-halo-
BODIPYs has subsequently been described.121 
 
Entry X R2Zn or RZnBr R Product Yield/% 
1 Br ZnEt2 Et di 86 
2 Br ZnEt2 Et mono 61 
3 Cl ZnEt2 Et di 73 
4 Cl ZnEt2 Et mono 75 
5 Cl ZnMe2 Me di 80 
6 Cl ZnMe2 Me mono 77 
7 Cl BuZnBr Bu di 52 
8 Cl BuZnBr Bu mono 62 
9 Cl BnZnBr Bn di 20 
10 Cl BnZnBr Bn mono 18 
11 Cl PhZnBr Ph di 56 
12 Cl PhZnBr Ph mono 70 
13 Cl PhC≡CZnBr PhC≡C di 54 
14 Cl PhC≡CZnBr PhC≡C mono 56 
15 Cl TMSC≡CZnBr TMSC≡C di 65 
Table 1.1: Negishi cross-couplings of 3,5-dihalo BODIPYs 1.37 and 1.82. Reagents and conditions: 
Pd(PPh3)2Cl2 (10 mol %), R2Zn or RZnBr, toluene. 
1.3 Chirality in BODIPYs 
One of the main considerations in the investigation of BODIPYs as CPL-SOMs is the induction of 
chirality to these planar fluorophores. There have been a number of reports of chiral BODIPY systems 
CHAPTER 1 - INTRODUCTION 
26 
 
before the exploration of BODIPYs as CPL-SOMs. We will now discuss some of the methodologies 
which have been used to induce chirality in mono-BODIPY systems. 
1.3.1 Strategies to induce chirality in BODIPYs 
1.3.1.1 BODIPYs with chiral substituents 
The most obvious method to induce chirality in BODIPYs is the covalent attachment of chiral 
substituents to the BODIPY core. One example of the application of this methodology was described 
by Grimme, Daub et al. in their synthesis of the 1,1’-binapthyl (BINOL) derived BODIPY 1.84.122 BODIPY 
1.84 was synthesised through condensation between an enantiomerically pure BINOL carbaldehyde 
precursor 1.83 and 2,4-dimethyl pyrrole 1.12. Subsequent oxidation and chelation afforded an 
enantiomerically pure sample of BODIPY 1.82. 
 
Scheme 1.28: Synthesis of 1,1’-binapthyl (BINOL) derived BODIPY 1.84. 
The chiroptical properties of enantiomerically pure BODIPY 1.84 were then investigated. The 
electronic circular dichrosim (ECD) spectrum showed a number of short wavelength transitions 
corresponding to the BINOL moiety, as well as a longer wavelength absorption corresponding to the 
BODIPY S0-S1 transition (λ = 495 nm). In the ECD spectrum, a moderate positive Cotton effect was 
observed (Δεmax = +10 L mol-1cm-1) in the S0-S1 absorption band of the BODIPY core. This result supports 
the notion that the inclusion of chiral substituents successfully induces chirality in BODIPY systems. 
1.3.1.2 BODIPYs with a chiral boron centre 
A further methodology to induce chirality in BODIPY systems is the assembly of a BODIPY with a chiral 
boron centre. Ulrich, Ziessel et al. disclosed the first example of a BODIPY containing a chiral boron 
centre (named B*-BODIPY).123 The design requirements of B*-BODIPYs outlined by Ziessel, Ulrich et 
al. included: 
• an asymmetrical BODIPY core, 
• a polar group in the 3- or 5-position of the BODIPY capable of interacting with the boron centre 
and 
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• a polyaromatic moiety to induce steric hindrance around the boron centre. 
Thus racemic B*-BODIPY 1.86 was synthesised in a multi-step procedure from the corresponding 
parent BODIPY 1.85. The first step was to displace one of the fluorine atoms through reaction of 
BODIPY 1.85 with napthylmagnesium bromide at low temperature. This was then followed by 
selective oxidation of the 5-methyl group with DDQ to desymmetrise the BODIPY core. The resulting 
5-formyl moiety formed an intramolecular CHF hydrogen bond, which was confirmed by the 
observation in the 1H NMR spectrum of long-range coupling between the proton of the formyl moiety 
and the fluorine atom of the BF2 moiety. 
 
 
Scheme 1.29: Reagents and conditions: (i) napthylmagnesium bromide, THF, 20 °C (25%); (ii) DDQ, 
THF/H2O, 0 °C (61%). 
Following resolution by chiral HPLC (Chiralcel-OD, hexane/2-propanol), the ECD spectra of the 
corresponding enantiomers were obtained. A strong Cotton effect was observed in the short 
wavelength transitions, which are associated with the carbonyl group. However the S0-S1 transition 
band of the BODIPY chromophore only gave a weak signal in the ECD spectrum. 
1.3.1.3 Axially chiral BODIPYs 
The highly aromatic, planar structure of the BODIPY core lends itself well to the induction of axial 
chirality. The formation of atropisomers based on the BODIPY architecture can be achieved through 
both the desymmetrisation of the BODIPY core and the inclusion of a rotationally restricted BODIPY-
aryl bond. For example Hall et al. have described the synthesis of axially chiral BODIPY 1.29 (section 
1.2.1.2). The axial chirality in this system arises from the lateral differentiation of the BODIPY core 
(due to the 2-ethyl acrylate moiety) and the restricted rotation of the 8-aryl substituent (due to a 
methyl-methyl clash). 




Figure 1.7: (R)- and (S)- enantiomers of the axially chiral BODIPY 1.29. 
Resolution of the (R)- and (S)- enantiomers of BODIPY 1.29 was achieved through semi-preparative 
chiral HPLC (Chiralpak, AD-H, heptane/2-propanol). Subsequently the ECD spectra of the resolved 
enantiomers was measured, however there was no significant Cotton effect observed in the 
absorption band corresponding to the S0-S1 transition of the BODIPY. Instead the only significant 
Cotton effect was observed in the short wavelength transitions corresponding to the 8-aryl 
substituent. 
1.3.1.4 Helically chiral BODIPYs 
The group of Burgess et al. have described the synthesis of N,N,O,O-BODIPY 1.64 (section 1.2.2.3).79 
In this system helical chirality arises from the tetrahedral geometry at boron, which ensures that the 
aryl rings are twisted to direct the B-O bonds to opposite faces of the planar BODIPY core. The racemic 
mixture of (P)- and (M)-1.64 was shown to be separable by chiral HPLC (Pirkle covalent (S,S) whelk-01, 
hexane/2-propanol), however isolation of the single enantiomers was not achieved and thus no 
chiroptical measurements were made. 
  
Figure 1.8: Helically chiral N,N,O,O- BODIPY 1.64 ((P)-enantiomer shown). 
Following this work, several other helically chiral N,N,O,O-BODIPY systems have been disclosed.80,81,124 
However in these instances the bathochromic shift induced by the highly constrained and conjugated 
ring system was the focus of the discussion, rather than the chiroptical properties of this BODIPY 
architecture. 
Subsequently similar helically chiral BODIPY systems were disclosed wherein only one of the ortho-
phenolic moieties is chelated to the central boron atom. For example, Nabeshima et al. reported the 
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synthesis of the N,N,O,C-BODIPY 1.80 through the chelation of the corresponding dipyrromethene by 
an aryl boronic acid (section 1.2.2.3).125 
 
Figure 1.9: Helically chiral N,N,O,C-BODIPY 1.80. 
More recently, Nabeshima et al. have reported the synthesis of a similar helically chiral N,N,O,C-
BODIPY system.103 An initial Suzuki-Miyaura cross-coupling between 2-bromo-BODIPY 1.87 and the 
biaryl boronic acid 1.88 gave BODIPY 1.89. The following steps included: an oxidative annulation of 
BODIPY 1.89 and removal of the BF2 moiety using anhydrous FeCl3, demethylation of the methoxy 
substituents with boron tribromide and finally rechelation by phenylboronic acid to form N,N,O,C-
BODIPY 1.90. 
 
Scheme 1.30: Reagents and conditions: (i) 1.88, Pd2(dba)3, tBu3PH.BF4, Cs2CO3, THF, H2O, R.T., 16 h 
(quant.). 
Following resolution of the enantiomers of N,N,O,C-BODIPY 1.90 by chiral HPLC (Daicel Chiralpak IA, 
hexane/CHCl3), mirror image ECD spectra were obtained. A moderate Cotton effect (Δεmax = ±20 L mol-
1cm-1) was observed in the S0-S1 transition of the BODIPY chromophore (λ = 655 nm), however no CPL 
studies were reported on this system. 
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1.3.2 CPL-active BODIPYs 
As we have seen, the induction of chirality to BODIPYs can be achieved through a number of different 
strategies. However in order for a BODIPY system to be applicable as a CPL-SOM, a CPL signal must be 
observable upon irradiation. We will now discuss some chiral BODIPY systems which are CPL-emissive. 
1.3.2.1 BODIPYs with chiral substituents 
The first report of CPL emission from a BODIPY fluorophore was described by Gossauer et al., in studies 
into the urobilin derivative BODIPY 1.91.126 The ECD spectrum of the non-racemisable BODIPY 1.91 
showed a Cotton effect in the long-wavelength absorbance band corresponding to the S0-S1 transition 
of the BODIPY fluorophore (λ ≈ 535 nm), suggesting that the peripheral chiral carbon centres are 
sufficient to induce chirality to the BODIPY chromophore. Interestingly it was found that upon 
changing the solvent from CHCl3 to DMF, inversion of the Cotton effect was observed in the long 
wavelength transition at approximately 535 nm. This indicates that there is a conformational change 
in BODIPY 1.91 upon solvation in a polar solvent, due to the competition between intramolecular 
NHF hydrogen bond in CHCl3 and intermolecular NHF hydrogen bond in DMF. Furthermore CPL 
emission was recorded from urobilin-derived BODIPY 1.91 in CHCl3, and a glum value of +0.94×10-3 was 
measured. Thus BODIPY 1.91 represents the first chiral BODIPY system from which CPL emission was 
reported. 
 
Figure 1.10: Molecular structure of urobilin-derived BODIPY 1.91, showing the suggested 
conformational change upon solvation in non-polar (left, CHCl3) and polar (right, DMF) solvents. 
1.3.2.2 Axially chiral BODIPYs. 
The group of de la Moya reported the enantioselective synthesis of the axially chiral, BINOL-derived 
BODIPY 1.92.127 Substitution of the fluorine atoms of BODIPY 1.57 by (R)- or (S)- BINOL through the 
use of aluminium trichloride (section 1.2.2.3) afforded enantiopure samples of (R)- and (S)-BODIPY 
1.92 in high yields. The commercial availability of the precursors (i.e. achiral F-BODIPYs and 
enantiopure 1,1’-biphen-2-ols) make this an accessible route to enantiopure, chiral BODIPYs. 




Scheme 1.31: Reagents and conditions: (i) AlCl3, DCM, reflux; (ii) either (R)- or (S)-1,1’-bi(2-napthol), 
R.T., 6 h ((R)-1.92 60%, (S)-1.92 58%). 
A study of the chiroptical properties of (R)- and (S)-BODIPY 1.92 was conducted. In the ECD spectra, a 
strong Cotton effect was observed in the BODIPY S0-S1 transition (λ ≈ 525 nm), which was opposite for 
each enantiomer. This suggests that the BINOL moiety is successfully inducing chirality to the achiral 
BODIPY fluorophore. Further evidence to support this is the successful measurement of CPL emission 
from the enantiomers of BODIPY 1.92 (|glum| ≈ 10-3). The CPL maxima (λ ≈ 570 nm) were consistent 
with the emission maxima recorded for the BODIPY fluorophore, indicating that the CPL emission 
arises from the BODIPY moiety, and not the BINOL moiety. 
1.3.2.3 Helically chiral BODIPYs 
Inspired by the work of Burgess et al.,79 the group of Hall, Knight et al. synthesised a series of N,N,O,O-
BODIPYs 1.93-1.96 to evaluate the potential use of these systems as CPL-SOMs.84 The meso-aryl 
substituents are electronically separated from the BODIPY chromophore, however subtle changes to 
the photophysical properties are evident due to the steric influence of these groups on the 
conformational flexibility of the BODIPY core. 
 
Figure 1.11: Helically-chiral N,N,O,O-BODIPYs 1.93-1.96 ((M)-enantiomer shown in each case) and 
the associated glum values and fluorescence quantum yields.  
The N,N,O,O-BODIPYs 1.93-1.96 were formed as racemic mixtures, and so following resolution of the 
enantiomers by chiral HPLC (Daicel Chiralpak OB, toluene/n-hexane (1.93); Daicel Chiralpak OD-H, i-
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PrOH/n-hexane (1.94-1.96) chiroptical measurements were performed. ECD spectra of the resolved 
enantiomers showed strong Cotton effects in the transitions corresponding to the S0-S1 transition of 
the BODIPY chromophore. Moreover red-shifted CPL emission was observed from all four related 
systems ((|glum| = 4.7×10-3, 3.3×10-3, 4.3×10-3 and 4.2×10-3 for 1.93-1.96 respectively), with the 
emission maxima corresponding to the S1-S0 transition of each BODIPY chromophore. In the case of 
N,N,O,O-BODIPY 1.93, the relatively large |glum| combined with the high fluorescence quantum yield 
gave an overall quantum efficiency (|glum|·φF ) of 3×10-3. Thus at the time of publishing, N,N,O,O-
BODIPY 1.93 represented the most efficient single-fluorophore, red-emitting CPL-SOM described.18,128 
1.4 Project Aims 
The aim for this thesis was to synthesise novel chiral BODIPYs, to explore their chiroptical properties 
(with a focus on CPL) en route to the development of new small organic fluorophores capable of 
solution phase CPL (CPL-SOMs). 
In chapter 2 we will report the results of our initial investigations into the synthesis of the N,N,O,O-
BODIPYs described by Hall et al. (figure 1.11), with a focus on both the improvement of synthetic yields 
and the synthesis of further analogues. We hoped to thus identify new chiral BODIPYs which would 
be CPL-emissive and through the study of their chiroptical properties, including glum, gain insight into 
CPL-SOM BODIPY design. Furthermore in chapter 2 we will seek to employ computational techniques 
to support our experimental findings, and thus hope to validate the computational method for 
predicting the glum of helically chiral BODIPYs. 
In chapter 3 we will discuss our attempts to produce helically chiral BODIPYs with enhanced glum 
values. Our hypothesis was that an increase the orbital angular momentum of helically chiral BODIPYs 
would lead to an increase in the magnetic (m) transition dipole moment, in turn leading to an increase 
in glum. We planned to achieve this increase in orbital angular momentum by the induction of sulfur 
atoms to the helically chiral BODIPY architecture. Therefore in chapter 3 we will discuss the synthetic 
methodologies we have examined to introduce sulfur atoms into helically chiral BODIPYs. 
Finally in chapter 4 we will report our investigations into the effect that modulation of the helical pitch 
of helically chiral N,N,O,O-BODIPYs has on the angle (τ) between the magnetic (m) and electronic (µ) 
transition dipole moments. We thought that through the extension of the BODIPY π-system we would 
be able to exhibit control over the helical pitch, and thus over the angle τ, potentially leading to the 
development of helically chiral N,N,O,O-BODIPYs with enhanced glum values. Thus in chapter 4 we will 
discuss the synthesis and chiroptical characterisation of an N,N,O,O-BODIPY with an extended π-
system. 
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Chapter 2. Synthesis and Chiroptical Characterisation of N,N,O,C-BODIPYs 
2.1 Introduction 
2.1.1 Aims and molecular design principles 
In this chapter we will discuss our progress towards investigating new chiral BODIPYs as CPL-SOMs. A 
significant challenge in the design of new CPL-SOMs is that they often exhibit low CPL quantum 
efficiencies (|glum|·φF) due to low luminescence dissymmetry factors (glum). In order to produce 
BODIPY-based CPL-SOMs with improved glum values, there are some fundamental design principles 
which must be considered. 
2.1.1.1 Twisting deformations/chiral perturbations of the inherently planar BODIPY core 
The first of these design principles was highlighted by Gossauer et al., in their comparison of three 
chiral BODIPY derivatives. Gossauer et al. reported the first example of CPL emission from a chiral 
BODIPY 1.91, derived from urobilin (glum = +0.94(±0.1)×10-3).126 In a later report from the same group, 
two further homochiral dyes were described, containing asymmetric phenyl substituents at either the 
8- (2.2) or 3,5-positions (2.1)129. However neither of these two dyes displayed an appreciable CPL 
signal. Comparison of the crystal structures of these three chiral BODIPY revealed that only the urobilin 
derivative 1.91 contained a twisting deformation of the planar BODIPY core. This led Gossauer to 
speculate that “both a “chiral perturbation” of an inherently planar dipyrrin chromophore and a 
twisting deformation of the latter may (be required to) give rise to high optical activity”. 
 
Figure 2.1: Early chiral BODIPYs: urobilin based BODIPY 1.91 and homochiral BODIPYs 2.1 and 2.2. 
Thus in our planned work towards new CPL-SOM BODIPYs, we aim to design and synthesise BODIPY 
dyes which are both chiral and possess a twisting deformation of the planar BODIPY core. 
2.1.1.2 Controlling the magnetic and electric transition dipole moments in CPL-SOMs 
In the design of new BODIPY based CPL-SOMs we must also consider the underlying physical chemistry 
principles which determine the glum value for a compound. The luminescence dissymmetry factor is 
theoretically defined by the equation: 




4(𝝁 ∙ 𝒎 ∙ 𝑐𝑜𝑠𝜏)
(𝝁2 + 𝒎2)
 
Where m and µ are the magnetic and electric transition dipole moment vectors and τ is the angle 
between them. The maximum value of glum is 2, and can only be obtained when m is equal in 
magnitude to µ, and when τ = 0° or 180°. In chiral lanthanide complexes, glum values are typically large. 
This is a consequence of the magnetic-dipole-allowed, electric-dipole-forbidden f→f transitions130–133 
common to these complexes, which result in magnetic (m) and the electronic (µ) transition dipole 
moments of similar magnitudes. Small glum values are common for typical CPL-SOMs as m is usually 
several orders of magnitude smaller than µ for the π-π* transition of most simple organic 
fluorophores. Therefore to increase |glum| for a typical CPL-SOM, the magnitude of the magnetic 
transition dipole moment (|m|) must be increased, and the magnitude of the electric transition dipole 
moment (|µ|) must be decreased, so that these vectors are of a similar magnitude. Additionally τ 
should be as close to either 0° or 180° as possible. 
Thus in our planned work towards new CPL-SOM BODIPYs, we aim to control these fundamental 
molecular properties, decreasing |µ| whilst simultaneously increasing |m| and controlling the angle 
between these vectors (τ). 
2.1.1.3 Rapid evaluation of glum by CD spectroscopy 
In a recent review article from Mori et al.134, the relationship between gabs and glum was examined. 
These values were correlated for a range of CPL-SOMs, including cyclophanes, helicenes and biaryls. 
Most importantly for our work, the relationship between gabs and glum were also examined for a range 
CPL-SOM BODIPYs (figure 2.2). 
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Figure 2.2: CPL-active BODIPYs for which gabs and glum are correlated.134 
Mori and co-workers found that for rigid homochiral mono(BODIPY)s (1.93-1.96, 1.92 and 2.3-2.5) gabs 
and glum exhibit a good linear correlation (ie. |glum| = 1.02×|gabs| (r2=0.90)). However flexible 
homochiral di(BODIPY)s (2.6 and 2.7) deviate from this correlation, and the inclusion of these data 
points results in a worse linear correlation (|glum| = 0.77×|gabs| (r2=0.49)). It is postulated that the 
linear correlation between gabs and glum factors is much improved for rigid chiral BODIPYs, due to 
significant structural similarity between the S0 ground states and the excited S1 states of these 
molecules. This similarity is a result of minimal vibrational relaxation of the excited S1 state. 
Therefore in our planned work towards new CPL-SOM BODIPYs we will attempt to use the 
measurement of gabs as a preliminary assessment of the potential for high glum. Since we are planning 
to synthesise rigid, homochiral mono(BODIPY)s we will attempt to corroborate the good linear 
correlation between gabs and glum for these systems, as observed by Mori. 
2.1.1.4 Chapter Aims 
Our aim for this chapter is to examine the design of new CPL-SOM BODIPYs, which include induced 
twists in the planar BODIPY core. We will also attempt to control the magnitudes of the electric (µ) 
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and magnetic (m) dipole moments and the angle between them (τ) to maximise possible glum for these 
systems. 
As a starting point for our work we first decided to re-examine helically chiral N,N,O,O-BODIPY 1.93 
(figure 2.3). The N,N,O,O-BODIPY architecture was first reported by Burgess et al.79, and subsequently 
the N,N,O,O-BODIPYs 1.93 and 1.95 were reported by Hall and co-workers. In particular N,N,O,O-
BODIPY 1.93 was shown to be an efficient emitter of CPL (|glum| = 4.7×10-3)84. In keeping with the 
design principles outlined above, N,N,O,O-BODIPY 1.93 has a chirally perturbed BODIPY core, with a 
twist angle of 11.2° between the planes of two pyrrolic rings. We therefore thought that the N,N,O,O-
BODIPY architecture would be an appropriate starting point to validate the design principles outlined 
in section 2.1.1. 
 
Figure 2.3: Helically chiral N,N,O,O-BODIPY 1.93 and N,N,O,O-BODIPY 1.95. 
In the original work by Hall et al., the synthetic routes towards the helically chiral N,N,O,O-BODIPYs 
were un-optimised and as such had poor overall yields. Therefore our initial plan was to re-examine 
the synthesis of N,N,O,O-BODIPY 1.95 in order to improve yields over some of the more problematic 
synthetic steps. We reasoned that this would allow us to efficiently synthesise further analogues of 
the N,N,O,O-BODIPYs, detailed study of which would allow us an improved understanding of the key 
molecular properties (m, µ and τ), and thus the required design constraints for the production of 
homochiral mono(BODIPY) CPL-SOMs with improved |glum|. 
2.1.2 Synthetic strategy towards an N,N,O,O-BODIPY 
2.1.2.1 Planned synthesis of N,N,O,O-BODIPY 2.13 
Aryl substituents at the 8-position of BODIPYs are electronically separated from the chromophore, 
and as such do not have a considerable impact on the photophysical properties. Since our ultimate 
aim is to use CPL-SOMs in CPL bioimaging, we wished to include a handle for possible late-stage 
functionalisation. We therefore elected to incorporate an aromatic ring at the 8-position, containing 
a methyl ester functional group, which can be used as a functionalisation handle. 
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In order to synthesise N,N,O,O-BODIPY 2.13, we planned to first synthesise the intermediate 3,5-
dibromo-BODIPY 2.11 (scheme 2.1). In Hall’s reported synthesis of N,N,O,O-BODIPY 1.95, the total 
overall yield over the three steps (condensation, bromination, oxidation and chelation) was 47%.84 We 
aimed to improve the overall yield of this approach to 3,5-dibromo-BODIPY 2.11. In particular the 
condensation reaction had a poor yield (69%) and we looked to improve this step. 
 
Scheme 2.1: Planned synthetic route to 3,5-dibromo-BODIPY 2.11. 
Following Hall’s reported synthesis,84 we planned to use a Suzuki-Miyaura cross-coupling between 3,5-
dibromo-BODIPY 2.11 and 2-methoxyphenyl boronic acid to give 3,5-diaryl-BODIPY 2.12. This would 
be followed by a double demethylation reaction and in situ double B-O bond formation to give 
N,N,O,O-BODIPY 2.13 (route A, scheme 2.2). We also considered an alternative approach involving the 
use of 2-hydroxyphenylboronic acid 2.13 (route B, scheme 2.2). We reasoned that this alternative 
approach should eliminate the need for a double demethylation step, since the double B-O bond 
formation event would occur in situ after the Suzuki-Miyaura cross-coupling was complete. We 
planned to test both route A and route B, and compare the overall obtained yields of N,N,O,O-BODIPY 
2.13. 




Scheme 2.2: Planned synthetic routes A and B to N,N,O,O-BODIPY 2.13. 
2.1.2.2 Synthesis of N,N,O,O-BODIPY 2.13 
In the previously reported synthesis of N,N,O,O-BODIPY 1.95,84 Lindsey’s method43 was used to 
perform the condensation between 4-methylbenzaldehyde and 1H-pyrrole (i.e. the use of a large 
excess of 1H-pyrrole). However this approach has a number of practical limitations, for example the 
removal of the residual excess pyrrole from the reaction mixture. Therefore we decided to evaluate 
alternative approaches to this key condensation step involving the use of stoichiometric amounts of 
the pyrrole condensation partner. 
Therefore our first step was to examine the feasibility of an alternative condensation route, following 
a procedure optimised by Dehaen (section 1.2.1.2).44 Dehaen’s procedure involves an acid catalysed 
condensation reaction between a benzaldehyde and a pyrrole under aqueous conditions. The use of 
water as a solvent is key to success in this reaction, allowing precipitation of the product 
dipyrromethane during the course of the reaction. The precipitation of dipyrromethane from the 
reaction prevents the formation of higher oligomers, and therefore allows the use of close to 
stoichiometric amounts of the pyrrole condensation partner. 
The first reaction we attempted was the condensation between benzaldehyde 2.8 and 1H-pyrrole 
(scheme 2.3) on a 1 mmol (280 mg) scale of benzaldehyde 2.8. Immediately after the addition of 1H-
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pyrrole to the reaction mixture, precipitation of dipyrromethane 2.9 began to occur. After four hours 
at room temperature no further precipitation was observed, indicating that the reaction was 
complete. In order to obtain an analytically pure sample of dipyrromethane 2.9, we elected to perform 
purification by silica gel chromatography. Purification by silica gel chromatography, with 
dichloromethane as eluent, gave dipyrromethane 2.9 in an 88% yield. The structure of 
dipyrromethane 2.9 was confirmed by the observation of a set of signals in the 1H NMR spectrum 
corresponding to the pyrrolic hydrogens typical of a C-2 substituted pyrrole (δH 6.75 ppm, m, 2H; 6.19 
ppm, dd, 2H, J = 3.7, 3.2 Hz; 5.92 ppm, m, 2H) and a signal corresponding to the methyl group of the 
aryl ester (δH 3.93 ppm, s, 3H).  
The condensation reaction between benzaldehyde 2.8 and 1H-pyrrole was repeated a number of 
times, at scales of up to 9 mmol of benzaldehyde 2.9 (2.5 g). Dipyrromethane 2.9 could be obtained 
in isolated yields of up to 90 %. In the case of the larger scale reactions, analysis of the crude 1H NMR 
spectrum showed that dipyrromethane 2.9 could be isolated in high purity following a simple filtration 
step, thus we elected to forgo silica gel chromatography to improve experimental efficiency. Therefore 
dipyrromethane 2.9 was typically used in the next synthetic steps following purification by filtration. 
 
Scheme 2.3: Reagents and conditions: (i) 1H-pyrrole (3 eq.), HCl(aq) (0.05 M), R.T., 4 h (>90%). 
The next synthetic step we wished to investigate was the one-pot bromination/oxidation of 
dipyrromethane 2.9. We wished to dibrominate the 1,9-positions of dipyrromethane 2.9, 
corresponding to the 3,5-positions of the target 3,5-dibromo-BODIPY 2.11. The resulting bromo-
groups of 3,5-dibromo-BODIPY 2.11 will be used in subsequent steps to introduce the required 3,5-
aryl groups using Suzuki-Miyaura cross-coupling chemistry. To ensure selective 1,9-dibromination of 
dipyrromethane 2.9, we planned to use the brominating agent NBS at low temperatures.57,58 
Our initial attempts at this reaction resulted in complex mixtures of bromination products, from which 
we were unable to isolate the desired 1,9-dibrominated dipyrromethene 2.10. Analysis of the 1H NMR 
spectrum of a typical crude reaction mixture revealed that there were at least three different 
brominated dipyrromethenes formed as major products, shown by the presence of three overlapping 
peaks pertaining to the methyl groups of at least three different aryl methyl esters (δH 3.99-3.95 ppm, 
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figure 2.4). Further analysis of the 1H NMR spectrum of the crude reaction mixture confirmed the 
presence of at least three different dipyrromethenes, through the observation of sets of signals 
corresponding to C-2,5 disubstituted and C-2,3,5 trisubstituted pyrrolic moieties, which we have 
attributed to the presence of a mixture of 1,9-dibrominated dipyrromethene 2.10, 1,2,9-
tribrominated dipyrromethene 2.14 and 1,2,8,9-tetrabrominated dipyrromethene 2.15 (figure 2.5). 
 
Figure 2.4: 1H NMR spectrum of a crude reaction mixture of the bromination/oxidation of 
dipyrromethane 2.9, showing three overlapping peaks pertaining to the methyl groups of at least 









Figure 2.5: (a) 1H NMR spectrum of a crude reaction mixture of the bromination/oxidation of 
dipyrromethane 2.9, showing sets of signals corresponding to C-2,5 disubstituted and C-2,3,5 
trisubstituted pyrrolic moieties; (b) brominated dipyrromethenes 2.10, 2.14 and 2.15 proposed to be 
the products of the bromination/oxidation of dipyrromethane 2.9. 
Further analysis of the proposed brominated dipyrromethenes 2.10, 2.14 and 2.15 was hindered due 
to their poor solubility in organic solvents, making separation by silica gel chromatography 
challenging. To confirm the formation of multiple brominated dipyrromethenes in the 
bromination/oxidation of dipyrromethane 2.9, we elected to transform them into the corresponding 
brominated BODIPYs to facilitate isolation and further analysis. Thus we reacted the mixture of 
brominated dipyrromethenes 2.10, 2.14 and 2.15 with boron trifluoride diethyl etherate in the 
presence of Hunig’s base. Once boron chelation was complete, the resulting mixture of brominated 
BODIPYs (2.11, 2.16 and 2.17) was then separated by silica gel chromatography. 
Analysis of the 1H NMR spectra of the three isolated brominated BODIPYs (2.11, 2.16 and 2.17) allowed 
us to confirm their structures (figure 2.6). The 1H NMR spectrum of BODIPY 2.11 showed the presence 
of an AB system consisting of a pair of roofed doublets pertaining to a C-2,5 disubstituted pyrrolic 
(a) 
(b) 
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moiety (δH 6.73 ppm, d, 2H, J = 4.2 Hz and 6.55 ppm, d, 2H, J = 4.2 Hz), suggesting a BODIPY with a 3,5-
dibromination pattern. The 1H NMR spectrum of BODIPY 2.17 showed the presence of a singlet peak 
(δH 6.85 ppm, s, 2H) corresponding to a C-2,3,5 trisubstituted pyrrolic moiety, consistent of a BODIPY 
with a 2,3,5,6-tetrabromination pattern. Finally analysis of the 1H NMR spectrum of BODIPY 2.16 
showed the presence of an AB system consisting of a pair of roofed doublets corresponding to a C-2,5 
disubstituted pyrrolic moiety (6.60 ppm, d, 1H, J = 4.5 Hz). The appearance of a singlet peak (6.80 ppm) 
corresponding to a C-2,3,5 trisubstituted pyrrolic moiety allowed us to conclude that BODIPY 2.16 has 
a 2,3,5-tribromination pattern. 
  
 
Figure 2.6: (a) 1H NMR spectrum of 3,5-dibromo-BODIPY 2.11; (b) 1H NMR spectrum of 2,3,5-
tribromo-BODIPY 2.16; (c) 1H NMR spectrum of 2,3,5,6-tetrabromo-BODIPY 2.17; (d) 1H NMR 
spectrum of the crude reaction mixture arising from the boron chelation of the mixture of 
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Following the structural assignment of brominated BODIPYs 2.11, 2.16 and 2.17, re-analysis of the 1H 
NMR spectrum of the crude reaction mixture (arising from the boron chelation of the mixture of 
brominated dipyrromethenes 2.10, 2.14 and 2.15) showed that brominated BODIPYs 2.11, 2.16 and 
2.17 had been formed in a 8:3:1 ratio. This implies a significant degree of over-bromination in the 
original bromination/oxidation reaction, thus further optimisation of this step focused on minimising 
over-bromination products. 
After further reaction optimisation, we found that over-bromination in the bromination/oxidation 
reaction of dipyrromethane 2.9 could be avoided by using lower reaction temperatures, and through 
the controlled addition of NBS (portion-wise addition of solid NBS to the reaction at -78 oC, scheme 
2.4). This allowed us isolate 1,9-dibrominated dipyrromethene 2.10 in a much improved yield of 86%. 
 
Scheme 2.4: Reagents and conditions: (i) NBS (2 eq.), THF, -78 °C, 1 h; (ii) DDQ, -78 °C to R.T., 10 min 
(86%). 
Our next step was to perform the boron chelation of 1,9-dibrominated dipyrromethene 2.10 to access 
3,5-dibromo-BODIPY 2.11. Therefore we reacted 1,9-dibrominated dipyrromethane 2.10 under 
standard conditions (boron trifluoride diethyletherate, Hunig’s base, DCM) which afforded 3,5-
dibromo-BODIPY 2.11 in an excellent isolated yield of 85% (scheme 2.5). 
 
Scheme 2.5: Reagents and conditions: (i) BF3.OEt2, iPr2NEt, DCM, R.T., 1 h (85%). 
From 3,5-dibromo-BODIPY 2.11 we next examined two pathways to produce our target N,N,O,O-
BODIPY 2.13. The first involves a Suzuki-Miyaura cross-coupling with 2-methoxyphenyl boronic acid, 
followed by a boron tribromide mediated double demethylation and in situ double B-O bond 
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formation to form N,N,O,O-BODIPY 2.13, following the original procedures.79,84 In the second 
approach we will attempt the Suzuki-Miyaura cross-coupling of 3,5-dibromo-BODIPY 2.11 with 2-
hydroxyphenylboronic acid, with the aim that the desired B-O bond formation event would occur in 
situ to allow direct access to N,N,O,O-BODIPY 2.13. 
Therefore in our first approach, we attempted a Suzuki-Miyaura cross-coupling between 3,5-dibromo-
BODIPY 2.11 and 2-methoxyphenyl boronic acid, using catalytic Pd(PPh3)4 (5 mol %). After 80 minutes 
we observed the disappearance of the 3,5-dibromo-BODIPY 2.11 and the appearance of a new major 
compound by TLC analysis. After purification by silica gel chromatography, 3,5-diaryl BODIPY 2.12 was 
isolated in a moderate yield of 58%. The structure of 3,5-diaryl BODIPY 2.12 was confirmed by the 
presence of peaks in the 1H NMR spectrum corresponding to both the methyl group of the aryl ester 
(δH 4.00 ppm, s, 3H) and the two methoxy groups of the 3,5-diaryl substituents (δH 3.78 ppm, s, 6H). 
 
Scheme 2.6: Reagents and conditions: (i) 2-methoxyphenyl boronic acid (4 eq.), Pd(PPh3)4 (5 mol %), 
K3PO4, toluene, 1,4-dioxane, 90 °C, 1 h 20 min (58%). 
The next step in our planned synthetic pathway was the double demethylation reaction of 3,5-diaryl-
BODIPY 2.12, followed by in situ double B-O bond formation between the two ortho-phenolic hydroxyl 
groups and the central boron atom. Our first attempt at this reaction was performed at 0 °C using 
boron tribromide in DCM. The formation of target N,N,O,O-BODIPY 2.13 could be observed in the 1H 
NMR spectrum of the reaction mixture, due to the presence of signals corresponding to the pyrrolic 
hydrogens (δH 7.05 ppm, d, 2H, J = 4.4 Hz and 6.93 ppm, d, 2H, J = 4.4 Hz), the hydrogens of the 3,5-
phenolic rings (δH 7.35 ppm, ddd, 2H, J = 8.3, 7.4, 1.5 Hz; 7.08 ppm, dd, 2H, J = 7.4, 1.5 Hz; 6.97 ppm, 
dd, 2H, J = 8.3, 1.2 Hz) and the loss of the signals corresponding to the two methoxy groups. However 
following silica gel column chromatography the isolated yield of N,N,O,O-BODIPY 2.13 was low, (<10%) 
with no starting material recovered. We therefore looked to test an alternative Suzuki-Miyaura cross-
coupling partner to synthesise N,N,O,O-BODIPY 2.13. 




Scheme 2.7: Reagents and conditions: (i) BBr3 (10 eq.), DCM, 0 °C (<10%). 
Thus we turned our attention to the second approach towards N,N,O,O-BODIPY 2.13, using a Suzuki-
Miyaura cross-coupling between 3,5-dibromo-BODIPY 2.11 and 2-hydroxyphenylboronic acid. Under 
these conditions we anticipated the desired B-O bond formation would occur in situ following the 
Suzuki-Miyaura cross-coupling, allowing direct access to N,N,O,O-BODIPY 2.13. 
We therefore performed a Suzuki-Miyaura cross-coupling between 3,5-dibromo-BODIPY 2.11 and 2-
hydroxyphenyl boronic acid, catalysed by Pd(PPh3)4 (5 mol%). Gratifyingly this reaction gave a 43% 
isolated yield of N,N,O,O-BODIPY 2.13, resulting from a successful double Suzuki-Miyaura cross-
coupling and in situ double intramolecular B-O bond formation. The formation of the B-O bonds within 
N,N,O,O-BODIPY 2.13 was confirmed by comparison of the 11B NMR spectra of 3,5-dibromo-BODIPY 
2.11 and of N,N,O,O-BODIPY 2.13. The 11B NMR spectrum of 3,5-dibromo-BODIPY 2.11 showed a 
triplet at δB 0.33 ppm (t, JB-F = 28 Hz) corresponding to a BF2 moiety in which the boron signal is split 
by coupling to two equivalent fluorine atoms. Conversely the 11B NMR spectra of N,N,O,O-BODIPY 2.13 
showed only a singlet at δB -0.90 ppm. Typical 11B NMR shifts for unconstrained N,N,O,O-BODIPYs are 
typically in the range of δB 1.8 – 2.6 ppm93,135,136, and typical 11B NMR shifts of a constrained N,N,O,O-
BODIPY are in the range of δB  -0.3 – -1.8 ppm.84,137,138 Based on this information, we concluded that 
that the fluorines of the central boron atom had been successfully replaced by oxygens. 
 
Scheme 2.8: Reagents and conditions: (i) 2-hydroxyphenyl boronic acid (4 eq.), Pd(PPh3)4 (5 mol %), 
Na2CO3, toluene, 1,4-dioxane, 90 °C, 1 h 20 min (43%). 
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We have successfully developed a new route to N,N,O,O-BODIPY 2.13 (four steps, 28% overall yield) 
through the use of a Suzuki-Miyaura cross-coupling/B-O bond formation reaction between 2-
hydroxyphenylboronic acid and 3,5-dibromo-BODIPY 2.11, eliminating the need for a late stage 
demethylation. However the overall yield of this synthetic approach is limited by the low yielding 
(43%) final Suzuki-Miyaura cross-coupling/B-O bond formation, thus we decided that further 
investigation of this key reaction was warranted. 
Interestingly we observed that another highly coloured compound (which we will designate 2.18) was 
formed during the Suzuki-Miyaura cross-coupling/B-O bond formation reaction between 3,5-dibromo-
BODIPY 2.11 and 2-hydroxyphenyl boronic acid, and could be isolated following silica gel 
chromatography (scheme 2.9). 
 
Scheme 2.9: Reagents and conditions: (i) 2-hydroxyphenyl boronic acid (4 eq.), Pd(PPh3)4 (5 mol %), 
Na2CO3, toluene, 1,4-dioxane, 90 °C, 1 h 20 min (2.13 43%). 
We therefore endeavoured to elucidate the structure of 2.18 in order to better understand how this 
by-product was formed under the reaction conditions. In this way, we hoped to be able to improve 
the Suzuki-Miyaura cross-coupling/B-O bond formation and thus the overall yield to N,N,O,O-BODIPY 
2.13. 
2.1.3 Isolation and structural determination of unknown compound 2.18 
Postulating that compound 2.18 may be a BODIPY, we first obtained absorption and emission spectra 
for the isolated molecule (figure 2.7a). The absorption and emission spectra of 2.18 were indeed 
characteristic of a BODIPY dye, showing an intense absorption band (ε = 30 000 M-1cm-1 with a half-
height band width of 46 nm) at λmax = 587 nm, and a fluorescence emission band at λmax = 613 nm with 
a small Stoke’s shift (3.85×105 cm-1). 




Figure 2.7: (a) Absorption (solid line) and emission (dotted line) spectra of 2.18 in DCM; (b) 
Absorption (solid line) and emission (dotted line) spectra of 2.13 in DCM. 
We next obtained high resolution mass spectrometry (HRMS) spectra of both N,N,O,O-BODIPY 2.13 
and unknown BODIPY 2.18 (provided by the EPSRC National Mass Spectrometry Service at Swansea 
University). N,N,O,O-BODIPY 2.13 was analysed on a Xevo G2-S mass spectrometer by ASAP-ToF 
(Atmospheric Solids Analysis Probe-Time of Flight) HRMS in positive mode. We observed a peak at 
471.1519 m/z assigned as [M+H]+ in the mass spectrum of N,N,O,O-BODIPY 2.13, suggesting a 
molecular formula of C29H19BN2O4. Unknown BODIPY 2.18 was analysed on a LTQ Orbitrap XL mass 
spectrometer using nanospray ionisation in positive mode. We observed a peak at 471.1508 m/z 
assigned as [M+H]+ in the mass spectrum, suggesting that molecular formula of unknown BODIPY 2.18 
was also C29H19BN2O4. Therefore both N,N,O,O-BODIPY 2.13 and unknown BODIPY 2.18 have 
molecular formulae of C29H19BN2O4, and as such are structural isomers. 
We then compared the 1H NMR spectra of N,N,O,O-BODIPY 2.13 and unknown BODIPY 2.18 (figure 
2.8). We found that in the 1H NMR spectrum of N,N,O,O-BODIPY 2.13, we could observe an AB system 
consisting of two roofed doublets pertaining to the pyrrolic hydrogens H1 and H2 (δH 7.05 ppm, d, 2H, 
J = 4.4 Hz and δH 6.93 ppm, d, 2H, J = 4.4 Hz). In the 1H NMR spectrum of unknown BODIPY 2.18, we 
observed that there were four doublets pertaining to pyrrolic hydrogens. Furthermore, analysis of the 
13C NMR spectra of N,N,O,O-BODIPY and unknown BODIPY 2.18 revealed that there were ten 
additional peaks in the spectra of 2.18, indicating that there had been a loss of C2 symmetry. 




Figure 2.8: 1H NMR spectra of N,N,O,O-BODIPY 2.13 (green, top) and unknown BODIPY 2.18 (red, 
bottom) showing the signals corresponding to the pyrrolic hydrogens of 2.13 and 2.18. 
In order to unambiguously determine the structure of BODIPY 2.18, we grew crystals by slow 
evaporation from a chloroform solution, suitable for single crystal X-ray diffraction analysis. Analysis 
of the crystal structure enabled us to determine the structure of N,N,O,C-BODIPY 2.18 (figure 2.9) as 
containing an unusual N,N,O,C-boron chelated motif. The structure of N,N,O,C-BODIPY 2.18 obtained 
from X-ray diffraction analysis was consistent with the 1H and 13C NMR spectra obtained previously, 
containing an inverted phenolic ring (i.e. connected to the BODIPY core through the phenolic oxygen 
instead of via an aryl-aryl C-C bond), thereby breaking the C2 symmetry. 
It can be observed from the X-ray crystal structure of N,N,O,C-BODIPY 2.18 that the 3,5-ortho-phenolic 
substituents are held in a ‘propeller-like’ arrangement, which gives rise to helical chirality. Thus 
N,N,O,C-BODIPY 2.18 represents a new structural class of helically chiral BODIPYs. 
As discussed previously (section 2.1.1.1), Gossauer has suggested that in order for a BODIPY to be CPL-
emissive, it must contain a perturbed or ‘twisted’ core.126,129 Examination of the X-ray crystal structure 
of 2.18 revealed that there is a twist in the core of N,N,O,C-BODIPY 2.18, with a twist angle of 
approximately 7.7° between the planes of the two pyrrolic rings. As such isolated enantiomers of 
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N,N,O,C-BODIPY 2.18 might be expected to be CPL active, since 2.18 contains both a intrinsically chiral 
structure and a chiral perturbation of the BODIPY core. 
 
Figure 2.9: (a) Two views of a molecule in the crystal structure of (rac)-2.18 illustrating the 
asymmetry in the fluorophore core and the helical arrangement of the phenolic substituents (H 
atoms are omitted for clarity, M-isomer is shown); (b) Molecular structure of (rac)-2.18. 
This N,N,O,C-boron chelation motif is highly unusual in BODIPY dyes. When we elucidated the 
structure of N,N,O,C-BODIPY 2.18 there were only 14 N,N,O,C-boron chelated BODIPYs known across 
3 articles.101,102,139 These included examples from the group of Vicente, wherein chelation of a 
dipyrromethane (2.19 or 2.20) with dichlorophenylborane is followed by substitution of the chloride 
with oxygen-centered nucleophiles to produce N,N,O,C-BODIPYs (2.21-2.22).139 N,N,O,C-BODIPYs 
(2.21-2.22) are examples of bidentate N,N-dipyrromethene ligands. 
 
Scheme 2.10: Reagents and conditions: (i) Et3N, DCM; (ii) PhBCl2, R.T., 1 h; (iii) Nucleophile, 1-2 h (R = 
Et or H, R1 = COMe, OCH2CCH, O(CH2CH2O)3Me, OCH2Ch2NHCOOtBu). 
Further examples of N,N,O,C-BODIPYs were synthesised by Nabeshima et al. through the chelation of 
a dipyrromethene (1.79 or 2.23) by an arylboronic acid to produce N,N,O,C-BODIPYs (1.80, 2.24b-f and 
2.25a-f, scheme 2.11).101,102 These examples from the group of Nabeshima are tridentate N,N-
dipyrromethene ligands. 
(a) (b) 




Scheme 2.11: Reagents and conditions: (i) Ar-B(OH)2, toluene or chloroform (Ar = Ph, naphth-1-yl, 4-
methoxyphenyl, pyrid-4-yl, pyrid-3-yl, pyren-1-yl). 
It should be noted that since the discovery of N,N,O,C-BODIPY 2.18, a number of other bi-140–142 and 
tridentate102,103 N,N,O,C-BODIPYs have been reported.  
N,N,O,C-BODIPY 2.18 is, to the best of our knowledge, the only N,N,O,C-BODIPY which is a 
tetradentate N,N-dipyrromethene ligand, thus imparting a high degree of rigidity to the structure. This 
rigid structure should result in a high fluorescence quantum yield (φF), because less energy is lost from 
the S1 excited state through vibrational relaxation. We hoped that a high φF would result in an 
improvement in our overall CPL quantum efficiency (|glum|·φF). 
Preliminary computational modelling of N,N,O,C-BODIPY 2.18 (performed by Dr Thomas Penfold) 
indicated that there was an increase in excited-state charge-transfer character in N,N,O,C-BODIPY 2.18 
(as compared to N,N,O,O-BODIPY 2.13). We would predict that an increase in excited-state charge-
transfer character would result in a decrease in the magnitude of the electric dipole moment, which 
in turn would lead to an increased |glum| (section 2.1.1.2). We were therefore eager to study the CPL 
capability of N,N,O,C-BODIPY 2.18, and thus examine the effect this charge-transfer character has on 
|glum|. 
2.2 Investigation of a new chiral BODIPY architecture 
2.2.1 Resolution of N,N,O,C-BODIPY 2.18 by chiral HPLC 
In order to investigate the chiroptical properties of N,N,O,C-BODIPY 2.18, it was first necessary to 
resolve our racemic mixture of 2.18 into its respective enantiomers. We therefore performed semi-
preparative chiral HPLC separation on a racemic mixture of 2.18 using a Daicel Chiralpak® IB column 
(1 mL/ minute, 85:15 hexane:ethyl acetate) to give approximately 10 µg of each enantiomer after 
combining multiple runs. We assigned the two isolated enantiomers as (+)-2.18 and (-)-2.18 
respectively by retention time and by measuring the specific optical rotation ([α]D). 
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Figure 2.10: A typical chiral HPLC trace of a racemic sample of 2.18. Daicel Chiralpak® IB column, 4.6 
x 250 mm, 5μm particle size, hexane : ethyl acetate (85:15), 1 mL/min. 
After separation of the enantiomers of N,N,O,C-BODIPY 2.18, the enantiomeric excess (ee) of each 
enantiomer was measured by resubmitting them to the chiral HPLC conditions ((+)-2.18 %ee = >95%, 
(-)-2.18 %ee = >95%). Once we were satisfied that we had isolated enantiopure samples of each 
enantiomer of N,N,O,C-BODIPY 2.18, we turned our attention to the measurement of the chiroptical 
properties. 
2.2.2 Electronic Circular Dichroism of N,N,O,C-BODIPY 2.18 
With our single enantiomers in hand, our next step was to measure electronic circular dichroism 
spectra (ECD, performed by Jonathan Bogaerts). Electronic circular dichroism spectroscopy involves 
the differential absorption of left- and right-handed light by an intrinsically chiral chromophore or a 
chromophore in a chiral environment. We expect that for a pair of enantiomers, we should observe 
equal and opposite (or ‘mirror image’) ECD spectra. 
As we had expected, we obtained mirror image ECD spectra from the (+)-and (-)-enantiomers of 
N,N,O,C-BODIPY 2.18 (figure 2.11a). The ECD spectra of the enantiomers showed strong Cotton effects 
corresponding to the S0-S1 transition of N,N,O,C-BODIPY 2.18 (λmax = 593 nm, Δεmax = ±92 L mol-1cm-1 
in hexane), which confirmed that the chiral species in the sample is indeed N,N,O,C-BODIPY 2.18. We 
were then able to measure a gabs value of 3.1×10-3 at 593 nm in hexane. 
Boltzmann-weighted ECD spectra for the postulated enantiomer were then obtained from TD-DFT 
calculations at the cam-B3LYP/6-311++G(93df,2pd) level for the M enantiomer of 2.18 (figure 2.11b, 
calculations performed by Professor Wouter Herrebout). By comparing the theoretical ECD spectra 
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with our experimental ECD spectra, we were able to assign the enantiomers as (P)-(-)-2.18 (blue) and 
(M)-(+)-2.18 (red). 
 
Figure 2.11: (a) Experimental ECD spectra (red – (M)-2.18, blue – (P)-2.18) and UV/Vis absorption 
spectrum (black) measured in hexane; (b) Calculated Boltzmann-weighted spectra, ECD (red – 
postulated (M)-2.18 (wavelength uncorrected) and UV/Vis absorption spectra (black – postulated 
(M)-2.18 (wavelength uncorrected); (c) (P)-2.18 and (M)-2.18. 
 Solvent λabs /nm ε /mol-1 cm-1 λem /nm φF |gabs| Δεmax / L mol-1cm-1 
2.18 hexane 593 30 000 622 0.49 3.1×10-3 ±92 
Table 2.1: Experimental photophysical and chiroptical properties of N,N,O,C-BODIPY 2.18. 
2.2.3 Evidence to support increased charge-transfer character in N,N,O,C-BODIPY 2.18 
Since preliminary computational modelling of N,N,O,C-BODIPY 2.18 had suggested that there was 
increased charge-transfer character in the excited state of N,N,O,C-BODIPY 2.18 (as compared to 
N,N,O,O-BODIPY 2.13), we decided to seek evidence to support this notion. We elected to perform 
cyclic voltammetry of (rac)-2.18 (performed by Dr Owen Woodford). 
Cyclic voltammetry of N,N,O,C-BODIPY 2.18 was performed in deoxygenated, freshly distilled 
dichloromethane containing 0.2 M tetra-N-butyl ammonium hexafluorophosphate as the background 
electrolyte. The working electrode was a highly polished glassy carbon disk, and the counter electrode 
was a Pt wire. An Ag/Ag+ reference electrode was used, and was calibrated against ferrocene. 
On reductive scans of N,N,O,C-BODIPY 2.18, a reversible one-electron wave was observed with a half 
wave potential of -1.17 V vs Ag/Ag+ with a peak separation of 100 mV at a scan rate of 0.1 V per second 
(figure 2.12). On oxidative scans, an irreversible one-electron wave was found, with a peak potential 
CHAPTER 2 – SYNTHESIS AND CHIROPTICAL CHARACTERISATION OF N,N,O,C-BODIPYS 
53 
 
of 0.84 V vs Ag/Ag+. A second oxidation wave could be observed at higher potentials (approximately 
1.01 V, as estimated using simulation techniques), and was electrochemically irreversible at all scan 
rates. 
 
Figure 2.12: Cyclic voltammogram recorded for N,N,O,C-BODIPY 2.18 in deoxygenated 
dichloromethane. The x-axis is referenced to the Ag/Ag+ electrode. 
A series of DFT calculations were made (performed by Dr Owen Woodfood, see Appendix) to calculate 
the energies and electronic distribution of the HOMO, HOMO(-1) and LUMO of N,N,O,C-BODIPY 2.18, 
and thus assign the oxidation and reduction peaks observed in the CV of (rac)-2.18. 
The reduction wave at -1.17 V was thereby assigned as the preferential addition of a single electron 
to the dipyrrin unit (i.e. a single electron reduction of the dipyrrin unit). The first oxidation wave at 
0.84 V was assigned to the removal of a single electron from the dipyrrin unit (i.e. a single electron 
oxidation of the dipyrrin unit). The second oxidation wave (1.01 V) can be assigned to the removal of 
a single electron from the boron-chelated phenolic rings. Based on these findings, we should expect 
to find a charge-transfer state located slightly above the lowest energy π-π* excited-singlet state. 
2.2.4 Circularly polarised luminescence of N,N,O,C-BODIPY 2.18 
We next measured the CPL spectra of the enantiomers (P)-(-)-2.18 and (M)-(+)-2.18 of N,N,O,C-BODIPY 
2.18 (performed by Dr Robert Pal). Gratifyingly, we obtained mirror image CPL spectra for (M)-(+)-2.18 
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and (P)-(-)-2.18, which confirmed that N,N,O,C-BODIPY 2.18 is a CPL-active BODIPY dye. As we would 
expect for a pair of enantiomers, the signals were opposite at the emission maxima (624 nm in 
hexane), corresponding to the S1-S0 transition of N,N,O,C-BODIPY 2.18. 
We measured the |glum| of N,N,O,C-BODIPY 2.18, and it was found to be 3.7×10-3 at 624 nm in hexane 
(figure 2.13). In order to compare the brightness of CPL with other CPL-SOM systems, we can calculate 
the overall quantum efficiency (|glum|·φF), which for 2.18 is 1.8×10-3. 
 
Figure 2.13: Normalised CPL (IL-IR) (red – (M)-(+)-2.18, blue – (P)-(-)-2.18) and fluorescence spectra 














2.18 hexane 593 30 000 622 0.49 3.1×10-3 ±92 3.7×10-3 1.8×10-3 
Table 2.2: Experimental photophysical and chiroptical properties of N,N,O,C-BODIPY 2.18. 
Thus we have reported the isolation, structural determination and full chiroptical characterisation of 
N,N,O,C-BODIPY 2.18. The observation of CPL emission from (P)-(-)-2.18 and (M)-(+)-2.18 validates 
Gossauer’s theory (section 2.1.1.1), since N,N,O,C-BODIPY 2.18 contains both an intrinsically chiral 
structure, and a chirally perturbed planar core. 
2.2.4.1 Rationalising the glum value observed for N,N,O,C-BODIPY 2.18 
As a consequence of the increased charge-transfer character in the excited state of N,N,O,C-BODIPY 
2.18, we had hoped to observe a higher glum value for N,N,O,C-BODIPY 2.18 than that which had been 
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previously reported for N,N,O,O-BODIPY 2.18. However the |glum| measured for N,N,O,C-BODIPY 2.18 
(3.7×10-3) was marginally lower than that of N,N,O,O-BODIPY 1.93 (4.7×10-3). We therefore sought to 
investigate why the presence of the increased charge-transfer character in the excited state of 
N,N,O,C-BODIPY 2.18 did not improve the glum. 
The electronic (µ) and magnetic (m) transition dipole moments and the angle between these vectors 
(τ) are related to glum by the following equation: 
𝑔𝑙𝑢𝑚 =
4(𝝁 ∙ 𝒎 ∙ 𝑐𝑜𝑠𝜏)
(𝝁2 + 𝒎2)
 
We wished to calculate the magnitude of m, µ and the angle τ, in order to investigate the effect the 
charge-transfer character in the excited state of 2.18 had on these molecular properties. Furthermore 
by comparing our theoretically determined glum values with our experimentally determined glum 
values, we can assess the accuracy of the computational method. If theoretically derived glum values 
are proven to be accurate, this would open up the possibility of designing new BODIPY CPL-SOMs 
based upon theoretical predictions. 
Thus the excited states of both N,N,O,C-BODIPY (P)-2.18 and N,N,O,O-BODIPY (P)-1.93 were calculated 
using DFT(PBE0) with a def2-TZVP basis set (table 2.3, performed by Dr Thomas Penfold) as 
implemented within the ORCA quantum chemistry package.143 
Compound µ [au] m [au] τ [°] |glum|calc |glum|exp[a] 
2.18 6.0×10-1 7.3×10-4 70 1.7×10-3 3.7×10-3 
1.93 7.6×10-1 1.4×10-3 65 3.1×10-3 4.7×10-3 
Table 2.3: Calculated magnitudes of the electric (µ) and magnetic (m) transition dipole moments, the 
angle between them (τ) and |glum|calc compared to |glum|exp for (P)-2.18 and (P)-1.93. [a]|glum|exp given 
at the respective λmax value in hexane. 
We were pleased to discover that the trend observed in the calculated glum values for N,N,O,O-BODIPY 
1.93 and N,N,O,C-BODIPY 2.18 matched the trend observed in our experimental measurement of the 
glum values of 2.18 and 1.93. This validates the accuracy of the computational method, and thus we 
continued with our analysis of the theoretically derived values of m, µ and τ. 
Comparison of the calculated electric (µ) transition dipole moments for N,N,O,C-BODIPY 2.18 and 
N,N,O,O-BODIPY 1.93 confirmed the presence of increased charge-transfer in the excited state of 
N,N,O,C-BODIPY 2.18, since a smaller value for µ was calculated. This indicates that the introduction 
of charge-transfer character would increase |glum|. However any potential increase in glum, which 
might have arisen from the reduced |µ|, was offset by a reduced |m| and an unfavourable change in 
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the angle (τ) between these two vectors (from 65° in N,N,O,O-BODIPY 1.93 to 70° in N,N,O,C-BODIPY 
2.18). 
Interestingly we observed from these calculations that m aligns with the helical axis, whilst µ aligns 
with the π system in both N,N,O,C-BODIPY 2.18 and N,N,O,O-BODIPY 1.93 (figure 2.14). This is also the 
observed orientation of m and µ in the carbo[n]helicenes series.144 This observation leads us to believe 
that it may be possible to control the relative directions of m and µ by controlling the helical pitch and 
the extent of the π-conjugation of the BODIPY. 
 
Figure 2.14: Electronic (red) and magnetic (blue) transition dipole moments for N,N,O,C-BODIPY 2.18 
(left) and N,N,O,O-BODIPY 1.93 (right). 
We have concluded that the introduction of charge-transfer character does decrease |µ|, however 
we must also attempt to control |m| and the angle τ. We have also validated the use of computational 
modelling to predict glum values. Based on predictive models (given by Dr Thomas Penfold), we 
identified some new strategies to increase glum: 
▪ Inclusion of sulfur, in order to increase |m| (chapter 3) 
▪ Inclusion of 3,5-dinapthyl rings, in order to increase the helical pitch (resulting in a favourable 
angle between m and µ, i.e. τ ≈ 0° or 180°, chapter 4). 
2.2.5 Mechanistic investigation and new synthetic strategy 
N,N,O,C-BODIPY 2.18 is the first reported CPL-active ‘tetradentate’ N,N,O,C-BODIPY system (section 
2.1.3), and as such represents a new structural class of CPL-active BODIPYs. We were therefore 
interested in studying analogues of N,N,O,C-BODIPY 2.18 to further understand both their synthetic 
chemistry and their chiroptical properties. N,N,O,C-BODIPY 2.18 was initially formed as a minor 
product of the Suzuki-Miyaura cross-coupling between 3,5-dibromo-BODIPY 2.11 and 2-
hydroxyphenyl boronic acid (scheme 2.12). Our highest isolated yield of N,N,O,C-BODIPY 2.18 was 
36%, but this does not reflect the typical obtained yields of 2.18. Attempts to repeat the synthesis of 
N,N,O,C-BODIPY 2.18 resulted in much lower obtained yields, ranging from 2%-9% over 7 experiments 
with a mean of 6% (±3%). 




Scheme 2.12: Reagents and conditions: (i) 2-hydroxyphenyl boronic acid (4 eq.), Pd(PPh3)4 (5 mol %), 
Na2CO3, toluene, 1,4-dioxane, 90 °C, 1 h 20 min (43% 2.13, average of 7% 2.18). 
This capricious synthesis limited our investigations into this new class of CPL-active BODIPYs. We 
therefore sought to better understand how N,N,O,C-BODIPY 2.18 was formed under the reaction 
conditions, in order to improve the isolated yield of 2.18 and the accessibility of this class of BODIPYs. 
Our first challenge was to carry out some initial mechanistic investigation, which was performed in 
collaboration with Jake Weatherston. We proposed that there were two possible reaction pathways 
to N,N,O,C-BODIPY 2.18 (route A and route B, scheme 2.13). 
Route A involves the boron metathesis of the BF2 group with the boron of the 2-hydroxyphenylboronic 
acid (step A1), followed by an intramolecular SNAr between the phenolic hydroxyl and the 3-bromo 
substituent (step A2). Then a Suzuki-Miyaura cross-coupling with 2-hydroxyphenyl boronic acid would 
install the 3-phenolic ring (step A3), and finally B-O bond formation between the free phenolic 
hydroxyl group and the chelating boron atom (step A4) would produce N,N,O,C-BODIPY 2.18. 
Route B first involves a Suzuki-Miyaura cross-coupling with 2-hydroxyphenyl boronic acid (step B1), 
followed by B-O bond formation between the phenolic hydroxyl group and the boron atom (step B2). 
This is followed by boron metathesis of the BF2 moiety with the 2-hydroxyphenyl boronic acid (step 
B3) and finally an intramolecular SNAr between the free phenolic hydroxyl and the 3-bromo 
substituent (step B4) to form N,N,O,C-BODIPY 2.18. 




Scheme 2.13: Two proposed routes A and B to N,N,O,C-BODIPY 2.18, showing the different step 
order possibilities. 
We first wanted to investigate the synthetic pathway taken to form N,N,O,C-BODIPY 2.18 (ie. route A 
or route B). We reasoned that if N,N,O,C-BODIPY 2.18 is formed via route A, excluding palladium from 
the reaction might result in the formation of the intermediate BODIPY 2.27. However experiments 
carried out in the absence of a palladium catalyst (entry 2, table 2.4) did not form either N,N,O,O-
BODIPY 2.13, N,N,O,C-BODIPY 2.18 or any intermediate compounds 2.26-2.31. This suggested to us 
that N,N,O,C-BODIPY 2.18 is formed via a palladium catalysed pathway. 
We therefore wished to investigate the role of palladium(0)/palladium(II) in a possible boron 
metathesis (step A1 or B3, scheme 2.13), involving the exchange of the BF2 moiety with the boron on 
the incoming arylboronic acid. Examples in the literature of the spontaneous chelation of 
dipyrromethenes by boronic acids101,102,104,145 led us to examine instead precedent for the loss of BF2 
from BODIPY dyes. 
There are examples in the literature of BF2 removal from BODIPYs using Brønsted acids (for example, 
trifluoroacetic acid146,147 and methanolic hydrogen chloride147), and ligand exchange at boron is known 
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to be mediated by Lewis acids (for example, aluminium trichloride,17,148,149 trimethylsilyl 
trifluoromethanesulfonate,150 trimethylsilylchloride,95,151 tin tetrachloride,152 and boron 
tribromide146). We concluded that trace amounts of Lewis acidic palladium(II) could be formed by air 
oxidation, and subsequently mediate the loss of BF2 from 3,5-dibromo-BODIPY 2.11. 
We therefore reacted together 3,5-dibromo-BODIPY 2.11, 2-hydroxyphenyl boronic acid and 
Pd(PPh3)4 (5 mol%) in the presence of air, to allow for oxidation by air of palladium(0) to palladium(II) 
(entry 3, table 2.4). We also tested the use of a palladium(II) catalyst, Pd(OAc)2 (entry 4, table 2.4). 
These experiments resulted in a lower isolated yield of both BODIPYs, but gratifyingly, we observed a 
change in selectivity from N,N,O,O-BODIPY 2.13 to N,N,O,C-BODIPY 2.18. 
 
Scheme 2.14: Reagents and conditions: (i) 2-hydroxyphenyl boronic acid (4 eq.), Pd catalyst (5 mol 
%), Na2CO3, toluene, 1,4-dioxane, 90 °C. 
 Catalyst Yield of 2.13 /% Yield of 2.18 /% 
Ratio 
2.13:2.18 
1 Pd(PPh3)4 34 14 2.4 : 1 
2[a] - 0 0 - 
3[b] Pd(PPh3)4 9 16 1 : 1.7 
4 Pd(OAc)2 3 39 1 :13 
Table 2.4: Isolated yields of 2.13 and 2.18 from test reactions intended to probe the mechanism of 
the formation of 2.18. [a]Reaction performed without palladium catalyst. [b]Reaction performed in the 
presence of air. 
The change in selectivity from N,N,O,O-BODIPY 2.13 to N,N,O,C-BODIPY 2.18 upon using a 
palladium(II) catalyst suggested that Lewis acidic palladium(II) is aiding in the removal of the BF2 
moiety, improving the rate of the boron metathesis step (step A1 or B3, scheme 2.13). We reasoned 
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that by starting from dipyrromethene 2.10, which does not contain a BF2 moiety, we should further 
improve the synthesis of N,N,O,C-BODIPY 2.18. 
Indeed when we reacted dipyrromethene 2.10 together with 2-hydroxyphenyl boronic acid in the 
presence of Pd(OAc)2 (5 mol%), we observed the selective formation of N,N,O,C-BODIPY 2.18. 
However the yield was sub-optimal, owing to the poorer activity of palladium(II) catalysts in Suzuki-
Miyaura cross-couplings. By reverting to the palladium(0) catalyst Pd(PPh3)4 (5 mol%), we were able 
to selectively synthesise N,N,O,C-BODIPY 2.18 in a high yield of 85%. 
 
Scheme 2.15: Reagents and conditions: (i) 2-hydroxyphenyl boronic acid (4 eq.), Pd catalyst (5 mol 
%), Na2CO3, toluene, 1,4-dioxane, 90 °C. 
 Catalyst Yield of 2.18 /% 
1 Pd(OAc)2 22 
2 Pd(PPh3)4 85 
Table 2.5: Isolated yields of 2.18 from our optimised synthetic pathway. 
This new synthetic strategy offers high yields and selectivity for N,N,O,C-BODIPY 2.18, which was 
previously isolated as a minor product in capricious yields. Furthermore we have also reduced the 
number of synthetic steps taken to N,N,O,C-BODIPY 2.18 by one step. This work represents the first 
key step in investigating this class of CPL-active BODIPY dyes. 
2.3. Expansion of the N,N,O,C-BODIPY series 
2.3.1 Testing the substrate scope 
If improving the synthesis of N,N,O,C-BODIPY 2.18 was the first step in investigating the N,N,O,C-
BODIPYs, the second step is the expansion of the N,N,O,C-BODIPY series. We planned to do this by 
applying our new synthetic strategy to a range of substrates. We therefore selected a range of 
commercially available aryl boronic acids which contained a 2-hydroxy functional group. 
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We chose an electron poor (entry 5, table 2.6) and an electron rich (entry 3, table 2.6) boronic acid, to 
examine the effect electronics might have on the reaction. We also chose an example which we 
anticipated would be sterically challenging, due to a 3-methyl substituent close to the 2-hydroxy 
functional group (entry 2, table 2.6). Finally we selected 5-chloro-2-hydroxyphenyl boronic acid, as the 
chloride functional group could be used as a handle for further functionalisation. 
 
Scheme 2.16: Reagents and conditions: (i) Pd(PPh3)4 (5 mol %), boronic acid (4 eq.), Na2CO3, 
toluene:1,4-dioxane 1:1, 90 °C. 




1 H H 2.18 1 85 
2 H Me 2.32 18 38 
3 Me H 2.33 1 55 
4 Cl H 2.34 1 71 
5 F H 2.35 1 73 
Table 2.6: Results of testing the substrate scope. 
We found that all of the boronic acids tested successfully formed the corresponding N,N,O,C-BODIPYs 
2.32-2.35 under our reaction conditions. After some reaction optimisation, we found that for all but 
the most sterically hindered system (entry 2, table 2.6), the best yield was obtained after 1 hour. For 
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2.3.1.1 X-ray crystallography of N,N,O,C-BODIPY 2.33 
In order to unambiguously determine the structure of N,N,O,C-BODIPY 2.33, we performed 
crystallisation of (rac)-2.33 by slow diffusion from a chloroform solution. This afforded single crystals 
suitable for single-crystal X-ray analysis. Analysis of the crystal structure (figure 2.15) allowed us first 
to confirm the structure of N,N,O,C-BODIPY 2.33. Furthermore we measured a twist angle of 8.2° 
between the two pyrrolic rings of N,N,O,C-BODIPY 2.33. Comparison of the twist angle observed in 
the crystal structure of N,N,O,C-BODIPY 2.33 (8.2°) with that observed in N,N,O,C-BODIPY 2.18 (7.7°) 
revealed that the aryl methyl groups impart a higher degree of chiral perturbation to the planar 
BODIPY core. We look to grow single crystals suitable for X-ray analysis of the remaining N,N,O,C-
BODIPYs 2.32, 2.34 and 2.35 in the future, in order to assess the effect of the twist angle has on the 
glum of N,N,O,C-BODIPYs. 
 
Figure 2.15: Two views of a molecule in the crystal structure of (rac)-2.33: (a) illustrating the 
asymmetry in the fluorophore core (H atoms are omitted for clarity, M-isomer is shown); (b) the 
twist in the planar BODIPY core (H atoms and meso-aryl ring are omitted for clarity, M-isomer is 
shown). 
2.3.2 Synthesis of ‘mixed’ N,N,O,C-BODIPYs 2.38 and 2.39 
It occurred to us that it would be interesting to examine the chiroptical properties of ‘mixed’ N,N,O,C-
BODIPYs (ie. containing two rings derived from different boronic acids). We considered that an 
electron deficient arylboronic acid may undergo chelation with dipyrromethene 2.10 faster than an 
electron rich arylboronic acid. We therefore selected the most electron rich (2.37) and the most 
electron deficient (2.36) arylboronic acids from our series to examine any selectivity present in the 
step involving the chelation of dipyrromethene 2.10 by the boronic acid. 
Initial experiments using two equivalents of 2-hydroxy-5-fluorophenyl boronic acid (2.36) and two 
equivalents of 2-hydroxy-5-methylphenyl boronic acid (2.37) revealed that there were four products 
formed under the reaction conditions. Separation of these four products was challenging using silica 
(a) (b) 
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gel column chromatography, due to mixed column fractions. However we were able to isolate a small, 
impure sample of each product. 
Two of the products were shown to be N,N,O,C-BODIPYs 2.33 and 2.35 by comparison of the 1H and 
19F NMR spectra of the impure samples (obtained from the reaction between 2-hydroxy-5-
fluorophenyl boronic acid, 2-hydroxy-5-methylphenyl boronic acid and dipyrromethene 2.10) with the 
previously obtained NMR data for N,N,O,C-BODIPYs 2.33 and 2.35. 
We assigned the remaining two products as ‘mixed’ N,N,O,C-BODIPYs 2.38 and 2.39. We confirmed 
the synthesis of ‘mixed’ N,N,O,C-BODIPYs 2.38 and 2.39 through analysis of the 1H NMR and 19F NMR 
spectra of the remaining impure samples obtained from the reaction between 2-hydroxy-5-
fluorophenyl boronic acid, 2-hydroxy-5-methylphenyl boronic acid and dipyrromethene 2.10. In each 
set of spectra (1H NMR and 19F NMR) for ‘mixed’ N,N,O,C-BODIPYs 2.38 and 2.39 we observed one 
singlet peak in the 19F NMR spectra and one singlet peak corresponding to the methyl group of the 3- 
or 5- aryl ring in the 1H NMR spectra. 
 
Scheme 2.17: Reagents and conditions: (i) Pd(PPh3)4 (5 mol %), Na2CO3, toluene:1,4-dioxane (1:1),  
90 °C, 1 h. 
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2.3.2.1 Structural assignment of N,N,O,C-BODIPY 2.35 
Due to the structural similarity between ‘mixed’ N,N,O,C-BODIPYs 2.38 and 2.39, we could not 
confidently assign the impure samples obtained from the reaction between boronic acids 2.36 and 
2.37 and dipyrromethene 2.10 as either 2.38 or 2.39. We therefore elected to perform HMQC (13C-
19F) HMBC (1H-13C, multiple bond correlation), and ROESY NMR experiments on N,N,O,C-BODIPY 2.35, 
in order to assign the 19F NMR signals corresponding to the fluorine substituents (performed by 
Professor William McFarlane, see Appendix). We then planned to assign the structures of N,N,O,C-
BODIPYs 2.38 and 2.39 through comparison of the 19F NMR spectra of N,N,O,C-BODIPY 2.35 and the 
19F NMR spectra of the impure samples of N,N,O,C-BODIPYs 2.38 and 2.39. 
Through our analysis of the ROESY NMR spectra of N,N,O,C-BODIPY 2.35, we observed a correlation 
from a doublet signal at 6.84 ppm to a double doublet signal at 7.42 ppm. No correlation was observed 
from the doublet signal at 6.44 ppm to any aryl protons. We therefore assigned these protons as H20 
(6.84 ppm), H23 (7.42 ppm) and H10 (6.44 ppm) (figure 2.16). Analysis of the 13C-19F HMQC showed a 
correlation from the fluorine singlet at -117.0 ppm to a carbon signal at 156.8 ppm, and a second 
correlation from the fluorine singlet at -123.1 ppm to a carbon signal at 159.3 ppm. Finally analysis of 
the 1H-13C HMBC spectrum showed a correlation between the carbon signal at 156.8 ppm to the 
proton H23 (7.42 ppm). We therefore concluded that the signal in the 19F NMR spectrum at -123.1 ppm 
corresponded to F28, and that H23 and F28 resided within the directly C-C linked aryl ring. We can 
conclude that F29 resides within the indirectly C-O-C linked aryl ring. 
  
Figure 2.16: 1H and 19F assignment of key atoms of N,N,O,C-BODIPY 2.35, showing key ROESY (red), 
13C-19F HMQC (green) and HMBC (blue) correlations. 
Further confirmation of this assignment was found by performing 1H-{19F} NMR spectra of N,N,O,C-
BODIPY 2.35 (performed by Professor William McFarlane). We observed that when the spectra was 
irradiated at -123.005 ppm the signal at 7.42 ppm corresponding to H23 was now a doublet, instead of 
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a double doublet (figure 2.17). Furthermore, when the spectra was irradiated at -117.935 ppm the 
signal at 7.42 ppm remained a double doublet. We were therefore confident in our assignment of the 
fluorine signals of N,N,O,C-BODIPY 2.35. 
 
Figure 2.17: 1H-{19F} NMR spectra of N,N,O,C-BODIPY 2.35 showing the signal corresponding to H23 
decoupled at -123.005 ppm (top, blue), -117.935 ppm (middle, green) and the 1H NMR spectrum of 
N,N,O,C-BODIPY 2.35 (bottom, red). 
Once we had confidently assigned the 19F NMR spectrum of N,N,O,C-BODIPY 2.35, we were able to 
assign the impure samples obtained from the reaction between boronic acids 2.36 and 2.37 and 
dipyrromethene 2.10 as N,N,O,C-BODIPYs 2.39 and 2.38 respectively by retention time on silica gel. 
Once we had completed the assignment of N,N,O,C-BODIPYs 2.38 and 2.39, we decided to examine 
the reaction conditions used to synthesise N,N,O,C-BODIPYs 2.38 and 2.39 to see if we could improve 
the selectivity for either N,N,O,C-BODIPY. 
2.3.2.2 Examination of the reaction conditions to synthesise ‘mixed’ N,N,O,C-BODIPYs 
We tested how changing the ratio of boronic acids 2.36, 2.37 and dipyrromethane 2.10 affected which 
N,N,O,C-BODIPYs were formed under the reaction conditions. Since the ‘mixed’ N,N,O,C-BODIPYs 2.38 
and 2.39 have both an aryl methyl group and a fluorine in their structure, we were able to estimate 
the yields of each product N,N,O,C-BODIPY by analysis of the crude 19F and 1H NMR spectra (table 2.7). 




Scheme 2.18: Reagents and conditions: (i) Pd(PPh3)4 (5 mol %), Na2CO3, toluene:1,4-dioxane (1:1), 90 





2.33 2.38 2.39 2.35 
1:1:1 
Product ratio[a] 1 1.6 1.2 1.5 
Yield /% 15 25 18 23 
2:2:1 
Product ratio[a] 1 1.5 1.1 1.2 
Yield /% 14 22 16 18 
1.5:1.5:1 
Product ratio[a] 1 1.2 1.2 1.2 
Yield /% 15 17 17 17 
2:1:1 
Product ratio[a] 1 0.8 0.5 0.26 
Yield /% 20 16 10 5 
1:2:1 
Product ratio[a] 1 3.8 2.2 4.6 
Yield /% 4 14 8 17 
Table 2.7: Results from the mixed experiments, including ratios of boronic acids 2.36, 2.37 and starting 
material 2.10 used. [a]Ratio of products determined by 19F and 1H NMR. 
The outcomes of these experiments suggest that the selective synthesis of N,N,O,C-BODIPY 2.38 or 
2.39 is not possible using our synthetic strategy. However we did observe that when the molar ratio 
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of boronic acids 2.36:2.37 is equal, N,N,O,C-BODIPY 2.38 is formed in the highest proportion. This 
indicates that the boron chelation step occurs faster with an electron deficient boronic acid. In order 
to achieve the selective synthesis of a ‘mixed’ N,N,O,C-BODIPY such as N,N,O,C-BODIPY 2.38, we 
suggest that a more electron deficient boronic acid should be used. 
With our series of N,N,O,C-BODIPYs in hand, we turned our attention to the resolution of the 
enantiomers of each N,N,O,C-BODIPY, in order to investigate the chiroptical properties of the series. 
2.3.3 Resolution of the enantiomers of N,N,O,C-BODIPYs 2.32-2.35 
Resolution of the racemic mixtures of N,N,O,C-BODIPYs 2.32-2.35 was performed by semi-preparative 
chiral HPLC (table 2.8). After combining multiple runs, we were able to isolate approximately 20 µg of 
each enantiomer of N,N,O,C-BODIPYs 2.32-2.35. We then assigned the enantiomers of the N,N,O,C-
BODIPYs as (+)-2.32-2.35 and (-)-2.32-2.35 by measuring the specific optical rotation ([α]D). 
The enantiomeric excess (ee) of the isolated enantiomers was then assessed by resubmitting them to 
the chiral HPLC conditions. Once we confirmed that we had isolated enantiopure (%ee = >95%) 
samples, we then turned our attention to the measurement of the chiroptical properties of the series. 
 Column / Conditions 
Retention time / min 
(+)-X (-)-X 
2.32 
Daicel Chiralpak® IA / 85:15 
Hexane : DCM, 1 mL/min 
14.95 17.36 
2.33 
Daicel Chiralpak® IA / 
Toluene, 1 mL/min 
5.51 3.77 
2.34 
Daicel Chiralpak® IA / 80 : 20 
Toluene : Hexane, 1 mL/min 
5.82 4.46 
2.35 
Daicel Chiralpak® OD-H / 95 : 
5 Hexane : IPA, 1 mL/min 
18.07 21.19 
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2.3.4 Chiroptical properties of the series 
2.3.4.1 ECD spectroscopy of N,N,O,C-BODIPYs 2.32-2.35 
With our set of single enantiomers of N,N,O,C-BODIPYs 2.32-2.35 in hand, our next step was to 
measure ECD spectra (performed by Jonathan Bogaerts). As previously discussed (section 2.2.2), we 
would expect to observe equal and opposite (or ‘mirror image’) ECD spectra for each pair of 
enantiomers. 
As we had anticipated, mirror image ECD spectra were obtained for each set of enantiomers (figures 
2.18a-2.21a). The ECD spectra of each enantiomer of N,N,O,O-BODIPYs 2.32-2.35 showed strong 
Cotton effects corresponding to the S0-S1 transition of each N,N,O,O-BODIPY 2.32-2.35 (table 2.9). 
Once we had recorded the experimental ECD spectra, we looked to assign each enantiomer as either 
(P) or (M) through a comparison of experimental to calculated ECD spectra. 
Therefore Boltzmann-weighted ECD spectra were obtained from TD-DFT calculations at the cam-
B3LYP/6-311++G(3df,2pd) level for the (P) enantiomer of each N,N,O,C-BODIPY ((b), blue, figures 2.18-
2.21, calculations performed by Jonathan Bogaerts). By comparison of the calculated ECD spectra and 
the experimental ECD spectra, we were able to assign the (P) and (M) isomers of N,N,O,C-BODIPYs 
2.32-2.35 (figures 2.18c-2.21c). Our next step was to measure the CPL spectra of each enantiomer and 
assess the glum values across the series. 
 
Figure 2.18: (a) Experimental ECD spectra (red – (M)-2.32, blue – (P)-2.32) and UV/Vis absorption 
spectrum (black) measured in DCM; (b) Calculated Boltzmann-weighted spectra, ECD (blue – 
postulated (P)-2.32 (wavelength uncorrected) and UV/Vis absorption spectra (black – postulated (P)-
2.32 (wavelength uncorrected); c) (P)-2.32 and (M)-2.32. 




Figure 2.19: (a) Experimental ECD spectra (red – (M)-2.33, blue – (P)-2.33) and UV/Vis absorption 
spectrum (black) measured in DCM; (b) Calculated Boltzmann-weighted spectra, ECD (blue – 
postulated (P)-2.33 (wavelength uncorrected) and UV/Vis absorption spectra (black – postulated (P)-
2.33 (wavelength uncorrected); c) (P)-2.33 and (M)-2.33. 
 
Figure 2.20: (a) Experimental ECD spectra (red – (M)-2.34, blue – (P)-2.34) and UV/Vis absorption 
spectrum (black) measured in DCM; (b) Calculated Boltzmann-weighted spectra, ECD (blue – 
postulated (P)-2.34 (wavelength uncorrected) and UV/Vis absorption spectra (black – postulated (P)-
2.34 (wavelength uncorrected); c) (P)-2.34 and (M)-2.34. 




Figure 2.21: (a) Experimental ECD spectra (red – (M)-2.35, blue – (P)-2.35) and UV/Vis absorption 
spectrum (black) measured in DCM; (b) Calculated Boltzmann-weighted spectra, ECD (blue – 
postulated (P)-2.35 (wavelength uncorrected) and UV/Vis absorption spectra (black – postulated (P)-
2.35 (wavelength uncorrected); c) (P)-2.35 and (M)-2.35. 
 Solvent λabs /nm ε /mol-1 cm-1 |gabs| Δεmax / L mol-1cm-1 
2.18 hexane 593 30 000 3.1×10-3 ±92 
2.32 DCM 590 24 000 3.2×10-3 ±80 
2.33 DCM 594 39 000 3.4×10-3 ±133 
2.34 DCM 586 52 000 2.9×10-3 ±142 
2.35 DCM 585 32 000 2.8×10-3 ±87 
Table 2.9: Photophysical and chiroptical data for N,N,O,C-BODIPYs 2.18 and 2.32-2.35. 
2.3.4.2 CPL spectroscopy of N,N,O,C-BODIPYs 2.32-2.35 
Lastly CPL spectra of the (P) and (M) enantiomers of N,N,O,C-BODIPYs 2.32-2.35 were obtained (figure 
2.22). Mirror image CPL spectra were obtained for all four BODIPYs, with glum values ranging between 
2.1-2.6×10-3 (table 2.10). 




Figure 2.22: (a) Normalised CPL (IL-IR) (red – (M)-2.32, blue – (P)-2.32 and fluorescence spectra (black 
– (rac)-2.32) measured in DCM; (b) Normalised CPL (IL-IR) (red – (M)-2.33, blue – (P)-2.33 and 
fluorescence spectra (black – (rac)-2.33) measured in DCM; (c) Normalised CPL (IL-IR) (red – (M)-2.34, 
blue – (P)-2.34 and fluorescence spectra (black – (rac)-2.34) measured in DCM; (d) Normalised CPL 
(IL-IR) (red – (M)-2.35, blue – (P)-2.35 and fluorescence spectra (black – (rac)-2.35) measured in DCM. 
Interestingly it can be observed in this series of dyes that if one enantiomer absorbs circularly polarised 
light with a particular handedness, then it also emits light with the same handedness. In the case of 
all of the helically chiral BODIPY dyes which have been hitherto reported, including N,N,O,C-BODIPYs 
2.18 and 2.32-2.35,8,84 the P-isomer both absorbs and emits mostly left handed circularly polarised 
light. 
An improved |glum| value from that observed from N,N,O,C-BODIPY 2.18 was not found among the 
four derivatives 2.32-2.35. However the glum values obtained are typical when compared to the glum 
values usually observed from CPL-SOMs. Additionally the glum values obtained for N,N,O,C-BODIPYs 
2.18 and 2.32-2.35 are consistent across the series, which suggests that modifications to the 3,5-aryl 
rings can be made without detriment to the CPL capability of the dye. This opens up the possibility of 
maintaining a predictable CPL output, while introducing functionality to the system. 
 
 











φF |glum| |gabs| |glum|/|gabs| (|glum|·φF) 
2.18 hexane 593 ±92 622 0.49 3.7×10-3 3.1×10-3 1.19 1.8×10-3 
2.32 DCM 590 ±80 633 0.41 2.3×10-3 3.2×10-3 0.72 9.4×10-4 
2.33 DCM 594 ±133 637 0.25 2.6×10-3 3.4×10-3 0.76 6.5×10-4 
2.34 DCM 586 ±142 622 0.37 2.1×10-3 2.9×10-3 0.72 7.8×10-4 
2.35 DCM 585 ±87 623 0.43 2.2×10-3 2.8×10-3 0.79 9.46×10-4 
Table 2.10: Photophysical and chiroptical properties of N,N,O,C-BODIPYs 2.18 and 2.32-2.35. 
2.3.4.3 Assessing the correlation between gabs and glum for the N,N,O,C-BODIPY series 
As discussed in section 2.1.1.3 Mori et al.134 have assessed the relationship between gabs and glum for 
a range of CPL-SOMs, including BODIPYs. It was found that for rigid BODIPY systems, a good linear 
correlation was observed (|glum| = 1.02×|gabs| (r2=0.90)). Since one of our chapter aims was to 
corroborate this observation, we correlated the glum and gabs values recorded for our N,N,O,C-BODIPY 
series (in red, figure 2.23) along with the rigid CPL-active BODIPYs studied by Mori et al. (in black, 
figure 2.23). 
 
Figure 2.23: Correlation between gabs and glum for the rigid CPL-active BODIPYs studied by Mori 
(black) and the N,N,O,C-BODIPYs 2.18 and 2.32-2.35 (red). 
We found that the good linear correlation between glum and gabs was maintained (|glum| = 1.18×|gabs| 
(r2=0.80)) when we included our new N,N,O,C-BODIPY systems. Although we observe a decrease in 
the r2 value of the trend line (r2 = 0.80 vs. 0.90), we can still consider this to be a good linear correlation.  
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2.4 Conclusions and Future work 
In this chapter we aimed to synthesise new chiral BODIPYs according to two main design principles: a 
chirally perturbed BODIPY core (section 2.1.1.1), and a rigidified structure (section 2.1.1.3). We have 
considered these design principles in the examination of new chiral BODIPYs for use as CPL-SOMs. 
The serendipitous discovery of N,N,O,C-BODIPY 2.18 has led to the identification of a new class of 
helically chiral BODIPYs, the N,N,O,C-BODIPYs. Chiroptical characterisation of N,N,O,C-BODIPY 2.18, 
including the measurement of CPL (glum = 3.7×10-3) confirmed that N,N,O,C-BODIPY 2.18 is a CPL-active 
BODIPY. Furthermore comparison of our experimental glum values and those obtained through 
computational modelling has allowed us to validate a computational method for the prediction of glum. 
By establishing the validity of computational modelling, we have gained valuable insight into the 
design of CPL-active BODIPYs. 
Through a mechanistic investigation into the synthesis of N,N,O,C-BODIPY 2.18 we have designed and 
validated a new, reliable synthetic route to the N,N,O,C-BODIPYs. Subsequently, we have expanded 
the N,N,O,C-BODIPY series and have completed the chiroptical characterisation of all N,N,O,C-BODIPYs 
2.32-2.35. 
We have thus shown that it is possible to include additional functionality into the 3,5-aryl rings of 
N,N,O,C-BODIPYs, without detriment to CPL emission. This opens up the possibility of creating more 
complex BODIPY systems based upon the N,N,O,C-BODIPY architecture, in order to synthesise highly 
functionalised CPL-active BODIPYs. 
The validation of computational modelling to predict glum has promising applications to the future 
design of CPL-active BODIPYs. So far we have identified two possible strategies to increase the glum of 
these helically chiral BODIPY systems. The first of which is the inclusion of sulfur atoms (chapter 3), 
and the second is the extension of the BODIPY π-system to increase the helical pitch (chapter 4). 




Chapter 3. Investigation of Sulfur Atom Inclusion on CPL Activity 
3.1 Introduction 
3.1.1 Effect of sulfur atom inclusion on glum 
In this chapter, we will discuss our investigations into synthetic methodologies to introduce sulfur 
atoms to chiral BODIPY systems. We will then assess the effect of sulfur atom inclusion on CPL 
emission. 
As discussed in section 2.2.4.1, we can control the |glum| of a CPL-SOM by controlling the magnitudes 
of the magnetic (|m|) and electric (|µ|) dipole moments. The equation which relates glum to m and µ 
is as follows: 
𝑔𝑙𝑢𝑚 =
4(𝝁 ∙ 𝒎 ∙ 𝑐𝑜𝑠𝜏)
(𝝁2 + 𝒎2)
 
In small organic molecules µ is typically several orders of magnitude larger than m, resulting in low 
glum values. In order to achieve a maximum glum value, we would look to increase |m| or decrease |µ| 
in order to result in more similar magnitudes for these vectors. In chapter 2 we examined the effect 
of increased charge-transfer character in the excited state on the |glum| of N,N,O,C-BODIPY 2.18. 
Although the increased charge-transfer character did result in a reduced |µ| as we had hoped, we 
found that a detrimental change in the angle τ resulted in a slight overall decrease in |glum|. We 
therefore looked to examine an alternative strategy to increase |glum|. 
We thought that instead of attempting to decrease |µ|, we could instead attempt to increase |m| to 
result in a higher |glum|. The equation which describes the magnetic transition dipole moment is as 
follows: 
𝝐 ∙ 𝒅𝑖𝑓 =
1
2𝑚𝑒𝑐
𝒃 ∙ ⟨𝑖|𝑳 + 2𝑺|𝑓⟩ 
Where the term ϵ is the unity vector and dif is the dipole matrix, together these terms describe the 
magnetic (m) dipole moment vector. Furthermore me is the mass of an electron, c is the speed of light, 
b is the polarisation direction of the magnetic component and S is the electron spin. Pertinently the 
term L represents the orbital angular momentum. Thus we can conclude that if we increase the orbital 
angular momentum (L), we can increase |m|. 
Chiral lanthanide complexes have been shown to be efficient emitters of CPL,5,6,153 with typically high 
glum values (≤1.38).7,154 The success of chiral lanthanide complexes as CPL-emitters arises from the 
involvement of f-orbital character in their optical transitions. This f-orbital character results in higher 




orbital angular momentum, which in turn increases |m|. Small organic molecules typically only have 
p-orbital character in their optical transitions, which results in lower orbital angular momentum and 
thus small |m|. 
Sulfur has been shown to increase angular momentum,155 due to the increased d-orbital character 
imparted by sulfur atoms. One strategy to achieve this increase in |m| was identified by 
computational modelling (performed by Dr Thomas Penfold). Thus N,N,S,S-BODIPY 3.1 was proposed 
as a sulfur containing, helically chiral BODIPY with an increased glum. Preliminary computational 
modelling of N,N,S,S-BODIPY 3.1 gave a predicted gum value of 9×10-3. 
 
Figure 3.1: N,N,S,S-BODIPY 3.1. 
3.1.2 Chapter Aims 
Thus our aim for this chapter is the synthesis of N,N,S,S-BODIPY 3.1, in order to examine the effect of 
sulfur atom inclusion on glum. 
We considered an approach towards N,N,S,S-BODIPY 3.1 which involves a late-stage Suzuki coupling 
between the intermediate 3,5-dibromo-BODIPY 2.11 and (2-(methylthio)phenyl)boronic acid. The 
resulting 3,5-diaryl-BODIPY 3.2 will then undergo a double demethylation reaction and in situ 
intramolecular double B-S bond formation to form the target N,N,S,S-BODIPY 3.1. 
 
Scheme 3.1: First planned approach towards N,N,S,S-BODIPY 3.1. 




3.2 Results and Discussion 
3.2.1 Synthesis of N,N,S,S-BODIPY 3.1 via a late-stage Suzuki-Miyaura coupling approach 
3.2.1.1 Synthesis of 3,5-diaryl-BODIPY 3.2 
Our first step was the synthesis of the intermediate 3,5-dibromo-BODIPY 2.11. To do this, we followed 
the same procedure described in section 2.1.2.2. For the next step, we planned to use a Suzuki-
Miyaura cross-coupling between 3,5-dibromo-BODIPY 2.11 and 2-(methylthio)phenyl boronic acid to 
synthesise 3,5-diaryl-BODIPY 3.2. 
Thus we performed a Suzuki-Miyaura cross-coupling between 3,5-dibromo-BODIPY 2.11 and 2-
(methylthio)phenyl boronic acid, catalysed by Pd(PPh3)4 (5 mol%). Following purification by silica gel 
chromatography, we were able to isolate 3,5-diaryl-BODIPY 3.2 in a good yield of 63%. We confirmed 
the formation of 3,5-diaryl-BODIPY 3.2 by analysis of the 1H NMR spectrum, which showed a signal 
corresponding to the hydrogens of the thiomethyl groups (δH 2.39 ppm, s, 6H) and signals 
corresponding to the pyrrolic hydrogens (δH 6.84 ppm, d, 2H, J = 4.3 Hz; 6.64 ppm, d, 2H, J = 4.3 Hz). 
 
Scheme 3.2: Reagents and conditions: (i) 2-(methylthio)phenyl boronic acid (4 eq.), Pd(PPh3)4 (5 
mol%), Na2CO3, toluene, 1,4-dioxane, 90 °C, 18 h (63%). 
3.2.1.2 Examination of the double demethylation reaction of 3,5-diaryl-BODIPY 3.2 
Our next planned step in our synthetic pathway was the double demethylation of 3,5-diaryl-BODIPY 
3.2 and in situ intramolecular double B-S bond formation, resulting in the formation of N,N,S,S-BODIPY 
3.1. To achieve this, we planned to use boron tribromide at low temperatures.84 
Therefore we reacted 3,5-diaryl-BODIPY 3.2 with boron tribromide at 0 °C. After 80 minutes, we 
observed the appearance of a new compound by TLC analysis. Purification of the crude reaction 
mixture by silica gel chromatography was challenging, due to poor solubility. Despite this challenging 
purification, we were able to analyse the 11B NMR and 1H NMR spectra of the impure product. 
Examination of the 1H NMR spectrum suggested the loss of one methyl group of one of the thiol 
moieties (δH 2.30 ppm, s, 3H), however the 11B NMR spectrum showed that boron had been lost during 
the course of the reaction. We thought that the demethylation was failing due to the boron tribromide 




preferentially mediating the loss of BF2 from 3,5-diaryl-BODIPY 3.2 instead of mediating the loss of the 
methyl groups of the thiol moieties.156 We decided to first remove the BF2 moiety from 3,5-diaryl-
BODIPY 3.2, and then repeat the demethylation procedure. 
 
Scheme 3.3: Reagents and conditions: (i) BBr3 (10 eq.), DCM, 0 °C, 1h. 
We elected to use a BODIPY deprotection strategy described by Sánchez et al., which involves the use 
of a Lewis acid (trifluoroacetic acid) to mediate the loss of BF2 from the BODIPY core.146 Therefore we 
dissolved 3,5-diaryl-BODIPY 3.2 in a solution of DCM:methanol:trifluoroacetic acid (90:5:5). Simple 
purification by removal of the reaction solvents under reduced pressure led to the isolation of 
dipyrromethene 3.3 in an almost quantitative yield (99%). Analysis of the 11B NMR spectrum confirmed 
that we had successfully removed the BF2 moiety. Thus we were then able to attempt the double 
demethylation of dipyrromethene 3.3. 
 
Scheme 3.4: Reagents and conditions: (i) DCM:MeOH:TFA (90:5:5), R.T., 1 h (99%). 
In our first attempt at the double demethylation of dipyrromethene 3.3, we added boron tribromide 
to a solution of dipyrromethene 3.3 at 0 °C and then allowed the reaction mixture to reach room 
temperature before work-up (entry 1, table 3.1). Analysis of the crude 1H NMR spectrum showed that 
we had retained the methyl groups of the thiol moieties (δH 2.31 ppm, s, 6H), and had instead lost the 
methyl group of the methyl ester (δH 3.98 ppm, s, 3H). Extending the reaction time (entry 2, table 3.1) 
and increasing the reaction temperature (entry 3, table 3.1) did not result in the loss of the methyl 
groups of the thiol moieties, and again the methyl group of the methyl ester was removed. 




We decided to examine the use of an alternative source of boron tribromide. Therefore we repeated 
the demethylation procedure using boron tribromide dimethyl sulfide. Our first attempt at this 
transformation resulted in the recovery of starting material dipyrromethene 3.3, and increasing the 











BBr3 (1 M in 
hexane, 10 eq.) 
DCM 1 0 °C to R.T. 
loss of methyl group from 
methyl ester 
2 
BBr3 (1 M in 
hexane, 10 eq.)) 
DCM 24 0 °C to R.T. 
loss of methyl group from 
methyl ester 
3 
BBr3 (1 M in 
DCM, 10 eq.)) 
CHCl3 2 reflux 
loss of methyl group from 
methyl ester 
4 
BBr3SMe2 (1 M 
in DCM, 10 eq.)) 
DCM 21 R.T. 
starting material 
dipyrromethene 3.3 recovered 
5 
BBr3SMe2 (1 M 
in DCM, 10 eq.)) 
CHCl3 19 reflux 
loss of methyl group from 
methyl ester 
Table 3.1: Examination of the reaction conditions to achieve the double demethylation of 
dipyrromethene 3.3, reaction outcomes determined by analysis of the crude 1H NMR spectra. 
Given the difficulties we encountered in our attempts to remove the methyl groups of the thiol 
moieties of 3,5-diaryl-BODIPY 3.2 and dipyrromethene 3.3, we decided instead to examine a second 
approach towards N,N,S,S-BODIPY 3.1. 
3.2.2 Synthesis of N,N,S,S-BODIPY 3.1 via a prefunctionalisation route 
3.2.2.1 Planned second approach towards the synthesis of N,N,S,S-BODIPY 3.1 
The second approach we examined to synthesise N,N,S,S-BODIPY 3.1 involves a pre-functionalisation 
strategy, whereby the pyrrole moiety is functionalised prior to the formation of the BODIPY 
architecture. We planned to use a Suzuki-Miyaura cross-coupling reaction to introduce the desired 




functionality to the pyrrole. However thiols are known to poison palladium catalysts157,158 thus 
requiring the use of more than stoichiometric amounts of catalyst. 
We therefore planned to protect the sulfur of 2-bromothiophenol prior to the Suzuki-Miyaura cross-
coupling reaction (step A, scheme 3.5).159 The resulting protected benzenethiol 3.4 will then be used 
in a Suzuki-Miyaura cross-coupling reaction with N-Boc-2-pyrroleboronic acid to produce Boc-
protected 2-arylpyrrole 3.5 (step B).160 A subsequent Boc deprotection (step C) allows for the next 
step, in which a condensation reaction between 2-arylpyrrole 3.6 and methyl 4-formylbenzoate is 
followed immediately by oxidation in a one-pot procedure to form dipyrromethene 3.7 (step D). A 
sulfur double deprotection (step E) and subsequent boron chelation (step F) would then form the 
target N,N,S,S-BODIPY 3.1. 
 
Scheme 3.5: Second planned approach towards N,N,S,S-BODIPY 3.1. 
3.2.2.2 Synthesis of MOM-protected dipyrromethene 3.7a 
The first step in our second approach to N,N,S,S-BODIPY 3.1 is the protection of the sulfur atom of 2-
bromothiophenol. Protection of the sulfur moiety is required at this stage to allow for the subsequent 
Suzuki-Miyaura coupling to produce the desired 2-arylpyrrole. 
We chose to use a methoxymethyl ether (MOM) protecting group, which are typically removed using 
acidic conditions. Since we were not planning to use strongly acidic conditions for any of our 
subsequent synthetic steps, we concluded that a MOM protecting group is compatible with our 
planned synthetic route. Additionally Yamamoto et al. have shown that the MOM protected ortho-
bromobenzenethiols undergo Sonogashira cross-couplings,159 so we reasoned that we would observe 




good reaction compatibility between this protecting group and our planned Suzuki-Miyaura cross-
coupling reaction. 
Therefore 2-bromothiophenol was reacted with methoxymethyl chloride in the presence of a suitable 
base (scheme 3.6). Disappearance of the starting material and the appearance of a new compound by 
TLC analysis indicated that the reaction was complete. Purification of the crude reaction mixture by 
silica gel chromatography allowed us to isolate benzenethiol 3.4a in a quantitative yield. The 
successful protection of 2-bromothiophenol was confirmed by the appearance of two singlets in the 
1H NMR spectrum corresponding to the methoxymethyl moiety (δH 5.02 ppm, s, 2H; 3.45 ppm, s, 3H). 
 
Scheme 3.6: Reagents and conditions: (i) NaOtBu (1 eq.), MOMCl (1.1 eq.), THF, R.T., 30 minutes 
(quant.). 
The next step in our synthetic pathway involved a Suzuki-Miyaura cross-coupling between 
benzenethiol 3.4a and N-Boc-2-pyrroleboronic acid. Thus a Suzuki-Miyaura cross-coupling reaction 
between benzenethiol 3.4a and N-Boc-2-pyrroleboronic acid (catalysed by Pd(PPh3)4, 5 mol%), was 
followed by silica gel chromatography to give Boc-protected 2-arylpyrrole 3.5a in a good yield of 77%. 
We confirmed the formation of 3.5a by analysis of the FT-IR spectrum, which showed a peak at 1736 
cm-1 corresponding to the C=O bond of the Boc protecting group. 
 
Scheme 3.7: Reagents and conditions: (i) N-Boc-2-pyrroleboronic acid (1.5 eq.), Pd(PPh3)4 (5 mol%), 
K3PO4, THF, H2O, 75 °C, 24 h (77%). 
In order to successfully form the dipyrromethene 3.7a, we must first remove the sterically demanding 
Boc group. Thus next step we examined in our synthetic pathway was the Boc deprotection of 2-
arylpyrrole 3.5a. 
The removal of the Boc protecting group was performed following a thermolytic deprotection 
procedure.161 The advantage of this method are that there is no solvent, acid or base required. 




We heated a round bottomed flask containing Boc-protected 2-arylpyrrole 3.5a to 200 °C for 30 
minutes. Examination of the FT-IR spectrum of the crude product showed that the peak at 1736 cm-1 
corresponding to the C=O bond of the Boc protecting group was no longer present, confirming the 
successful deprotection of Boc-protected 2-arylpyrrole 3.5a. Analysis of the crude 1H NMR spectrum 
showed that Boc-deprotected 2-arylpyrrole 3.6a had been formed in sufficient purity to continue with 
the next step in our synthetic pathway without further purification. 
 
Scheme 3.8: Reagents and conditions: (i) 200 °C, 30 minutes. 
Once we had synthesised 2-arylpyrrole 3.6a, the next step we wished to examine was the one-pot 
condensation/oxidation procedure to form dipyrromethene 3.7a. We opted to use a trifluoroacetic 
acid (TFA) catalysed condensation procedure, followed immediately by oxidation with p-chloranil. 
We therefore reacted the 2-arylpyrrole 3.6a together with methyl 4-formylbenzoate in the presence 
of a catalytic amount of TFA. After the disappearance of methyl 4-formylbenzoate was observed by 
TLC analysis, we added a solution of p-chloranil in DCM and saw an instant colour change. We were 
concerned that the oxidant (p-chloranil) may oxidise the sulfide groups to the corresponding 
sulfoxides or sulfones, so we left the reaction mixture to stir for only ten minutes after the addition of 
p-chloranil. The appearance of a new compound by TLC analysis indicated that we had formed 
dipyrromethene 3.7a. After work up, dipyrromethene 3.7a was isolated in an exceptional 87 % yield, 
and examination of the 1H NMR spectrum indicated that 3.7a did not require further purification. We 
confirmed the structure of dipyrromethene 3.7a by the observation of signals in the 1H NMR spectrum 
corresponding to the aryl methyl ester (δH 3.99 ppm, s, 3H) and signals corresponding to the MOM 
protecting groups (δH 4.80 ppm, s, 4H; 3.23 ppm, s, 6H). 





Scheme 3.9: Reagents and conditions: (i) methyl 4-formylbenzoate, TFA (cat.), DCM, R.T., 3.5 h; (ii) p-
chloranil (1 eq.), R.T., 10 minutes (87%). 
Once we had successfully synthesised dipyrromethene 3.7a, we turned our attention to the MOM 
deprotection of the sulfide functional groups and subsequent chelation of boron, to form N,N,S,S-
BODIPY 3.1. 
3.2.2.3 Attempts towards the MOM deprotection of dipyrromethene 3.7a 
MOM protecting groups are typically removed under acidic conditions. Therefore the first MOM 
deprotection approach we examined involved the treatment of dipyrromethene 3.7a with acid. 
Following an adapted literature procedure,162 we treated dipyrromethene 3.7a with a solution of 
hydrochloric acid in methanol (generated by the slow addition of acetyl chloride to anhydrous 
methanol at 0 °C). However after 24 hours there was no indication by TLC analysis that any new 
products had been formed. Analysis of the crude 1H NMR spectrum showed that we had recovered 
starting material dipyrromethene 3.7a. We therefore looked to examine an alternative deprotection 
strategy. 
 
Scheme 3.10: Reagents and conditions: (i) HCl (1 M in MeOH), DCM, R.T., 24 h. 
The second MOM deprotection strategy we examined was the treatment of dipyrromethene 3.7a with 
boron trichloride.163 We treated dipyrromethene 3.7a with boron trichloride at room temperature and 
after 5 minutes, the disappearance of starting material and the appearance of a new compound by 
TLC suggested that the reaction was complete. However upon analysis of the crude 1H NMR spectrum 




we observed signals corresponding to the MOM protecting group (δH 4.76 ppm, s, 4H; 2.16 ppm, s, 
6H). Since we had limited amounts of dipyrromethene 3.7a, we decided to attempt optimisation of 
this procedure on the benzenethiol 3.4a. 
 
Scheme 3.11: Reagents and conditions: (i) BCl3, DCM, R.T., 5 minutes. 
Treatment of benzenethiol 3.4a with boron trichloride at room temperature did not result in the 
formation of 2-bromothiophenol. Analysis of the crude 1H NMR spectrum revealed that the peak 
corresponding to the methyl group of the MOM protecting group was no longer visible, indicating the 
loss of this methyl group. However the peak corresponding to the hydrogens of the methylene moiety 
were still visible (δH 5.00 ppm, s, 2H). Given the difficulties we encountered in our attempts towards 
this MOM deprotection, we decided to repeat this synthetic route using an alternative protecting 
group for 2-bromothiophenol. 
 
Scheme 3.12: Reagents and conditions: (i) BCl3, DCM, R.T., 80 minutes. 
3.2.2.4 Synthesis of TMSE-protected dipyrromethene 3.7b 
The second sulfur protecting group that we considered was ethyltrimethylsilane (TMSE). This 
protecting group can be removed using a fluoride source, for example tetra-N-butylammonium 
fluoride (TBAF).164,165 The only step in our planned synthetic pathway which might generate a fluoride 
source is the boron chelation step, at which stage we would expect to have already performed the 
TMSE deprotection. Thus we considered TMSE to be an appropriate protecting group for this 
approach. 
The first step we examined in this approach was the protection of the sulfur of 2-bromothiophenol. 
Therefore we performed a radical reaction between 2-bromothiophenol and vinyltrimethylsilane in 
the presence of azobisisobutyronitrile (AIBN) as the radical initiator.166 After 2.5 hours the 




disappearance of the starting material 2-bromothiophenol and the appearance of a new compound 
by TLC analysis indicated that the reaction was complete. Purification by dry column flash 
chromatography, using petrol as the eluent, allowed for the isolation of benzenethiol 3.4b in a 
quantitative yield. We confirmed the formation of the benzenethiol 3.4b by analysis of the 1H NMR 
spectrum, which showed a distinctive AA’BB’ spin system arising from the ethyl moiety of the TMSE 
protecting group of 3.4b (figure 3.2). 
 
Scheme 3.13: Reagents and conditions: (i) vinyltrimethylsilane (1.2 eq.), AIBN (5 mol%), 100 °C, 2.5h 
(quant.). 
 
Figure 3.2: 1H NMR spectrum of benzenethiol 3.4b showing the AA’BB’ spin system corresponding to 
the ethyl moiety. 
The next step in our planned approach was the Suzuki-Miyaura cross-coupling reaction between 
benzenethiol 3.4b and N-Boc-2-pyrroleboronic acid. Thus following the cross-coupling reaction 
between 3.4b and N-Boc-2-pyrroleboronic acid (catalysed by Pd(PPh3)4, 5 mol %) and purification by 
silica gel chromatography, we isolated Boc- protected 2-arylpyrrole 3.5b in an excellent yield of 93%. 
We confirmed the synthesis of 3.5b through analysis of the FT-IR spectrum, which showed a peak at 
1737 cm-1 corresponding to the C=O bond of the Boc protecting group. 
 





Scheme 3.14: Reagents and conditions: (i) N-Boc-2-pyrroleboronic acid (1.5 eq.), Pd(PPh3)4 (5 mol%), 
K3PO4, THF, H2O, 75 °C, 24 h (93%). 
Using the same approach as that employed in section 3.2.2.1, we elected to remove the Boc protecting 
group by a thermolytic deprotection procedure.161 
We heated a round bottomed flask containing Boc-protected 2-arylpyrrole 3.5b to 200 °C for 30 
minutes. Examination of the FT-IR spectrum of the crude product indicated the loss of the Boc 
protecting group, due to the absence of the peak at 1737 cm-1 corresponding to the C=O bond of the 
Boc moiety. Pleasingly the 1H NMR spectrum of the crude product showed that we had formed 3.6b 
in sufficient purity to continue with the next step of our synthetic pathway without further 
purification. 
 
Scheme 3.15: Reagents and conditions: (i) 200 °C, 30 minutes. 
With our Boc-deprotected 2-arylpyrrole in hand, we next examined the one-pot 
condensation/oxidation procedure to form dipyrromethene 3.7b. 
We therefore performed a TFA-catalysed condensation reaction between 2-arylpyrrole 3.7b and 4-
methyl-4-formylbenzoate. After 30 minutes the disappearance of 4-methyl-4-formylbenzoate was 
observed by TLC analysis, and so a solution of p-chloranil in DCM was added. The appearance of a new 
compound, observed by TLC analysis, indicated that we had formed dipyrromethene 3.7b. Purification 
by silica gel chromatography gave dipyrromethene 3.7b in a good yield of 64%. We confirmed the 
structure of dipyrromethene 3.7b through the observation of a signal in the 1H NMR spectrum 
corresponding to the methyl groups of the TMSE protecting group (δH -0.01 ppm, s, 18H) and signals 
corresponding to the methyl group of the aryl methyl ester (δH 3.98 ppm, s, 3H). 





Scheme 3.16: Reagents and conditions: (i) methyl 4-formylbenzoate, TFA (cat.), DCM, R.T., 30 
minutes; (ii) p-chloranil, R.T., 10 minutes (64%). 
Once we had successfully synthesised dipyrromethene 3.7b, we turned our attention to the TMSE 
double deprotection of 3.7b. 
3.2.2.5 Attempts towards the TMSE deprotection of dipyrromethene 3.7b 
The TMSE protecting group may be removed using a fluoride source, such as tetra-N-butylammonium 
fluoride (TBAF).164,165 Due to the difficulties we had previously encountered in our attempts towards 
the MOM deprotection of dipyrromethene 3.7a, we decided to test our deprotection procedure on 
the benzenethiol 3.4b before attempting the double deprotection of dipyrromethene 3.7b. 
Therefore we treated benzenethiol 3.4b with an excess of TBAF in THF. After two hours at room 
temperature, the appearance of 2-bromothiophenol was observed by TLC analysis. Furthermore, 
examination of the crude 1H NMR spectrum suggested the formation of 2-bromothiophenol, due to 
the presence of a peak corresponding to the hydrogen of the thiol functional group (δH 4.00 ppm, s, 
1H).167 Once we had determined that our deprotection strategy should be successful, we decided to 
examine the double TMSE deprotection of dipyrromethene 3.7b. 
 
Scheme 3.17: Reagents and conditions: (i) TBAF (6.7 eq.), THF, R.T., 2 h. 
We treated dipyrromethene 3.7b with an excess of TBAF, and after 21 hours we observed the 
disappearance of starting material and the appearance of a new compound by TLC analysis. However 
we were unable to determine whether we had formed dipyrromethene 3.7b, because examination of 
the crude 1H NMR spectrum only showed peaks corresponding to TBAF. We chose to avoid silica gel 
chromatography because we thought that dipyrromethene 3.7b would chelate the trace metals in the 
silica, leading to a significant loss of product. Therefore we chose to proceed and continue with the 




next step in our synthetic pathway, and perform the boron chelation step on the crude reaction 
mixture. 
Treatment of the crude reaction mixture, arising from the attempted double TMSE deprotection step, 
using our standard boron chelation procedure resulted in a colour change. However TLC analysis 
suggested that purification by silica gel chromatography would not be workable, due to the high 
polarity of the crude reaction mixture. Analysis of the 11B NMR spectrum of the crude reaction mixture 
revealed that the only boron containing species present was residual boron triflouride diethyl 
etherate, suggesting that boron chelation had been unsuccessful. 
 
Scheme 3.18: Reagents and conditions: (i) TBAF (13.4 eq.), THF, R.T., 21 h; (ii) BF2.OEt2, NiPr2Et, DCM, 
R.T., 1h. 
We concluded that this approach was not workable. Due to our inability to confirm the loss of the 
TMSE protecting groups from 3.7b, we were unable to rationalise the unsuccessful boron chelation 
step. We suggest that this approach (i.e. the protection of 2-bromothiophenol and the successive 
steps to build dipyrromethene 3.7) is still viable, however future work would include repeating this 
synthetic pathway using an alternative sulfur protecting group. 
3.2.3 New sulfur-containing chiral BODIPY targets 
Due to the difficulties presented by the synthesis of N,N,S,S-BODIPY 3.1, we decided to re-examine 
our design of sulfur containing chiral BODIPYs. We wanted to retain the helically chiral architecture, 
along with the chirally induced twist to the planar BODIPY core. 
We envisioned three helically chiral, sulfur containing BODIPY targets: N,N,O,O-BODIPY 3.9 bearing 
3,5-dithiophenyl rings, N,N,O,F-BODIPY 3.10 bearing a 5-benzothiophene ring system and a 3-phenolic 
ring, and finally N,N,O,F-BODIPY 3.11 which contains a 5-thiophenol substituent and a 3-phenolic ring. 
All three of these targets are tri- or tetradentate dipyrromethene ligands, and so should have rigid 
structures. They should also be helically chiral, due to the inclusion of 3-aryl or 3,5-diaryl substituents 




containing a B-O bond. We therefore thought that these BODIPYs would be good examples of helically 
chiral, sulfur containing BODIPYs to examine the effect the inclusion of sulfur atoms has on glum. 
 
Figure 3.3: N,N,O,O-BODIPY 3.9, N,N,O,F-BODIPY 3.10 and N,N,O,F-BODIPY 3.11. 
3.2.4 Synthesis of N,N,O,O-BODIPY 3.9 
3.2.4.1 Planned synthetic approach towards N,N,O,O-BODIPY 3.9 
Our approach towards N,N,O,O-BODIPY 3.9 involves a late-stage Suzuki-Miyaura cross-coupling 
between 3,5-dibromo-BODIPY 2.11 and 3-methoxythiophene-2-boronic acid to form 3,5-dithiophene-
BODIPY 3.12. A subsequent double demethylation and in situ double B-O bond formation would then 
produce the target N,N,O,O-BODIPY 3.9. 
 
Scheme 3.19: Planned synthetic pathway to N,N,O,O-BODIPY 3.9. 
3.2.4.2 Synthesis of 3,5-dithiophene-BODIPY 3.12 
Our procedure for the synthesis of 3,5-dibromo-BODIPY 2.11 has been previously described in section 
2.1.2.2, and was followed without modification. Therefore the first step we attempted in the synthesis 
of N,N,O,O-BODIPY 3.9 was the Suzuki-Miyaura cross-coupling reaction between 3,5-dibromo-BODIPY 
2.11 and 3-methoxythiophene-2-boronic acid. 
We performed a Suzuki-Miyaura cross-coupling, catalysed by Pd(PPh3)4 (5 mol%), between 3,5-
dibromo-BODIPY 2.11 and 3-methoxythiophene-2-boronic acid. The disappearance of starting 
material 3,5-dibromo-BODIPY 2.11 indicated that the reaction was complete. Following purification 




by silica gel chromatography, 3,5-dithiophene-BODIPY 3.12 was isolated in an excellent yield of 84%. 
We confirmed the synthesis of 3,5-dithiophene-BODIPY 3.12 by analysis of the 1H NMR spectrum, 
which showed a pair of doublets with coupling constants consistent with a thiophene moiety (δH 7.48 
ppm, d, 2H, J = 5.6 Hz; 6.89 ppm, d, 2H, J = 5.6 Hz). 
 
Scheme 3.20: Reagents and conditions: (i) 3-methoxythiophene-2-boronic acid pinacol ester (4 eq.), 
Pd(PPh3)4 (5 mol%), Na2CO3, toluene, 1,4-dioxane, 90 °C, 23 h (84%). 
3.2.4.3 Attempts towards the double demethylation of 3,5-dithiophene-BODIPY 3.12 
Once we had completed the synthesis of 3,5-dithiophene-BODIPY 3.12, we turned our attention to 
the boron tribromide mediated double demethylation reaction of 3.12. This double demethylation 
reaction would be followed by in situ double B-O bond formation to form N,N,O,O-BODIPY 3.9. 
Therefore we treated 3,5-dithiophene-BODIPY 3.12 with boron tribromide at 0 °C. The disappearance 
of starting material 3.12 was observed by TLC analysis, which indicated that the reaction was 
complete. Examination of the crude 1H NMR spectrum indicated that the double demethylation had 
been successful, due to the absence of the peak at δH 3.94 ppm (s, 6H) corresponding to the methoxy 
functional groups. If we had formed N,N,O,O-BODIPY 3.9 we would observe a singlet in the 11B NMR 
spectrum, however examination of the crude 11B NMR spectrum showed a doublet at δB 0.98 ppm (J 
= 48.5 Hz, figure 3.4). This suggested to us that only one of the B-O bonds had been formed. We 
suggest that the substructure of this major product 3.13 contains only one B-O bond (scheme 3.21b). 
 





Scheme 3.21: (a) Reagents and conditions: (i) BBr3 (10 eq.), DCM, 0 °C to R.T.; (b) Proposed 
substructure of the major compound arising from the boron tribromide mediated double 
demethylation reaction of 3,5-dithiophene-BODIPY 3.12. 
 
Figure 3.4: 11B NMR spectrum of the crude reaction mixture arising from the boron tribromide 
mediated double demethylation reaction of 3,5-dithiophene-BODIPY 3.12. 
Purification of this major product was difficult due to its poor solubility, which prevented further 
analysis. Since this reaction had been initially performed on a small scale (0.018 mmol of starting 
material 3,5-dithiophene-BODIPY 3.12), we decided to scale up the reaction to make analysis of the 
resulting crude reaction mixtures more facile. We also decided that in future repeats of the double 
demethylation reaction, we would treat the resulting crude reaction mixture with boron triflouride 
diethyletherate in the presence of Hunig’s base. We hoped that this would encourage the second B-O 
bond formation event to occur, and thereby improve the solubility of the resulting reaction mixtures. 
We attempted the double demethylation of 3,5-dithiophene-BODIPY 3.12 multiple times at scales of 
up to 177 mg (0.32 mmol) of starting material 3.12. Unfortunately we were unable to detect N,N,O,O-
BODIPY 3.9 from any these reactions. Instead we consistently observed a doublet at δB 0.98 ppm (J = 




48.5 Hz) in the 11B NMR spectra of the crude reaction mixtures. Despite our attempts to improve the 
solubility of the crude reaction mixtures by treating them with boron triflouride diethyletherate, the 
resulting crude mixtures remained insoluble and difficult to purify. Similarly our attempts to 
encourage the formation of the second B-O bond by treatment of these reaction mixtures with tin 
tetrachloride168 did not form N,N,O,O-BODIPY 3.9. 
 
Scheme 3.22: Reagents and conditions: (i) BBr3 (10 eq.), DCM, 0 °C to R.T., (ii) BF3.OEt2, NiPrEt2, DCM, 
R.T. 
We concluded that the synthesis of N,N,O,O-BODIPY 3.9 may not be possible. We only found evidence 
that one of the required B-O bonds was formed, even after treatment with boron triflouride 
diethyletherate or treatment with tin tetrachloride. We have concluded that the proposed ring system 
might be too constrained, due to the smaller size of the thiophene rings as compared to the phenyl 
rings of N,N,O,O-BODIPY 2.13. We decided to focus instead on the synthesis of our other sulfur 
containing BODIPY targets. 
3.2.5 Synthesis of N,N,O,F-BODIPY 3.10 
3.2.5.1 Planned synthesis of N,N,O,F-BODIPY 3.10 
In order to synthesise N,N,O,F-BODIPY 3.10, we planned to use a late-stage Suzuki-Miyaura cross-
coupling reaction between 3,5-dibromo-BODIPY 2.11 and benzo[b]thiophene-2-boronic acid to form 
intermediate BODIPY 3.14. A further Suzuki-Miyaura cross-coupling reaction between BODIPY 3.14 
and 2-hydroxyphenyl boronic acid to install the phenolic ring would then be used to form N,N,O,F-
BODIPY 3.10. 





Scheme 3.23: Planned synthetic pathway to N,N,O,F-BODIPY 3.10. 
3.2.5.2 Synthesis of 3-benzo[b]thiophene-BODIPY 3.14 
Our first planned synthetic step towards N,N,O,F-BODIPY 3.10 was the Suzuki-Miyaura cross-coupling 
reaction between 3,5-dibromo-BODIPY 2.11 and benzo[b]thiophene-2-boronic acid to form the 3-
benzo[b]thiophene-BODIPY 3.14. We wanted to discourage the occurrence of the double Suzuki-
Miyaura cross-coupling reaction, which would produce 3,5-dibenzo[b]thiophene-BODIPY 3.15. We 
therefore chose to use fewer equivalents of benzo[b]thiophene-2-boronic acid than of 3,5-dibromo-
BODIPY 2.11. 
We performed a Suzuki-Miyaura cross-coupling reaction between 3,5-dibromo-BODIPY 2.11 and 0.8 
equivalents of benzo[b]thiophene-2-boronic acid, catalysed by Pd(PPh3)4 (entry 1, table 3.2). After 2 
hours we observed by TLC analysis that two new compounds had been formed. After purification by 
silica gel chromatography, we were able to isolate an impure sample of 3-benzo[b]thiophene-BODIPY 
3.14. We were able to confirm the structure of 3-benzo[b]thiophene-BODIPY 3.14 by the presence of 
peaks in the 1H NMR spectrum corresponding to one benzo[b]thiophene moiety (δH 8.56 ppm, s, 1H; 
7.99-7.93 ppm, m, 1H; 7.87-7.81 ppm, m, 1H; 7.45-7.36 ppm, m, 2H). However we also observed in 
the 1H NMR spectrum that 3-benzo[b]thiophene-BODIPY 3.14 was contaminated with a small amount 
of 3,5-dibenzo[b]thiophene-BODIPY 3.15, and with starting material 3,5-dibromo-BODIPY 2.11. 
Our approximate yield of 3-benzo[b]thiophene-BODIPY 3.14 was <5%. The low yield obtained over this 
step was due to the presence of a large amount of unreacted starting material in the crude reaction 
mixture. We decided to repeat this Suzuki-Miyaura cross-coupling reaction with an increased number 
of equivalents of benzo[b]thiophene-2-boronic acid, in order to improve the conversion of 3,5-
dibromo-BODIPY 2.11 to 3-benzo[b]thiophene-BODIPY 3.14 (table 3.2). 
In all of the crude 1H NMR spectra arising from these Suzuki-Miyaura cross-coupling reactions, we 
observed two singlet peaks at δH 8.57 ppm and δH 8.50 ppm, corresponding to the hydrogen of the 
thiophene moiety of BODIPYs 3.14 and 3.15 respectively. Thus we were able to estimate the ratio of 
3-benzo[b]thiophene-BODIPY 3.14 to 3,5-dibenzo[b]thiophene-BODIPY 3.15 through analysis of the 




1H NMR spectra of the crude reaction mixtures generated from the Suzuki-Miyaura cross-coupling 
reactions between 3,5-dibromo-BODIPY 2.11 and benzo[b]thiophene-2-boronic acid. 
 
Scheme 3.24: Reagents and conditions: (i) benzo[b]thiophene-2-boronic acid, Pd(PPh3)4 (5 mol%), 
Na2CO3, toluene, 1,4-dioxane, 90 °C. 
Entry Reaction scale /mmol 
Equivalents of boronic 
acid 
Reaction time /h 
Ratio of 
3.14:3.15[a] 
1 0.041 0.8 2 1:0.15 
2 0.10 1.2 2 1:1.04 
3 0.10 1.0 3 1:1.5 
4 0.13 1.0 2 1:0.40 
Table 3.2: Reaction conditions of the Suzuki-Miyaura cross-coupling reaction between 3,5-dibromo-
BODIPY 2.11 and benzo[b]thiophene-2-boronic acid examined. [a]Ratio of products determined by 1H 
NMR. 
After some reaction optimisation, we found that the best ratio of BODIPYs 3.14:3.15 (i.e. the highest 
ratio of the desired 3-benzo[b]thiophene-BODIPY 3.14) was attained when using 1 equivalent of 
benzo[b]thiophene-2-boronic acid and a reaction time of 2 hours. However despite multiple attempts 
to purify 3-benzo[b]thiophene-BODIPY 3.14 by silica gel chromatography, we were unable to separate 
3-benzo[b]thiophene-BODIPY 3.14 from 3,5-dibenzo[b]thiophene-BODIPY 3.15 due to mixed column 
fractions. To overcome this, we decided to continue with the second Suzuki-Miyaura cross-coupling 
reaction (with 2-hydroxyphenyl boronic acid) on a mixture of 3-benzo[b]thiophene-BODIPY 3.14 and 
3,5-dibenzo[b]thiophene-BODIPY 3.15. We postulated that the Rf of the target N,N,O,F-BODIPY 3.10 
would be sufficiently different from the Rf of 3,5-dibenzo[b]thiophene-BODIPY 3.15 to allow for 
separation by silica gel chromatography. 
3.2.5.3 Synthesis of N,N,O,F-BODIPY 3.10 
We performed a Suzuki-Miyaura cross-coupling reaction on a mixture of 3-benzo[b]thiophene-BODIPY 
3.14 and 3,5-dibenzo[b]thiophene-BODIPY 3.15, using 2-hydroxyphenyl boronic acid as the coupling 




partner. After 24 hours the disappearance of 3-benzo[b]thiophene-BODIPY 3.14 and the appearance 
of a new compound was observed by TLC analysis. Gratifyingly the Rf of the new compound was 
sufficiently different from the Rf of 3,5-dibenzo[b]thiophene-BODIPY 3.15 to allow for separation of 
these two compounds by silica gel chromatography. 
Following purification by silica gel chromatography, initial analysis of the 1H NMR spectrum of the new 
compound indicated that we had formed N,N,O,F-BODIPY 3.10. This was due to the observation of 
signals in the 1H NMR spectrum corresponding to the hydrogens of the phenolic ring (δH 7.49-7.41 
ppm, m, 2H; 7.38-7.28, m, 4H) and the absence of a broad singlet peak corresponding to a phenolic 
OH. However the observation of a triplet in the 11B NMR spectrum (δB 1.19 ppm, t, JB-F = 29.8 Hz) 
suggested to us that we had instead synthesised BODIPY 3.16. 
 
Scheme 3.25: Reagents and conditions: (i) 2-hydroxyphenyl boronic acid , Pd(PPh3)4 (5 mol%), 
Na2CO3, toluene, 1,4-dioxane, 90 °C, 24 h (17% over two steps). 
In order to encourage the B-O bond formation event to occur, we decided to treat BODIPY 3.16 with 
tin tetrachloride. Therefore we treated BODIPY 3.16 with tin tetrachloride in a solution of deuterated 
chloroform. Analysis of the resulting 11B NMR spectra revealed that there had been no change to the 
boron environment of BODIPY 3.16, as we could still observe a triplet signal (δB 1.19 ppm, t, J = 29.8 
Hz). 




Given the difficulties we encountered in our attempted synthesis of N,N,O,F-BODIPY 3.10, we decided 
to focus instead on the synthesis of our final sulfur containing chiral BODIPY, N,N,O,F-BODIPY 3.1. 
3.2.6 Synthesis of N,N,O,F-BODIPY 3.11 
3.2.6.1 Planned synthesis of N,N,O,F-BODIPY 3.11 
In order to install the thiophenol ring of our target N,N,O,F-BODIPY 3.11, we envisioned using a 
nucleophilic aromatic substitution (SNAr) reaction with thiophenol. Due to the increased reactivity of 
chloride functional groups to SNAr chemistry, we decided to first synthesise 3,5-dichloro-BODIPY 3.19. 
Our planned synthesis of 3,5-dichloro-BODIPY 3.19 involved the oxidation of dipyrromethane 2.9 to 
form dipyrromethene 3.17. Subsequent chelation of boron would then form BODIPY 3.18. In order to 
chlorinate the 3,5-positions, we then planned to use a regioselective chlorination procedure described 
by Jiao et al.169 to form 3,5-dichloro-BODIPY 3.19. 
 
Scheme 3.26: Planned synthetic pathway to 3,5-dichloro-BODIPY 3.19. 
We then planned to synthesise N,N,O,F-BODIPY 3.11 via a nucleophilic aromatic substitution reaction 
between thiophenol and 3,5-dichloro-BODIPY 3.19 to form 3-thiophenol-BODIPY 3.20. A Suzuki-
Miyaura coupling between 3-thiophenol-BODIPY 3.20 and 2-hydroxyphenyl boronic acid would then 
be used to form N,N,O,F-BODIPY 3.11. 
 
Scheme 3.27: Planned synthetic pathway to N,N,O,F-BODIPY 3.11. 
 
 




3.2.6.2 Synthesis of 3,5-dichloro-BODIPY 3.19 
The first step in the synthesis of 3,5-dichloro-BODIPY 3.19 was the synthesis of dipyrromethane 2.9. 
We synthesised dipyrromethene 2.9 according to the same procedure as described in section 2.1.2.2. 
Thus the first reaction we examined in the synthesis of 3,5-dichloro-BODIPY 3.19 was the oxidation of 
dipyrromethane 2.9. We planned to test two different oxidants, DDQ and p-chloranil, in order to 
determine which oxidant gives the cleanest conversion of dipyrromethane 2.9 to dipyrromethene 
3.17. 
Therefore we reacted dipyrromethane 2.9 together with 1.1 equivalents of DDQ for one hour. Analysis 
of the crude 1H NMR spectrum showed that dipyrromethene 3.17 was the major product from the 
oxidation, and the purity of dipyrromethene 3.17 was high (figure 3.5). We confirmed the successful 
oxidation of dipyrromethene 2.9 by the absence of a signal at δH 5.56 ppm (s, 1H) corresponding to 
the meso-proton of 2.9, which is lost during the oxidation of dipyrromethane 2.9. Signals in the 1H 
NMR spectrum of dipyrromethene 3.17 corresponding to the pyrrolic (δH 7.68 ppm, s, 2H; 6.53 ppm, 
d, 2H, J = 4.2 Hz; 6.41 ppm, d, 2H, J = 4.2 Hz) and aryl (δH 8.13 ppm, d, 2H, J = 8.4 Hz; 7.57 ppm, d, 2H, 
J = 8.4 Hz) protons further confirmed the synthesis of dipyrromethene 3.17. 
We then repeated the oxidation procedure using p-chloranil as the oxidant in DCM for 18 hours. 
Examination of the crude 1H NMR spectrum showed that dipyrromethene 3.17 was again the major 
product from the oxidation, and was formed in exceptional purity (figure 3.5). Although the reaction 
time using p-chloranil is longer, the higher purity offered by using this milder oxidising agent led us to 
use p-chloranil for all further oxidations of dipyrromethene 2.9. Owing to the exceptional purity 
offered using p-chloranil, we continued with the next step in our synthetic pathway without further 
purification of dipyrromethene 3.17. 
 
Scheme 3.28: Reagents and conditions: (i) DDQ, THF, R.T., 1 hour; or p-chloranil, DCM, R.T., 18 
hours. 





Figure 3.5: 1H NMR spectrum of a typical crude reaction mixture of the oxidation of dipyrromethane 
2.9 with DDQ (green, top) and p-chloranil (red, bottom) showing the meso-aryl and pyrrolic protons. 
The next step we examined was the boron chelation of dipyrromethene 3.17 to form BODIPY 3.18. 
We therefore treated dipyrromethene 3.17 with boron triflouride diethyl etherate in the presence of 
Hunig’s base. After purification by silica gel chromatography, using DCM as eluent, BODIPY 3.18 was 
isolated in a 41% yield over two steps. Analysis of the 11B NMR spectrum showed a triplet peak (δB 
0.25 ppm, t, J = 28.5 Hz), indicating the successful inclusion of a BF2 moiety. 
 
Scheme 3.29: Reagents and conditions: (i) BF2.OEt2, NiPr2Et, DCM, R.T., 1 hour (41% over two steps). 
The final step we examined in the synthesis of 3,5-dichloro-BODIPY 3.19 was the regioselective 
chlorination of BODIPY 3.18, following a modified procedure described by Jiao et al..169 This 
chlorination is thought to proceed through a single electron transfer (SET) from copper(II) to the 




BODIPY, which forms a radical cation. This is followed by nucleophilic attack of a chloride ion to form 
3-chloro-BODIPY. This process is then repeated on the 5-position to form 3,5-dichloro-BODIPY. 
We reacted BODIPY 3.18 together with copper(II) chloride dihydrate in acetonitrile. After one hour, 
we observed the disappearance of starting material BODIPY 3.18 by TLC analysis. However after 
purification by silica gel chromatography we isolated 3,5-dichloro-BODIPY 3.19 in a low yield (9%). This 
chlorination reaction is performed in the presence of air, which oxidises the reduced copper species 
(produced from each SET event) to the active copper(II) species. We thought that by reducing the scale 
of the reaction we would increase the surface area/volume ratio of the reaction mixture, thus allowing 
more efficient oxidation by air. We postulated that this would in turn result in an improved yield of 
3,5-dichloro-BODIPY 3.19. 
By reducing the scale of the reaction (0.31 mmol of BOIDPY 3.18) we saw a marked increase in the 
yield of 3,5-dichloro-BODIPY 3.19 from 9% to 32%. However the yields of 3,5-dichloro-BODIPY 3.19 
remained low, so we looked to further improve the chlorination. We postulated that the low yields 
were due to the poor solubility of copper(II) chloride dihydrate in acetonitrile. Therefore we chose to 
use 5 equivalents of copper(II) triflate as a more soluble source of copper(II). Additionally we added 2 
equivalents of ethanolamine, which we thought would improve the solubility of the copper(II) chloride 
dihydrate. These changes to the reaction conditions led to an improved yield of 52% of 3,5-dichloro-
BODIPY 3.19 (entry 5, table 3.3). 
 
Entry Scale / mmol of BODIPY 3.18 Reaction conditions Yield /% 
1 2.68 CuCl2.2H2O (9.8 eq.), MeCN, reflux, 1.5 h 9 
2 0.55 CuCl2.2H2O (9.8 eq.), MeCN, reflux, 1 h 8 
3 0.40 CuCl2.2H2O (9.8 eq.), MeCN, reflux, 1 h 22 
4 0.31 CuCl2.2H2O (9.8 eq.), MeCN, reflux, 1 h 32 
5 0.15 
CuOTf2 (5 eq.), CuCl2.2H2O (5 eq.), 
ethanolamine (2 eq.), MeCN, reflux, 1.5 h 
52 
Table 3.3: Reaction conditions of the regioselective chlorination of BODIPY 3.18 examined. 




With our improved reaction conditions, we were then able to isolate sufficient amounts of 3,5-
dichloro-BODIPY 3.19 to continue with the next step in our synthetic pathway. 
3.2.6.3 SNAr reaction of 3,5-dichloro-BODIPY 3.19 and thiophenol 
The next step we wished to examine in the synthesis of N,N,O,F-BODIPY 3.11 was the SNAr reaction of 
3,5-dichloro-BODIPY 3.19 and thiophenol. Adapting a procedure described by Dehaen et al.55, we 
reacted together 3,5-dichloro-BODIPY 3.19 and two equivalents of thiophenol in the presence of 
triethylamine. However upon examination of the crude 1H NMR spectrum, we discovered that the 
only product formed under the reaction conditions was 3,5-dithiophenol-BODIPY 3.21. We confirmed 
the structure of 3,5-dithiophenol-BODIPY 3.21 by the observation of two equivalent doublets in the 
1H NMR spectrum corresponding to the pyrrolic protons (6.54 ppm, d, 2H, J = 4.4 Hz; 5.88 ppm, d, 2H, 
J = 4.4 Hz). 
 
Scheme 3.30: Reagents and conditions: (i) thiophenol (2 eq.), Et3N (2 eq.), MeCN, R.T., 30 minutes 
(92%). 
Due to this unexpected result, we looked to reduce the equivalents of thiophenol used to minimise 
the formation of 3,5-dithiophenol-BODIPY 3.21 and thereby isolate 3-thiophenol-BODIPY 3.20. 
We therefore repeated the SNAr reaction between 3,5-dichloro-BODIPY 3.19 and thiophenol, using 
fewer equivalents of thiophenol and a lower reaction temperature. Analysis of the crude reaction 
mixture by TLC indicated that starting material 3,5-dichloro-BODIPY 3.19, 3,5-thiophenol-BODIPY 3.21 
and a third compound were present. 




Analysis of the crude 1H NMR spectrum confirmed that there were at least three BODIPY species 
present, owing to the observation of three signals corresponding to at least three aryl methyl groups 
(figure 3.6). Comparison of the crude 1H NMR spectrum and the 1H NMR spectra of 3,5-dichloro-
BODIPY 3.19 and of 3,5-dithiophenol BODIPY 3.21 confirmed that these two BODIPYs were present in 
the crude reaction mixture. 
 
Figure 3.6: 1H NMR spectra of 3,5-dichloro-BODIPY 3.19 (top, blue), a typical crude reaction mixture 
arising from the SNAr reaction between 3,5-dichloro-BODIPY 3.19 and thiophenol (green, middle) 
and 3,5-dithiophenol BODIPY 3.21 (red, bottom), showing the signals corresponding to the methyl 
groups of the aryl methyl esters. 
We concluded that the third compound, which is the major product, is therefore 3-thiophenol BODIPY 
3.21. This hypothesis was supported by the observation of a set of signals in the crude 1H NMR 
spectrum corresponding to two inequivalent C-2,5-substituted pyrrolic moieties (δH 6.65 ppm, d, 1H, 
J = 4.7 Hz; 6.60 ppm, d, 1H, J = 4.4 Hz; 6.34 ppm, d, 1H, J = 4.4 Hz; 5.89 ppm, d, 1H, J = 4.7 Hz). 
Separation of 3,5-dichloro-BODIPY 3.19, 3,5- and 3-thiophenol-BODIPYs 3.20 and 3.21 by silica gel 
chromatography was not possible, due to mixed column fractions. Consequently we looked to 




optimise the reaction further to minimise the formation of 3,5-dithiophenol-BODIPY 3.21 whilst 
maximising the conversion from 3,5-dichloro-BODIPY 3.19 to 3-thiophenol-BODIPY 3.20. 
Reducing the number of equivalents of thiophenol and the reaction temperature led to a decrease in 
the amount of 3,5-dithiophenol-BODIPY 3.21 generated. However these changes to the reaction 
conditions led to an increase in the amount of starting material 3,5-dichloro-BODIPY 3.19 present in 











Ratio of BODIPYs 
3.19:3.20:3.21[a] 
1 MeCN 2 R.T. 30 0:0:1 
2 MeCN 1.1 0 ° - R.T. 20 0.5:1:0.2 
3 MeCN 1.2 0 ° - R.T. 300 0.3:1:0.3 
4 MeCN 1.8 0 ° - R.T. 120 0.1:1:0.3 
5 THF 0.99 -78 °C 180 0.1:1:0.2 
6 THF 1 -78 °C 120 1:1:0 
7 THF 1 -90 °C 120 1:0:0 
8 THF 0.99 -110 °C 120 0.8:1:0 
Table 3.4: Reaction conditions of the SNAr reaction between 3,5-dichloro-BODIPY 3.19 and 
thiophenol examined. [a]Ratios determined by 1H NMR. 
Due to the challenging separation of 3,5-dichloro-BODIPY 3.19, 3,5-dithiophenol-BODIPY 3.21 and 3-
thiophenol-BODIPY 3.20 by silica gel chromatography, we decided to examine instead the SNAr 
reaction between 3,5-dibromo-BODIPY 2.11 and thiophenol. We reasoned that since bromide 
functional groups have lowered reactivity towards SNAr chemistry, we may be able to control the 
addition of thiophenol to 3,5-dibromo-BODIPY 2.11 in order to selectively synthesise the brominated 
analogue of 3-thiophenol-BODIPY 3.20. 
 
 




3.2.6.4 SNAr reaction of 3,5-dibromo-BODIPY 2.11 and thiophenol 
In order to synthesise 3-thiophenol-BODIPY 3.22, we reacted 3,5-dibromo-BODIPY 2.11 together with 
two equivalents of thiophenol in the presence of triethylamine. Upon the addition of thiophenol an 
immediate colour change was observed. Analysis of the TLC of the crude reaction mixture indicated 
the presence of starting material 3,5-dibromo-BODIPY 2.11 and two new compounds. 
Comparison of the crude 1H NMR spectrum with those of 3,5-dithiophenol-BODIPY 3.21 and 3,5-
dibromo-BODIPY 2.11 confirmed that these species were present in the crude reaction mixture, due 
to the presence of signals corresponding to their corresponding aryl methyl groups (figure 3.7). We 
concluded that 3-thiophenol-BODIPY 3.22 was also present as a minor compound, due to the presence 
of a set of signals corresponding to two inequivalent C-2,5-substituted pyrrolic moieties in the crude 
1H NMR spectrum (δH 6.66 ppm, d, 1H, J = 4.5 Hz; 6.55 ppm, m; 6.45 ppm, d, 1H, J = 3.9 Hz; 5.90 ppm, 
d, 1H, J = 3.9 Hz). 
 
Figure 3.7: 1H NMR spectra of 3,5-dibromo-BODIPY 2.11 (top, blue), a typical crude reaction mixture 
arising from the SNAr reaction between 3,5-dibromo-BODIPY 2.11 and thiophenol (green, middle) 
and 3,5-dithiophenol BODIPY 3.21 (red, bottom), showing the signals corresponding to the methyl 
groups of the aryl methyl esters. 




Separation of these three BODIPYs by silica gel chromatography was challenging, so we looked to 
optimise the reaction to minimise the formation of 3,5-dithiophenol-BODIPY 3.21 (table 3.5). However 
we found that decreasing the reaction temperature and using a lower number of equivalents of 
thiophenol did not improve the ratio of BODIPYs 2.11:3.22:3.21. We concluded that the selective 













1 2 1 R.T. 120 2:1:2 
2 1 0.5 R.T. 15 3:1:2 
3 1 0.5 0 °C 25 8:1:5 
Table 3.5: Reaction conditions for the SNAr reaction between 3,5-dibromo-BODIPY 2.11 and 
thiophenol examined. [a]Ratio determined by analysis of the crude 1H NMR spectra. 
We decided to examine the use of a thiophenol derivative. We thought that by using a thiophenol 
derivative with an electron withdrawing group, the resulting mixture of BODIPYs would be sufficiently 
different in polarity to allow for purification by silica gel chromatography. 
3.2.7 Synthesis of N,N,O,F-BODIPY 3.23 
We chose the thiophenol derivative 4-(trifluoromethyl)thiophenol, due to its strongly electron 
withdrawing group. Our new sulfur-containing BODIPY target was therefore N,N,O,F-BODIPY 3.23. 
We elected to use 3,5-dibromo-BODIPY 2.11 in our attempts towards the synthesis of the new target 
N,N,O,F-BODIPY 3.23. This was due to the low overall yield to 3,5-dichloro-BODIPY 3.19 (19% over four 
steps) as compared to the overall yield to 3,5-dibromo-BODIPY 2.11 (66% over three steps). Combined 
with the poor scalability of the regioselective chlorination step, we were unable to produce sufficient 
amounts of 3,5-dichloro-BODIPY 3.19 to complete the synthesis of N,N,O,F-BODIPY 3.23. 





Figure 3.6: N,N,O,F-BODIPY 3.23. 
3.2.7.1 SNAr reaction of 3,5-dibromo-BODIPY 2.11 and 4-(trifluoromethyl)thiophenol 
The first step we examined in the synthesis of N,N,O,F-BODIPY 3.23 was the SNAr reaction between 4-
(trifluoromethyl)thiophenol and 3,5-dibromo-BODIPY 2.11. 
We therefore reacted 3,5-dibromo-BODIPY 2.11 together with 4-(trifluoromethyl)thiophenol (1 
equivalent) at -78 °C. After 90 minutes, the presence of starting material 3,5-dibromo-BODIPY 2.11 
and the formation of two new compounds was observed by TLC analysis. Comparison of the crude 1H 
NMR spectrum and the 1H NMR spectrum of 3,5-dibromo-BODIPY 2.11 confirmed that starting 
material 2.11 was present in the crude reaction mixture. We postulated that the remaining two 
compounds were 3-thiophenol-BODIPY 3.24 and 3,5-dithiophenol-BODIPY 3.25. 
Gratifyingly the three compounds formed during the SNAr reaction between 3,5-dibromo-BODIPY 2.11 
and 4-(trifluoromethyl)thiophenol had polarities which were sufficiently different to allow for 
purification by silica gel chromatography. Thus we were able to isolate 3-thiophenol-BODIPY 3.24 in a 
43% yield following purification by silica gel chromatography. We confirmed the structure of 3-
thiophenol-BODIPY 3.24 by the observation of four doublet signals in the 1H NMR spectrum 
corresponding to two inequivalent C-2,5 substituted pyrrolic moieties (δH 6.71 ppm, d, 1H, J = 4.6 Hz; 
6.62 ppm, d, 1H, J = 4.2 Hz; 6.49 ppm, d, 1H, J = 4.2 Hz; 5.98 ppm, d, 1H, J = 4.6 Hz). 
 
Scheme 3.31: Reagents and conditions: (i) 4-(trifluoromethyl)thiophenol (1 eq.), Et3N (0.5 eq.), THF,  
-78 °C, 90 minutes (3.24 43%). 




Comparison of the 1H NMR spectra of 3,5-dibromo-BODIPY 2.11, 3-thiophenol-BODIPY 3.24 and of the 
crude reaction mixture allowed us to assign the third compound present in the crude reaction mixture. 
The presence of two doublet signals corresponding to two equivalent C-2,5 substituted pyrrolic 
moieties in the crude 1H NMR spectrum indicated the formation of 3,5-dithiophenol-BODIPY 3.25. 
 
 
Figure 3.8: a) 1H NMR spectra of a typical crude reaction mixture arising from the SNAr reaction 
between 3,5-dibromo-BODIPY 2.11 and 4-(trifluoromethyl)-thiophenol (red, top), 3-thiophenol 
BODIPY 3.24 (green, middle), and 3,5-dibromo-BODIPY 2.11 (bottom, blue), showing the signals 
corresponding to the pyrrolic hydrogens; b) 3,5-dibromo-BODIPY 2.11, 3-thiophenol BODIPY 3.24 
and 3,5-dithiophenol-BODIPY 3.25. 
(a) 
(b) 




Once we had synthesised sufficient amounts of 3-thiophenol-BODIPY 3.24, we were then able to 
continue with the next step in our synthetic pathway. 
3.2.7.2 Synthesis of N,N,O,F-BODIPY 3.23 
The next step in our synthesis of N,N,O,F-BODIPY 3.23 was the Suzuki-Miyaura cross-coupling reaction 
between 3-thiophenol-BODIPY 3.24 and 2-hydroxyphenyl boronic acid, followed by a subsequent in 
situ B-O bond formation to form N,N,O,F-BODIPY 3.23. 
We therefore performed a Suzuki-Miyaura cross-coupling reaction between 3-thiophenol-BODIPY 
3.24 and 2-hydroxyphenyl boronic acid. After 20 minutes the formation of two new compounds was 
observed by TLC analysis of the crude reaction mixture. Interestingly analysis of the crude 1H NMR 
spectrum showed that the major compound arising from this Suzuki-Miyaura cross-coupling reaction 
was 3,5-dithiophenol-BODIPY 3.25 (figure 3.9). 
 
Figure 3.9: 1H NMR spectra of 3,5-dithiophenol-BODIPY 3.25 (top, green) and of the crude reaction 
mixture arising from the Suzuki-Miyaura cross-coupling reaction between 3-thiophenol-BODIPY 3.24 
and 2-hydroxyphenyl boronic acid (red, bottom), showing peaks corresponding to the pyrrolic and 
aryl hydrogens. 




Despite this unexpected result, we continued with purification of the crude reaction mixture in order 
to elucidate the structure of the second compound formed under the reaction conditions. Following 
purification by silica gel chromatography, we isolated BODIPY 3.26 (20% yield) arising from the 
successful Suzuki-Miyaura cross-coupling reaction between 3-thiophenol-BODIPY 3.24 and 2-
hydroxyphenyl boronic acid. However the isolation of BODIPY 3.26 indicated that the in situ B-O bond 
formation step had not taken place. The appearance of a broad singlet in the 1H NMR spectrum 
corresponding to the hydrogen of the phenolic moiety (δH 5.74 ppm, br s, 1H) and the observation of 
a triplet signal in the 11B NMR spectrum (δB 0.97 ppm, t, JB-F = 32.0 Hz) corresponding to a BF2 moiety 
confirmed that the B-O bond formation step had not occurred. 
 
Scheme 3.32: Reagents and conditions: (i) 2-hydroxyphenyl boronic acid, Pd(PPh3)4 (5 mol%), 
Na2CO3, toluene, 1,4-dioxane, 90 °C, 20 minutes (20% 3.26). 
We decided to submit BODIPY 3.26 to our standard chelation conditions, in order to encourage the B-
O bond formation step to occur. We treated BODIPY 3.26 with boron trifluoride diethyl etherate in 
the presence of Hunig’s base, and after 75 minutes the formation of a new compound was observed 
by TLC analysis. Following purification by silica gel chromatography, we isolated N,N,O,F-BODIPY 3.23 
(15% yield). We confirmed that we had successfully formed the B-O bond between the oxygen atom 
of the phenolic moiety and the central boron atom by the observation of a doublet signal in the 11B 
NMR spectrum (δB 0.18 ppm, d, JB-F = 46.5 Hz). 





Scheme 3.33: Reagents and conditions: (i) BF3.OEt2, NiPr2Et, DCM, R.T., 75 minutes (15%). 
We have identified a successful route to our one of our target sulfur-containing BODIPYs, N,N,O,F-
BODIPY 3.23. In order to study the chiroptical properties of N,N,O,F-BODIPY 3.23 including possible 
CPL emission, we first needed to resolve the racemic mixture of N,N,O,F-BODIPY 3.23 into its 
respective enantiomers. 
3.2.8 Resolution of the enantiomers of N,N,O,F-BODIPY 3.23 and measurement of CPL 
emission 
3.2.8.1 Resolution of the enantiomers of N,N,O,F-BODIPY 3.23 
To perform the resolution of the enantiomers of N,N,O,F-BODIPY 3.23, we performed semi-
preparative chiral HPLC on a racemic mixture of N,N,O,F-BODIPY 3.23 using a Daicel Chiralpak® IA 
column (1 mL/minute, toluene). After combining multiple runs, we were able to obtain approximately 
20 µg of each enantiomer. We assigned the enantiomers as (-)-3.23 and (+)-3.23 respectively by 
retention time and by measuring the specific optical rotation ([α]D). 
 
Figure 3.10: A typical chiral HPLC trace of a racemic sample of 3.23. Daicel Chiralpak® IA column, 4.6 
x 250 mm, 5μm particle size, toluene, 1 mL/min. 




After separation of the enantiomers of N,N,O,F-BODIPY 3.23, the enantiomeric excess (ee) of each 
enantiomer was measured by resubmitting the enantiomers to the chiral HPLC conditions ((+)-3.23 
%ee = >95%, (-)-3.23 %ee = >95%). Once we were satisfied that we had isolated enantiopure samples 
of each enantiomer of N,N,O,F-BODIPY 3.23, we focused on the measurement of the CPL spectra of 
the enantiomers of N,N,O,F-BODIPY 3.23. 
3.2.8.2 Measurement of CPL emission of N,N,O,F-BODIPY 3.23 
Our next step was to measure the CPL spectra of the enantiomers of N,N,O,F-BODIPY 3.23 (performed 
by Dr Lewis Mackenzie). However we did not observe an appreciable CPL signal from either 
enantiomer (+)-3.23 or (-)-3.23 at the emission maxima (λ = 635 nm) of (rac)-3.23 (figure 3.11). 
 
Figure 3.11: CPL data (IL-IR) for (+)-3.23 (green) and (-)-3.23 (purple), and fluorescence spectra of 
(rac)-3.23 (black) measured in DCM. 
As discussed in section 2.1.1.1, Gossauer et al. have proposed that chiral BODIPY dyes must contain a 
twisted planar core in order to produce a CPL output.129 We suggest that the tridentate 
dipyrromethene ligand of N,N,O,F-BODIPY 3.23 does not induce a sufficiently pronounced twist to the 
planar core. This results in the lack of an appreciable CPL signal from the enantiomers of N,N,O,F-
BODIPY 3.23, and thus limits our investigations on the effect sulfur atom inclusion has on glum. 
3.3 Conclusions and Future Work 
We have successfully synthesised one of our target sulfur-containing chiral BODIPYs, N,N,O,F-BODIPY 
3.23. We were also able to successfully resolve (rac)-3.23 into its respective enantiomers, however 




there was no observable CPL emission from either enantiomer. We suggest that this is because the 
tridentate dipyrromethene ligand structure is not sufficient to induce a significant chiral twist to the 
planar BODIPY core. We therefore propose that the presence of a chirally perturbed core structure 
has a larger impact on CPL emission than the inclusion of sulfur atoms.  
 
Figure 3.12: N,N,O,F-BODIPY 3.23. 
However we still would like to investigate the effect of sulfur atom inclusion on CPL emission, by 
synthesising a sulfur-containing, C2-symmetric BODIPY such as N,N,S,S-BODIPY 3.1. We have made 
significant progress towards the synthesis of N,N,S,S-BODIPY 3.1 in that we have synthesised two 
dipyrromethene precursors, dipyrromethene 3.7a and 3.7b. However we were unable to isolate and 
characterise the sulfur-deprotected dipyrromethene 3.8 or N,N,S,S-BODIPY 3.1.  
 
Figure 3.13: Sulfur-protected dipyrromethenes 3.7a and 3.7b, sulfur-deprotected dipyrromethene 
3.8 and N,N,S,S-BODIPY 3.1. 
In the future we would like to revisit the synthetic pathway taken to dipyrromethenes 3.7a and 3.7b 
using an alternative sulfur protecting group. One such approach would involve the formation of a 
thioester, which can be removed by hydrolysis under basic conditions.170 




Chapter 4. Modulation of the Helical Pitch of N,N,O,O-BODIPYs 
4.1 Introduction 
In this chapter we will discuss our investigations into the effect modulation of the helical pitch of 
N,N,O,O-BODIPYs has on the direction of the magnetic dipole moment (m), and thus the angle 
between the magnetic and electric dipole moments (τ). 
4.1.1 Relationship between helical pitch and the direction of the magnetic transition dipole 
moment 
As discussed in section 2.1.1.2, the theoretical equation by which the luminescence dissymmetry 
factor (glum) is defined is as follows: 
𝑔𝑙𝑢𝑚 =
4(𝝁 ∙ 𝒎 ∙ 𝑐𝑜𝑠𝜏)
(𝝁2 + 𝒎2)
 
Where m is the magnetic transition dipole moment, µ is the electric transition dipole moment, and τ 
is the angle between these two vectors. From this equation, we can conclude that the highest value 
for glum can only be obtained when τ = 0° or 180°. 
In N,N,O,O- and N,N,O,C-BODIPY architectures we observed that m aligns with the helical axis whilst 
µ aligns with the π-system (section 2.2.4.1). This is the same pattern as is observed in the 
carbo[n]helicene series. In a computational study of a series of carbo[n]helicenes conducted by Mori, 
Inoue et al., it was observed that increasing the helical pitch of a helicene through the extension of 
the π-system resulted in a reduction in the angle (τ) between the magnetic and electric transition 
dipole moments.144 For the carbo[n]helicene with the most pronounced helical pitch (CH[10], figure 
4.1) it was calculated that τ ≈ 0°, since the direction of the magnetic transition dipole moment is almost 
parallel with the direction of the electric transition dipole moment. 





Figure 4.1: The calculated electric (solid arrow) and magnetic (dotted arrow) transition dipole 
moments of the carbo[n]helicenes CH[3]-CH[10] (reproduced from the report by Mori et al.).144 
We thought that if we could mimic this effect in helically chiral N,N,O,O-BODIPYs then we could 
achieve control over the angle τ. Successful control and reduction of the angle τ (such that τ tends to 
0°), would provide a route to high glum N,N,O,O-BODIPYs. Our new design principle is therefore the 
extension of the N,N,O,O-BODIPY π-system in order to increase the helical pitch, and thus foster a 
more favourable angle (τ) between the magnetic and electric transition dipole moments. 
4.1.2 Chapter Aims 
Our aim for this chapter was to examine the synthesis of a CPL-SOM BODIPY which will incorporate 
the design principles described in section 2.1.1 (i.e. chirally perturbed BODIPY core, rigid structure) 
along with an increase in the helical pitch. In this way we hoped to encourage a more favourable angle 
between the magnetic and electric transition dipole moments (i.e. τ < 65°). 
N,N,O,O-BODIPY 1.93 contains a chirally perturbed BODIPY core, and it has been observed that 1.93 
is an efficient emitter of CPL.84 We have also observed that BODIPYs based on this architecture are 
efficient emitters of CPL, and as such we decided to use this architecture as our starting point for this 
work. We planned to achieve an increase in the helical pitch of N,N,O,O-BODIPY 1.93 by extending the 
π-system of the 3,5-diaryl substituents. We therefore designed our target N,N,O,O-BODIPY 4.1 with 
3,5-dinapth-2-olic rings (figure 4.2). 





Figure 4.2: N,N,O,O-BODIPY 1.93 and target N,N,O,O-BODIPY 4.1. 
4.1.3 Synthetic strategy towards N,N,O,O-BODIPY 4.1 
Our planned synthesis of N,N,O,O-BODIPY 4.1 is outlined in scheme 4.1. This approach first involves a 
Suzuki-Miyaura cross-coupling reaction between 1-bromonaphthalen-2-ol 4.2 and N-Boc-2-
pyrroleboronic acid to form Boc-protected 2-arylpyrrole 4.3. A subsequent Boc deprotection would 
then afford Boc-deprotected 2-arylpyrrole 4.4. Finally, we planned to use a one-pot 
condensation/oxidation/chelation procedure to synthesise N,N,O,O-BODIPY 4.1. 
 
Scheme 4.1: Planned synthetic route to N,N,O,O-BODIPY 4.1. 
4.2 Results and Discussion 
4.2.1 Synthesis of N,N,O,O-BODIPY 4.1 
The first step we examined in the synthesis of N,N,O,O-BODIPY 4.1 was the Suzuki-Miyaura cross-
coupling reaction between 1-bromonaphthalen-2-ol 4.2 and N-Boc-2-pyrroleboronic acid, catalysed 
by Pd(PPh3)4 (5 mol%), adapted from a literature procedure.171 




In our first attempt at the Suzuki-Miyaura cross-coupling between 1-bromonaphthalen-2-ol 4.2 and 
N-Boc-2-pyrroleboronic acid, we observed the appearance of two new compounds by TLC analysis of 
the crude reaction mixture. However after purification by silica gel chromatography, we discovered 
that the major product from this Suzuki-Miyaura cross-coupling reaction was not 2-arylpyrrole 4.3 as 
we had expected, but instead an unexpected compound which we will designate 4.5. 
Analysis of the 1H NMR spectrum of 4.5 showed signals corresponding to pyrrolic hydrogens (δH 7.21 
ppm, dd, 1H, J = 3.7, 1.3 Hz; 6.75 ppm, t, 1H, J = 3.7 Hz), and signals corresponding to the hydrogens 
of the napthyl moiety (δH 8.49 ppm, d, 1H, J = 8.6 Hz; 7.88 ppm, d, 1H, J = 8.1 Hz; 7.77 ppm, d, 1H, J = 
8.9 Hz; 7.55 ppm, ddd, 1H, J = 8.1, 6.9, 1.2 Hz; 7.38 ppm, d, 1H, J = 8.9 Hz). This evidence led us to 
believe that the Suzuki-Miyaura cross-coupling reaction had been successful, in that a pyrrole to 
napthyl bond had been formed. 
Analysis of the FT-IR spectrum of 4.5 showed a strong signal at 1754 cm-1, corresponding to a carbonyl 
moiety contained in either a cyclic ketone or a cyclic carbamate. This was supported by analysis of the 
13C NMR spectrum of 4.5 which showed a signal at δc 146.3 corresponding to the carbon of a carbonyl 
moiety residing in either an amide or a carbamate. Therefore we postulated that 4.5 was in fact a 
carbamate (scheme 4.2), potentially formed via a successful Suzuki-Miyaura cross-coupling between 
1-bromonaphthalen-2-ol 4.2 and N-Boc-2-pyrroleboronic acid followed by an attack from the 
naptholic OH into the carbonyl of the Boc protecting group and a loss of tert-butanol. 
This observation is supported by the previous isolation of the phenolic analogue of 4.5 by Hall et al.,84 
which was synthesised by a Suzuki-Miyaura cross-coupling reaction between N-Boc-2-bromopyrrole 
and (2-hydroxyphenyl)boronic acid en route to N,N,O,O-BODIPY 1.93. 
Further analysis of the product mixture arising from the Pd(PPh3)4 catalysed by Suzuki-Miyaura cross-
coupling between 1-bromonaphthalen-2-ol 4.2 and N-Boc-2-pyrroleboronic acid showed the presence 
of a second compound. Analysis of the 1H NMR spectrum of this second compound suggested the 
formation of the deprotected 2-arylpyrrole 4.4, due to the presence of two broadened signals in the 
1H NMR spectrum corresponding to the N-H moiety (δH 8.31 ppm, br s, 1H) and of the O-H moiety (δH 
6.04 ppm, br s, 1H). We postulated that 4.4 arises from the basic hydrolysis of 4.5 under the Suzuki-
Miyaura cross-coupling reaction conditions. It has been previously shown that similar carbamates can 
undergo clean hydrolysis under basic conditions to the desired deprotected arylpyrroles.172 





Scheme 4.2: Reagents and conditions: (i) N-Boc-2-pyrroleboronic acid (1.5 eq.), Pd(PPh3)4 (5 mol%), 
K3PO4, THF, H2O, 90 °C, 20 h (4.5 32%, 4.4 58% approx.). 
Thus we attempted to optimise the coupling for the direct production of 4.5, which we would then 
hydrolyse to cleanly produce deprotected 2-arylpyrrole 4.4. We found that by using lower reaction 
temperatures (65 °C) for the Suzuki-Miyaura cross-coupling step, we were able improve the obtained 
yield of 4.5 from 32% to 64%. Once we had sufficiently improved the yield of 4.5, we examined the 
next step in our synthetic pathway. 
 
Scheme 4.3: Reagents and conditions: (i) N-Boc-2-pyrroleboronic acid (1.5 eq.), Pd(PPh3)4 (5 mol%), 
K3PO4, THF, H2O, 65 °C, 20 h (4.5 64%). 
The next step in our synthetic pathway was the hydrolysis of 2-arylpyrrole 4.5. Following an adapted 
literature procedure,172 we reacted 2-arylpyrrole 4.5 with a large excess of sodium hydroxide in 
ethanol. After one hour at room temperature, the formation of a new product was observed by TLC 
analysis. After purification by silica gel chromatography, we isolated the desired 2-arylpyrrole 4.4 in a 
good yield (74%). 1H NMR data obtained for 2-arylpyrrole 4.4 matched previously obtained data for 
4.4. Furthermore analysis of the 13C NMR spectrum of 4.4 showed the disappearance of the signal 
corresponding to the carbonyl carbon of carbamate 4.5 (δC 146.3). 
 
Scheme 4.4: Reagents and conditions: (i) NaOH (200 eq.), EtOH, R.T., 1 h (74%). 
The final step in our synthesis was the one-pot condensation/oxidation/boron chelation procedure to 
form N,N,O,O-BODIPY 4.1.  




Following an adapted procedure from Boens et al.173 we treated a solution of 2-arylpyrrole 4.4 and 4-
methyl-4-formylbenzoate in DCM with a catalytic amount of TFA at room temperature. After one hour, 
the appearance of a new compound by TLC indicated the formation of the corresponding 
dipyrromethane. We then added one equivalent of p-chloranil in order to oxidise the dipyrromethane 
to the corresponding dipyrromethene. An immediate colour change was observed, and the formation 
of a new compound was confirmed by TLC analysis. Thus after a further 15 minutes diisopropylamine 
and boron triflouride diethyletherate were added, resulting in the appearance of a new, highly 
coloured compound by TLC analysis. After purification by silica gel chromatography, N,N,O,O-BODIPY 
4.1 was isolated in a 16% yield over these three steps. 
We confirmed the structure of N,N,O,O-BODIPY 4.1 by the observation of a singlet in the 11B NMR 
spectrum with a chemical shift of δB 0.07 ppm. This result is in-keeping with the typical 11B NMR shifts 
observed from constrained N,N,O,O-BODIPYs79,84,138 (section 2.1.2.2), suggesting that we had formed 
N,N,O,O-BODIPY 4.1. Furthermore, analysis of the 1H NMR spectrum showed signals corresponding to 
the napthyl moiety (δH 8.47 ppm, d, 2H, J = 8.3 Hz; 7.53 ppm, d, 2H, J = 7.9 Hz; 7.22 ppm, ddd, 2H, J = 
7.9, 6.8, 1.2 Hz) and a singlet peak corresponding to the methyl group of the aryl methyl ester (δH 3.56 
ppm, s, 3H). 
 
Scheme 4.5: Reagents and conditions: (i) 4-methyl-4-formylbenzoate, TFA, DCM, R.T., 1 h; (ii) p-
chloranil, 15 minutes; (iii) NiPr2, BF3.OEt2, 20 minutes (16%). 
Further evidence to corroborate the formation of N,N,O,O-BODIPY 4.1 came from analysis of the 
UV/Visible and fluorescence spectra. The absorptive λmax (687 nm) and emissive λmax (730 nm) for 
N,N,O,O-BODIPY 4.1 are even more bathochromically shifted than those measured for N,N,O,O-
BODIPY 2.13 (λabs = 632 nm, λem = 653 nm), suggesting extended conjugation in the fluorophore of 4.1. 
The fluorescence quantum yield of N,N,O,O-BODIPY 4.1(φF = 0.24) is lower than that of N,N,O,O-
BODIPY 2.13 (φF = 0.58), which may arise from the additional flexibility imparted to the structure by 
the 3,5-dinapth-2-olic rings. 




N,N,O,O-BODIPY 4.1 is a previously unreported helically chiral, tetradentate N,N-dipyrromethene 
ligand, of which there are limited examples in the literature.8,79,84,124 
Now that we had identified a successful synthetic route to N,N,O,O-BODIPY 4.1, we wished to resolve 
the racemic mixture of N,N,O,O-BODIPY 4.1 into its respective enantiomers in order to measure the 
ECD and CPL spectra. 
4.2.2 Resolution of the enantiomers of N,N,O,O-BODIPY 4.1 
In order to separate the enantiomers of N,N,O,O-BODIPY 4.1, we performed semi-preparative chiral 
HPLC on a racemic mixture of 4.1 using a Daicel Chiralpak® IA column (1 mL/ minute, toluene). After 
multiple runs, we were able to collect approximately 20 µg of each enantiomer, which were assigned 
as (-)-4.1 and (+)-4.1 respectively by retention time and by measurement of their specific optical 
rotation ([α]D). 
 
Figure 4.3: A typical chiral HPLC trace obtained from a racemic sample of 4.1. Daicel Chiralpak® IA 
column, 4.6 x 250 mm, 5μm particle size,toluene, 1 mL/min. 
In order to validate the enantiopurity of the resolved enantiomers of 4.1, the ee of (-)-4.1 and (+)-4.1 
was measured by resubmission to the same chiral HPLC conditions ((+)-4.1 %ee = >95%, (-)-4.1 %ee = 
>95%). Once we had confirmed that we had obtained enantiopure samples of each enantiomer of 
N,N,O,O-BODIPY 4.1, we next studied the chiroptical properties of both (-)-4.1 and (+)-4.1. 
 




4.2.3 ECD spectroscopy of N,N,O,O-BODIPY 4.1 
We next measured the ECD spectra of both (+)-4.1 and (-)-4.1 (performed by Jonathan Bogaerts) and 
were pleased to observe that mirror image spectra were obtained. A strong Cotton effect was 
observed in the transition at 687 nm (±120 L mol-1cm-1), corresponding to the S0-S1 transition of 
N,N,O,O-BODIPY 4.1. 
Boltzmann-weighted ECD spectra for the postulated M enantiomer of 4.1 were then obtained from 
TD-DFT calculations at the B3LYP/6-311++G(3df,2pd) level (figure 4.4b, calculations performed by 
Jonathan Bogaerts). Through comparison of the theoretical ECD spectrum and the experimental ECD 
spectrum, we were able to assign the enantiomers as (P)-(-)-4.1 (blue) and (M)-(+)-4.1 (red). 
Interestingly in the case of N,N,O,O-BODIPY 4.1 the best agreement between the calculated and 
experimental ECD spectra was obtained using calculations at the B3LYP level, rather than calculations 
at the cam-B3LYP or B3PW91 level (see section 5.3.4.6). 
  






Figure 4.4: a) Experimental ECD spectrum (blue – (P)-(-)-4.1, red – (M)-(+)-4.1) and UV/Vis 
absorption spectrum (black) measured in DCM; b) Calculated Boltzmann-weighted spectra: ECD (red 
– postulated (M)-4.1 (wavelength uncorrected) and UV/Vis absorption spectra (black – postulated 
(M)-4.1(wavelength uncorrected); (c) (P)-4.1 and (M)-4.1. 
 Solvent λabs /nm ε /mol-1 cm-1 λem /nm φF |gabs| 
Δεmax / L mol-
1cm-1 
4.1 DCM 687 30 000 730 0.49 2.8×10-3 ±120 
Table 4.1: Experimental photophysical and chiroptical properties of N,N,O,O-BODIPY 4.1. 
4.3.4 CPL spectroscopy of N,N,O,O-BODIPY 4.1 
Finally CPL spectra of the (P)-(-)-4.1 and (M)-(+)-4.1 enantiomers of N,N,O,O-BODIPY 4.1 were 
recorded (performed by Dr Lewis Mackenzie). The signals observed were opposite at the emission 




maxima (λem = 730 nm) corresponding to the S1-S0 transition of N,N,O,O-BODIPY 4.1, as we would 
expect for a pair of enantiomers. 
We measured a glum of 1.7×10-3 from (P)-(-)-4.1 and -1.5×10-3 from (M)-(+)-4.1 (both measured at 730 
nm in DCM), giving an average magnitude |glum| of 1.6×10-3 (figure 4.4). To compare glum values to 
previously reported systems, we can calculate the overall CPL quantum efficiency (|glum|·φF). For 
N,N,O,O-BODIPY 4.1 the overall CPL quantum efficiency is 4.1×10-4. 
 
Figure 4.5: Normalised CPL (IL-IR) (blue – (P)-(-)-4.1, red – (M)-(+)-4.1 and fluorescence spectra (black 









Δεmax / L 
mol-1cm-1 
|glum| (|glum|·φF) 
4.1 DCM 687 43000 730 0.24 2.8×10-3 ±120 1.7×10-3 4.1×10-4 
Table 4.2: Experimental photophysical and chiroptical properties of N,N,O,O-BODIPY 4.1. 
4.3.5 Theoretical calculations of N,N,O,O-BODIPY 4.1 
Since our aim in the synthesis of N,N,O,O-BODIPY 4.1 was to attempt to control the angle (τ) between 
the magnetic (m) and electric (µ) dipole moments, we elected to perform theoretical calculations to 
determine the magnitude and direction of m, µ and the angle τ, which are related to glum by the 
following equation: 
𝑔𝑙𝑢𝑚 =
4(𝝁 ∙ 𝒎 ∙ 𝑐𝑜𝑠𝜏)
(𝝁2 + 𝒎2)
 




We would then be able to assess the effect the 3,5-dinapth-2-olic rings had on these molecular 
properties, and determine whether we had successfully exhibited control over the angle τ of N,N,O,O-
BODIPY 4.1. 
Thus the excited states of N,N,O,O-BODIPY (P)-4.1 were calculated (table 4.3) using DFT(PBE0) with a 
def2-TZVP basis set (table 4.3, performed by Dr Thomas Penfold) as implemented within the ORCA 
quantum chemistry package.143 
 
Compound µ [au] m [au] τ [°] |glum|calc |glum|exp[a] 
1.93 7.6×10-1 1.4×10-3 65 3.1×10-3 4.7×10-3 
4.1 6.0×10-1 9.6×10-6 93 2.4×10-4 1.7×10-3 
Table 4.3: Calculated magnitudes of the electric (µ) and magnetic (m) transition dipole moments, the 
angle between them (τ) and |glum|calc compared to |glum|exp for (P)-1.93 and (P)-4.1 [a] |glum|exp given 
at the respective λmax value in hexane (1.93) and in DCM (4.1). 
We can clearly observe through comparison of the calculated molecular properties of N,N,O,O-
BODIPYs 1.93 and 4.1 that the introduction of 3,5-dinapth-2-olic rings to the N,N,O,O-BODIPY 
architecture has induced a significant change in the angle τ, as we had anticipated. We did not achieve 
a reduction in τ as we had hoped, instead we observe a detrimental increase from 65° in N,N,O,O-
BODIPY 1.93 to 93° in N,N,O,O-BODIPY 4.1. However we were able to confirm that the direction of the 
magnetic (m) transition dipole moment still aligns with the helical axis, and that the direction of the 
electric (µ) transition dipole moment still aligns with the BODIPY π-system (figure 4.6). Thus we can 
conclude that control over the angle τ can be achieved through modulation of the 3,5-aryl ring system 
of N,N,O,O-BODIPYs. 





Figure 4.6: Electronic (red) and magnetic (blue) transition dipole moments for N,N,O,O-BODIPY 4.1 
(magnetic transition dipole moment has been increased in scale by a factor of ten, H atoms and the 
8-aryl ring have been omitted for clarity). 
A slight decrease in |µ| and a large reduction in |m| is also observed as a result of the inclusion of the 
3,5-dinapth-2-olic rings. This along with the detrimental change in the angle τ resulted in a decrease 
in the calculated glum value of N,N,O,O-BODIPY 4.1 (2.4×10-4) as compared to the calculated glum value 
of N,N,O,O-BODIPY 1.93 (3.1×10-3). This reduction in calculated glum is mirrored in our experimental 
measurements of the glum of N,N,O,O-BODIPYs 4.1 (1.7×10-3) and 1.93 (4.7×10-3). This observation 
further supports our previous validation of the use of a computational method for the prediction of 
glum. 
4.3 Conclusions and Future Work 
In summary we have described a successful synthetic route to N,N,O,O-BODIPY 4.1, which is a novel 
example of a tetradentate N,N-dipyrromethene ligand with helical chirality. We have characterised 
the chiroptical properties of 4.1, including CPL emission. Through theoretical modelling of N,N,O,O-
BODIPY 4.1 we have confirmed that the extension of the BODIPY π-system through the inclusion of 
3,5-dinapth-2-olic rings induces a significant change to the angle τ. This result has promising 
applications to the future design of helically chiral, CPL-SOM BODIPYs, since exhibiting control over 
the angle τ is a key step in the development of high glum BODIPY systems. 
In the future we would like to produce 3,5-diaryl-BODIPYs such as 4.6 and 4.7 (figure 4.6), whose aryl 
rings have structural similarity to the carbo[n]helicenes. We propose that the synthesis and study 
BODIPYs 4.6 and 4.7 (and further analogues) would enable us to recreate the trend observed in the 
carbo[n]helicene series, where an increase in helical pitch results in a decrease in the angle τ. 





Figure 4.6: Molecular structures of proposed 3,5-diaryl-BODIPYs 4.6 and 4.7. 




Chapter 5. Experimental Methods and Characterisation 
5.1 General Experimental Information 
5.1.1 Analysis 
Melting points were measured using Stuart SMP3 melting point apparatus. 1H, 13C, 11B and 19F NMR 
spectra were recorded directly with a Bruker Advance III HD 700 MHz, Jeol Lambda 500 MHz, Jeol ECS-
400 MHz or Bruker Advance III 300 MHz spectrometer. Infrared (IR) spectra were recorded on either 
a Varian Scimitar 800 FT-IR spectrometer or a Perkin Elmer Spectrum Two FT-IR spectrometer. High 
resolution mass spectra (HRMS) were provided by the EPSRC National Mass Spectrometry Service 
(University of Swansea). UV/Vis absorption spectra were recorded on a Shimadzu UV-1800 UV 
spectrophotometer. Emission spectra were recorded on a Shimadzu RF-6000 spectro-
fluorophotometer. ECD spectra were recorded on a ChirascanTM-Plus instrument using a SUPRASIL® 
quartz sample cell with a path length of 10 mm, using a scan speed of 60 nm/min. Specific optical 
rotation ([α]D) was measured using an Optical Activity PolAAR 2001 automatic polarimeter. 
5.1.2 Procedures 
Standard Schlenk techniques were used for all experiments involving air-sensitive reagents, under an 
atmosphere of nitrogen. Solvents were distilled under an atmosphere of nitrogen and used directly, 
DCM was distilled from calcium hydride, THF was distilled from sodium/benzophenone, and toluene 
was distilled from sodium. Manual flash chromatography was performed using Geduran silicagel 60 
(40-63 µm)




5.2 Experimental Procedures and Characterisation Data 
5.2.1 Chapter 2 
5.2.1.1 Methyl 4-(di(1H-pyrrol-2-yl)methyl)benzoate (2.9) 
 
To a round bottomed flask was added an aqueous solution of HCl (0.05 M, 100 mL), followed by the 
addition of pyrrole (2.0 mL, 30 mmol) and methyl-4-formylbenzoate (1.64 g, 10 mmol). The reaction 
mixture was stirred for 4 hours under room temperature before the pink precipitate formed was 
filtered out and washed with water and petroleum ether. The crude product was then purified by 
column chromatography (Eluent system: DCM) to give methyl 4-(di(1H-pyrrol-2-yl)methyl)benzoate 
(2.52 g, 9 mmol, 90%). 
Mp: 161-162 °C; Rf = 0.3 (DCM; UV light); 1H NMR (300 MHz, CDCl3): δH 8.04 (d, 2H, J = 8.3 Hz, 4), 7.31 
(d, 2H, J = 8.3 Hz, 5), 6.75 (m, 2H, 11), 6.19 (dd, 2H, J = 3.2, 3.7 Hz, 10), 5.92 (m, 2H, 9), 5.56 (s, 1H, 7), 
3.93 (s, 3H, 1); 13C NMR (75 MHz, CDCl3): δC 167.0 (2), 147.5 (6), 131.7 (8), 130.0 (4), 129.0 (3), 128.5 
(5), 117.7 (11), 108.7 (10), 107.6 (9), 52.3 (1), 44.1 (7); IR (neat): υmax/cm-1 3335 (m),1704 (m), 1607 
(w), 1568 (w), 1434 (m), 1291 (m), 1197 (w), 1115 (m), 1031 (m), 961 (w), 866 (w), 820 (w), 730 (s); 
HRMS (pNSI) calcd for C17H16N2O2 [M+H]+: 281.1285, found 281.1286.




5.2.1.2 Methyl (Z)-4-((5-bromo-1H-pyrrol-2-yl)(5-bromo-2H-pyrrol-2-ylidene)methyl)benzoate (2.10) 
 
To a round bottomed flask under a nitrogen atmosphere was added methyl 4-(di(1H-pyrrol-2-
yl)methyl)benzoate (1 g, 3.57 mmol) dissolved in THF (60 mL) and the reaction mixture was left to cool 
to -78 °C over 30 minutes. NBS (1.27 g, 7.14 mmol) was then added portion wise and the reaction 
mixture left to stir for 1 hour. DDQ (0.810 g, 3.57 mmol) was then added, and after 10 minutes the 
reaction mixture was warmed to room temperature. The reaction mixture was diluted with DCM (50 
mL) and washed with sodium sulfite solution. The organic layers were combined and dried over MgSO4 
and the solvent removed under reduced pressure. The crude product was purified by column 
chromatography (eluent system: 1:1 DCM:petrol 40-60) to give methyl (Z)-4-((5-bromo-1H-pyrrol-2-
yl)(5-bromo-2H-pyrrol-2-ylidene)methyl)benzoate (1.344 g, 3.08 mmol, 86%) 
Mp: 128-130 °C; Rf = 0.43 (1:1 DCM:petrol 40-60); 1H NMR (300 MHz, CDCl3): δH 8.11 (d, 2H, J = 8.2 Hz, 
4), 7.51 (d, 2H, J = 8.2 Hz, 5), 6.41 (d, 2H, J = 4.2, 9), 6.35 (d, 2H, J = 4.2 Hz, 10), 3.97 (s, 3H, 1); 13C NMR 
(75 MHz, CDCl3): δC 166.3 (2), 139.9 (6), 139.8 (8), 137.7 (9), 130.9 (7), 130.7 (4), 130.1 (5), 129.8 (3), 
129.0 (11), 120.8 (10), 52.4 (1); IR (neat): υmax/cm-1 3329 (w), 3139 (w), 2950 (w), 1714 (m); HRMS 
(pNSI) calcd for C17H12N2O281Br2 [M+H]+: 438.9298, found 438.9314.







To a round bottomed flask under an inert atmosphere was added methyl (Z)-4-((5-bromo-1H-pyrrol-
2-yl)(5-bromo-2H-pyrrol-2-ylidene)methyl)benzoate (2.54 g, 5.8 mmol) in DCM (10 mL) before adding 
iPr2NEt (2.52 mL, 14.5 mmol) and BF3.OEt2 (1.43 mL, 11.6 mmol). The reaction mixture was stirred at 
room temperature for 1 hour. The reaction mixture was then washed with sodium hydroxide solution 
(0.1 M, 115 mL) and HCl (0.1 M, 100 mL). The organic layers were then combined and dried over 
Na2SO4 and solvent removed under reduced pressure to give methyl 4-(3,7-dibromo-5,5-difluoro-5H-
4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (2.38 g, 4.90 mmol, 85%). 
Mp: 249-251 °C; Rf = 0.44 (1:1 DCM:toluene); 1H NMR (300 MHz, CDCl3): δH 8.18 (d, 2H, J = 8.4 Hz, 4), 
7.57 (d, 2H, J = 8.4 Hz, 5), 6.73 (d, 2H, J = 4.2 Hz, 9), 6.55 (d, 2H, J = 4.2 Hz, 10), 3.98 (s, 3H, 1); 13C NMR 
(75 MHz, CDCl3): δC 166.2 (2), 141.6 (6), 136.7 (7), 135.4 (4), 133.7 (3), 132.4 (5), 131.6 (8), 130.5 (9), 
129.8 (11), 123.3 (10), 52.7 (1); 11B NMR (96 MHz, CDCl3): δB 0.33 (t, JB-F = 28 Hz); 19F NMR (282MHz, 
CDCl3): δF -146.8 (q, JB-F = 28.2 Hz); IR (neat): υmax/cm-1 1711 (m); HRMS (pNSI) calcd for 
C17H11N2O281Br211BF2 [M+H]+: 486.9281, found 486.9277; ε = 84 000 M-1 cm-1 (DCM).







To a Schlenk flask under an inert atmosphere was added methyl 4-(3,7-dibromo-5,5-difluoro-5H-
4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (48 mg, 0.1 mmol), 2-
methoxyphenylboronic acid (61 mg, 0.4 mmol), Pd(PPh3)4 (6 mg, 5 mol %) and potassium phosphate 
(54 mg, 0.4 mmol) in toluene (0.5 mL) and 1,4-dioxane (0.5 mL).The reaction mixture was then refluxed 
at 90 °C for 1 hour 20 min. The reaction mixture was then diluted with DCM (50 mL) and washed with 
water (50 mL). The organic layers were then combined and dried over MgSO4 and solvent removed 
under reduced pressure. The crude product was then purified by column chromatography (eluent 
system: 5:1 petrol 40-60:EtOAc) to give methyl 4-(5,5-difluoro-3,7-bis(2-methoxyphenyl)-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (31 mg, 0.058 mmol, 58%). 
Mp: 118-120 °C; Rf = 0.16 (1:1 petrol 40-60:DCM); 1H NMR (300 MHz, CDCl3): δH 8.20 (d, 2H, J = 8.2 Hz, 
4), 7.74 (dd, 2H, J = 7.7, 1.7 Hz, 14), 7.70 (d, 2H, J = 8.2 Hz, 5), 7.34 (app. td, 2H, J = 8.2, 1.7 Hz, 16), 
7.00 (td, 2H, J = 7.7, 0.8 Hz, 15), 6.92 (dd, 2H, J = 8.2, 0.8 Hz, 17), 6.79 (d, 2H, J = 4.3 Hz, 9), 6.61  (d, 
2H, J = 4.3 Hz, 10), 4.00 (s, 3H, 1), 3.78 (s, 6H, 18); 13C NMR (176 MHz, CDCl3): δC 165.5 (2), 156.6, 154.9, 
140.6, 138.0, 134.1, 130.8, 130.4, 129.7, 129.5, 128.3, 128.3, 121.6, 120.8, 119.2, 109.9, 54.7 (1), 51.4 
(18); 11B NMR (96 MHz, CDCl3): δB 1.06 (t, JB-F = 30.9 Hz); 19F NMR (282 MHz, CDCl3): δF -135.05 (q, JB-F = 
30.9 Hz); IR (neat): υmax/cm-1 2961 (w), 1721 (m), 1602 (w), 1570 (m); HRMS (pNSI) calcd for 
C31H25N2O411BF2 [M+Na]+: 561.1767, found 561.1761.




5.2.1.5 N,N,O,O-BODIPY 2.13 
 
To a Schlenk flask under an inert atmosphere was added methyl 4-(3,7-dibromo-5,5-difluoro-5H-
4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (48 mg, 0.1 mmol), 2-
hydroxyphenolboronic acid (55 mg, 0.4 mmol), Pd(PPh3)4 (6 mg, 5 mol %) and sodium carbonate (114 
mg, 0.4 mmol) in toluene (0.5 mL) and 1,4-dioxane (0.5 mL).The reaction mixture was then refluxed 
at 90 °C for 1 hour 20 min. The reaction mixture was then diluted with DCM (50 mL) and washed with 
water (50 mL). The organic layers were then combined and dried over MgSO4 and solvent removed 
under reduced pressure. The crude product was then purified by column chromatography (eluent 
system: 5:1 petrol 40-60 : EtOAc) to give N,N,O,O-BODIPY 2.13 (20 mg, 0.043 mmol, 43%). 
Mp: 276-278 °C; Rf = 0.15 (5:1 petrol 40-60:EtOAc); 1H NMR (300 MHz, CDCl3): δH 8.22 (d, 2H, J = 8.6 
Hz, 4), 7.83-7.78 (m, 4H, 5,15), 7.35 (ddd, 2H, J = 8.3, 7.4, 1.5 Hz, 14), 7.08 (dd, 2H, J = 7.4, 1.5 Hz, 16), 
7.05 (d, 2H, J = 4.4 Hz, 9), 6.97 (dd, 2H, J = 8.3, 1.2 Hz, 13), 6.93 (d, 2H, J = 4.4 Hz, 10), 3.99 (s, 3H, 1); 
13C NMR (75 MHz, CDCl3): δC 166.5 (2), 154.4 (17), 150.6 (6), 138.5 (7), 137.1 (11), 134.2 (13), 132.6 
(15), 132.0 (4), 130.6 (5), 130.0 (14), 129.9 (12), 126.0 (5), 120.7 (16), 119.9 (8), 119.7 (3), 116.9 (9), 
52.6 (1); 11B NMR (96 MHz, CDCl3): δB -0.90 (s); IR (neat): υmax/cm-1 2923 (w), 2853 (w), 1713 (m); HRMS 
(TOF ASAP+) calcd for C29H19N2O411B [M+H]+: 471.1521, found 471.1519; ε = 24 000 M-1 cm-1 (DCM); ɸF 
= 0.58 (DCM).





ef]aceanthrylen-2a1-ium-16-uide (N,N,O,C-BODIPY 2.18) 
 
METHOD A: To a Schlenk flask under an inert atmosphere was added methyl 4-(3,7-dibromo-5,5-
difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (48 mg, 0.1 mmol), 2-
hydroxyphenolboronic acid (55 mg, 0.4 mmol), Pd(PPh3)4 (6 mg, 5 mol %) and sodium carbonate (114 
mg, 0.4 mmol) in toluene (0.5 mL) and 1,4-dioxane (0.5 mL).The reaction mixture was then refluxed 
at 90 °C for 16.5 hours. The reaction mixture was then diluted with DCM (50 mL) and washed with 
water (50 mL). The organic layers were then combined and dried over MgSO4 and solvent removed 
under reduced pressure. The crude product was then purified by column chromatography (eluent 
system: 5:1 petrol 40-60:EtOAc) to give 3-(4-(methoxycarbonyl)phenyl)-10,15-dioxa-2a1,3a1-diaza-
10a-borabenzo[5,6]indeno[1,7-ef]aceanthrylen-2a1-ium-16-uide (17 mg, 0.036 mmol, 36%). 
METHOD B: To a Schlenk flask under an inert atmosphere was added methyl (Z)-4-((5-bromo-1H-
pyrrol-2-yl)(5-bromo-2H-pyrrol-2-ylidene)methyl)benzoate (150 mg, 0.34 mmol), 2-
hydroxyphenylboronic acid (188 mg, 1.36 mmol), Pd(PPh3)4 (20 mg, 5 mol %) and sodium carbonate 
(389 mg, 1.36 mmol) in toluene (1.5 mL) and 1,4-dioxane (1.5 mL).The reaction mixture was then 
refluxed at 90 °C for 2 hours. The reaction mixture was then diluted with DCM (50 mL) and washed 
with water (50 mL). The organic layers were then combined and dried over MgSO4 and solvent 
removed under reduced pressure. The crude product was then purified by column chromatography 
(eluent system: 5:1 petrol 40-60:EtOAc) to give 3-(4-(methoxycarbonyl)phenyl)-10,15-dioxa-2a1,3a1-
diaza-10a-borabenzo[5,6]indeno[1,7-ef]aceanthrylen-2a1-ium-16-uide (137 mg, 0.29 mmol, 85%). 
Mp: 173-175 °C; Rf = 0.35 (5:1 petrol 40-60:EtOAc); 1H NMR (300 MHz, CDCl3): δH  8.22 (d, 2H, J = 8.45 
Hz, 4), 7.77 – 7.72 (m, 3H, 5, 13), 7.31 (d, 1H, J = 8.91 Hz, 16), 7.24 – 7.17 (m, 3H, 14, 15, 24), 7.02 – 
6.91 (m, 4H, 9, 10, 25, 26), 6.86 (d, 1H, J = 4.5 Hz, 19), 6.77 (d, 1H, J = 8.1 Hz, 23), 6.43 (d, 1H, J = 4.5 
Hz, 20), 3.99 (s, 3H, 1); 13C NMR (75 MHz, CDCl3): δC 166.6 (2), 163.2 (11), 156.9 (12), 154.6 (27), 148.4 
(6), 138.2 (8), 137.3 (9), 132.3 (16), 131.9 (7), 131.5 (21), 130.4 (5), 129.9 (4), 129.5 (15), 128.4 (25), 
127.7 (3), 127.5 (24), 125.2 (22), 124.6 (10), 121.5 (20), 120.4 (26), 120.3 (13), 117.0 (18), 115.7 (14), 
107.9 (19), 52.6 (1); 11B NMR (96 MHz, CDCl3): δB -2.21 (s); IR (neat): υmax/cm-1 2953 (w), 2921 (w), 2852 




(w), 1721 (m); HRMS (pNSI) calcd for C29H19N2O411B [M+H]: 471.1521, found 471.1517; ε = 30 000 M-1 
cm-1 (hexane); ɸF = 0.49 (hexane).





ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.32) 
 
To a Schlenk flask under an inert atmosphere was added added methyl (Z)-4-((5-bromo-1H-pyrrol-2-
yl)(5-bromo-2H-pyrrol-2-ylidene)methyl)benzoate (151 mg, 0.35 mmol), 3-methyl-2-hydroxyphenyl 
boronic acid (213 mg, 1.4 mmol), Pd(PPh3)4 (21 mg, 5 mol %) and sodium carbonate (401 mg, 1.4 
mmol) in toluene (1.5 mL) and 1,4-dioxane (1.5 mL).The reaction mixture was then refluxed at 90 °C 
for 18.5 hours. The reaction mixture was then diluted with DCM (50 mL) and washed with water (50 
mL). The organic layers were then combined and dried over MgSO4 and solvent removed under 
reduced pressure. The crude product was then purified by column chromatography (eluent system: 
5:1 petrol 40-60:EtOAc) to give methyl 4-(9,14-dimethyl-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-
borabenzo[5,6]indeno[3,4-ef]aceanthrylen-3-yl)benzoate (67 mg, 0.13 mmol, 38%). 
Mp: 235-236 °C; Rf = 0.61 (5:1 petrol 40-60:EtOAc); 1H NMR (300 MHz, CDCl3): δH  8.18 (d, 2H, J = 8.6 
Hz, 4), 7.75 (d, 2H, J = 8.6 Hz, 5), 7.57 (dd, 1H, J = 7.7, 1.7 Hz, 15), 7.05 (m, 2H, 14, 26), 7.01-6.96 (m, 
3H, 9, 13, 20), 6.90-6.78 (m, 3H, 10, 25, 27), 6.43 (d, 1H, J = 4.6 Hz, 21), 3.99 (s, 3H, 1), 2.47 (s, 3H, 17), 
1.95 (s, 3H, 29); 13C NMR (176 MHz, CDCl3): δC 166.5 (2), 163.2 (22), 155.4 (23), 153.2 (18), 149.2 (6), 
138.4 (19), 137.1 (20), 133.0 (7), 132.4 (15), 131.9 (27), 131.0 (25), 130.4 (5), 130.0 (4), 129.5 (3), 129.1 
(11), 128.2 (13), 127.4 (16), 127.1 (28), 125.9 (14), 124.1 (26), 122.8 (12), 120.9 (21), 119.7 (8), 115.8 
(9), 107.7 (10), 52.4 (1), 16.6 (17), 16.2 (29); 11B NMR (96 MHz, CDCl3): δB -2.93 (s); IR (neat): υmax/cm-1 
2981 (m), 2943 (w), 2936 (w), 1725 (m); HRMS (pNSI) calcd for C31H2311BN2O4 [M+H]: 499.1835, found 
499.1838; ε = 24 000 M-1 cm-1 (DCM); ɸF = 0.41 (DCM).





ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.33) 
 
To a Schlenk flask under an inert atmosphere was added added methyl (Z)-4-((5-bromo-1H-pyrrol-2-
yl)(5-bromo-2H-pyrrol-2-ylidene)methyl)benzoate (200 mg, 0.46 mmol), 5-methyl-2-hydroxyphenyl 
boronic acid (280 mg, 1.84 mmol), Pd(PPh3)4 (27 mg, 5 mol %) and sodium carbonate (526 mg, 1.84 
mmol) in toluene (2 mL) and 1,4-dioxane (2 mL).The reaction mixture was then refluxed at 90 °C for 2 
hours. The reaction mixture was then diluted with DCM (50 mL) and washed with water (50 mL). The 
organic layers were then combined and dried over MgSO4 and solvent removed under reduced 
pressure. The crude product was then purified by column chromatography (eluent system: 5:1:1 petrol 
40-60:toluene:EtOAc) to give methyl 4-(7,12-dimethyl-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-
borabenzo[5,6]indeno[3,4-ef]aceanthrylen-3-yl)benzoate (127 mg, 0.25 mmol, 55%). 
Mp: 249-250 °C; Rf = 0.39 (5:1:1 petrol 40-60:toluene:EtOAc); 1H NMR (300 MHz, CDCl3): δH 8.19 (d, 
2H, J = 8.3 Hz, 4), 7.74 (d, 2H, J = 8.3 Hz, 5), 7.55 (d, 2H, J = 2.2 Hz, 13), 7.21 (d, 1H, J = 8.1 Hz, 28), 7.05-
6.95 (m, 5H, 9, 10, 16, 17, 25), 6.86 (d, 1H, J = 4.5 Hz, 20), 6.70 (d, 2H, J = 8.1 Hz, 29), 6.40 (d, 1H, J = 
4.5 Hz, 21), 3.99 (s, 3H, 1), 2.36 (s, 3H, 27), 2.16 (s, 3H, 15); 13C NMR (176 MHz, CDCl3): δC 166.5 (2), 
163.5 (22), 155.4 (23), 152.7 (18), 148.7 (6), 138.4 (25), 136.9 (19), 133.8 (20), 133.2 (7), 132.4 (13), 
131.9 (14), 131.1 (11), 130.4 (5), 129.9 (26), 129.9 (28), 129.3 (16), 128.2 (4), 128.1 (3), 127.5 (12), 
125.2 (21), 121.1 (17), 120.0 (8), 116.7 (29), 115.6 (10), 107.7 (9), 52.5 (1), 21.0 (15), 20.8 (27); 11B 
NMR (96 MHz, CDCl3): δB – 2.39 (s); IR (neat): υmax/cm-1 2981 (m), 2933 (w), 1718 (m); HRMS (pNSI) 
calcd for C31H2311BN2O4 [M+H]: 499.1835, found 499.1846; ε = 39 000 M-1 cm-1 (DCM); ɸF = 0.25 (DCM).





ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.34) 
 
To a Schlenk flask under an inert atmosphere was added methyl (Z)-4-((5-bromo-1H-pyrrol-2-yl)(5-
bromo-2H-pyrrol-2-ylidene)methyl)benzoate (200 mg, 0.46 mmol), 5-chloro-2-hydroxyphenyl boronic 
acid (317 mg, 1.84 mmol), Pd(PPh3)4 (27 mg, 5 mol %) and sodium carbonate (526 mg, 1.84 mmol) in 
toluene (2 mL) and 1,4-dioxane (2 mL).The reaction mixture was then refluxed at 90 °C for 2 hours. 
The reaction mixture was then diluted with DCM (50 mL) and washed with water (50 mL). The organic 
layers were then combined and dried over MgSO4 and solvent removed under reduced pressure. The 
crude product was then purified by column chromatography (eluent system: 5:1:1 petrol 40-
60:EtOAc:toluene) to give methyl 4-(7,12-dichloro-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-
borabenzo[5,6]indeno[3,4-ef]aceanthrylen-3-yl)benzoate (177 mg, 0.33 mmol, 71%). 
Mp: 126-127 °C; Rf = 0.30 (5:1:1 petrol 40-60:EtOAc:toluene); 1H NMR (300 MHz, CDCl3): δH  8.12 (d, 
2H, J = 8.5 Hz, 4), 7.67 (d, 2H, J = 8.5 Hz, 5), 7.63 (d, 1H, J = 2.6 Hz, 24), 7.18 (m, 1H, 27), 7.10 (m, 1H, 
15), 7.07 (m, 1H, 26), 7.02 (d, 1H, J = 2.5 Hz, 13), 6.97 (d, 1H, J = 4.7 Hz, 19), 6.94 (d, 1H, J = 4.3 Hz, 9), 
6.78 (d, 1H, J = 4.3 Hz, 10), 6.64 (d, 1H, J = 8.5 Hz, 16), 6.37 (d, 1H, J = 4.7 Hz, 20), 3.91 (s, 3H, 1); 13C 
NMR (176 MHz, CDCl3): δC 166.6 (2), 163.4 (21), 155.3 (22), 154.7 (17), 152.7 (6), 146.9 (18), 137.8 (19), 
132.5 (7), 132.3 (11), 132.1 (26), 130.4 (5), 130.0 (15), 129.5 (16), 129.0 (4), 128.6 (3), 127.7 (13), 125.6 
(14), 125.5 (25), 124.7 (24), 122.2 (12), 121.6 (20), 118.6 (27), 116.9 (8), 115.9 (9), 108.4 (10), 52.6 (1); 
11B NMR (96 MHz, CDCl3): δB -3.26 (s); IR (neat): υmax/cm-1 2981 (w), 2970 (w), 1719 (m); HRMS (pNSI) 
calcd for C29H1711B35Cl2N2O4 [M+H]: 539.0742, found 539.0746; ε = 52 000 M-1 cm-1 (DCM); ɸF = 0.37 
(DCM).





ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.35) 
 
To a Schlenk flask under an inert atmosphere was added added methyl (Z)-4-((5-bromo-1H-pyrrol-2-
yl)(5-bromo-2H-pyrrol-2-ylidene)methyl)benzoate (169 mg, 0.39 mmol), 5-fluoro-2-hydroxyphenyl 
boronic acid (242 mg, 1.55 mmol), Pd(PPh3)4 (23 mg, 5 mol %) and sodium carbonate (444 mg, 1.55 
mmol) in toluene (1.5 mL) and 1,4-dioxane (1.5 mL).The reaction mixture was then refluxed at 90 °C 
for 2 hours. The reaction mixture was then diluted with DCM (50 mL) and washed with water (50 mL). 
The organic layers were then combined and dried over MgSO4 and solvent removed under reduced 
pressure. The crude product was then purified by column chromatography (eluent system: 6:1:1 petrol 
40-60:EtOAc:toluene) to give methyl 4-(7,12-difluoro-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-
borabenzo[5,6]indeno[3,4-ef]aceanthrylen-3-yl)benzoate (67 mg, 0.13 mmol, 73%). 
Mp: 122-123 °C; Rf = 0.30 (6:1:1 petrol 40-60:EtOAc:toluene);  
1H NMR (700 MHz, CDCl3): δH  8.19 (d, 2H, J = 8.6 Hz, 4), 7.74 (br s 2H, 5), 7.42 (dd, 1H, J = 8.5, 3.5 Hz, 
23), 7.28 (dd, 1H, J = 8.6, 4.0 Hz, 13), 7.03 (d, 1H, J = 4.6 Hz, 9), 7.00 (d, 1H, J = 4.2 Hz, 19), 6.92 (app. 
td, 1H, J = 8.5, 3.9 Hz, 25), 6.89 (app. td, 1H, J = 8.6, 3.1 Hz, 14), 6.84 (d, 1H, J = 4.2 Hz, 20), 6.79 (dd, 
1H, J = 8.0, 3.1 Hz, 16), 6.72 (dd, 1H, J = 9.0, 3.5 Hz, 26), 6.44 (d, 1H, J = 4.6 Hz, 10), 3.99 (s, 3H, 1); 13C 
NMR (75 MHz, CDCl3): δC 166.4 (2), 163.6 (11), 159.3 (d, JC-F = 245.5 Hz, 15), 156.8 (d, JC-F = 238.0 Hz, 
24), 152.5 (12), 150.3 (27), 146.8 (d, JC-F = 2.9 Hz, 22), 137.8 (6), 137.5 (7), 132.3 (9), 132.3 (21), 132.0 
(3), 130.5 (5), 130.0 (4), 128.3 (19), 127.6 (8), 121.4 (18), 121.2 (d, JC-F = 8.0 Hz, 26), 119.0 (d, JC-F = 23.2 
Hz, 25), 118.5 (d, JC-F = 7.9 Hz, 13), 115.7 (20), 115.2 (d, JC-F = 21.4 Hz, 16), 114.4 (d, JC-F = 24.5 Hz, 14), 
110.8 (d, JC-F = 24.1 Hz, 23), 108.5 (10), 52.6 (1); 11B NMR (96 MHz, CDCl3): δB -3.22 (s); 19F NMR (282 
MHz, CDCl3): δF -177.0 (s), -123.1 (s); IR (neat): υmax/cm-1 2951 (w), 2939 (w), 1723 (m); HRMS (pNSI) 
calcd for C29H1711BF2N2O4 [M+H]: 507.1333, found 507.1333; ε = 32 000 M-1 cm-1 (DCM); ɸF = 0.43 
(DCM). 








To a Schlenk flask under an inert atmosphere was added methyl 4-(3,7-dibromo-5,5-difluoro-5H-
4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (242 mg, 0.5 mmol), 2-
(methylthio)phenyl boronic acid (336 mg, 2 mmol), Pd(PPh3)4 (29 mg, 5 mol %) and sodium carbonate 
(572 mg, 2 mmol) in toluene (2 mL) and 1,4-dioxane (2 mL).The reaction mixture was then refluxed at 
90 °C for 18 h. The reaction mixture was then diluted with DCM and washed with water. The organic 
layers were then combined and dried over MgSO4 and solvent removed under reduced pressure. The 
crude product was then purified by column chromatography (eluent system: 3:1 petrol 40-60:EtOAc) 
to give methyl 4-(5,5-difluoro-3,7-bis(2-(methylthio)phenyl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-10-yl)benzoate (180 mg, 0.32 mmol, 63%). 
Mp: 117-118 °C; Rf = 0.43 (3:1 petrol 40-60:EtOAc); 1H NMR (700 MHz, CDCl3): δH 8.22 (d, 2H, J = 8.5 
Hz, 4), 7.74 (d, 2H, J = 8.5 Hz, 5), 7.58 (d, 2H, J = 7.5 Hz, 13), 7.33 (ddd, 2H, J = 8.0, 7.4, 1.5 Hz, 15), 
7.28-7.26 (m, 2H, 16), 7.18 (ddd, 2H, J = 7.5, 7.4, 1.2 Hz, 14), 6.84 (d, 2H, J = 4.3 Hz, 9), 6.64 (d, 2H, J = 
4.3 Hz, 10), 4.00 (s, 3H, 1), 2.39 (s, 6H, 18); 13C NMR (176 MHz, CDCl3): δC 166.5 (2), 157.4 (11), 143.1 
(6), 138.8 (17), 138.4 (15), 135.4 (12), 131.9 (7), 131.8 (3), 131.1 (5), 130.7 (4), 130.5 (8), 129.8 (9), 
129.6 (13), 126.1 (16), 124.7 (14), 122.6 (10), 52.6 (1), 16.6 (18); 11B NMR (96 MHz, CDCl3): δB 0.83 (t, 
JB-F = 30.3 Hz); 19F NMR (282 MHz, CDCl3): δF -147.0 (q, JB-F = 30.3 Hz), -147.3 (q, JB-F = 30.3 Hz); IR 
(neat): υmax/cm-1 1714 (m), 2989 (w); HRMS (pAPCI) calcd for C31H2511BF2N2O2S2 [M+H]+ 571.1497, 
found 571.1479; ε = 49 000 M-1 cm-1 (DCM).







To a round bottomed flask under an inert atmosphere was added methyl 4-(5,5-difluoro-3,7-bis(2-
(methylthio)phenyl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (414 mg, 
0.73 mmol), DCM (3.7 mL), MeOH (3.7 mL) and TFA (65.7 mL) were then added, and the reaction 
mixture stirred at room temperature for 1 hour. The solvent was removed under reduced pressure, 
and the residue redissolved in DCM (100 mL) and washed with water (200 mL). The organic layers 
were then combined and dried over MgSO4 and solvent removed under reduced pressure, to give 
methyl (Z)-4-((5-(2-(methylthio)phenyl)-1H-pyrrol-2-yl)(5-(2-(methylthio)phenyl)-2H-pyrrol-2-
ylidene)methyl)benzoate without the need for further purification (377 mg, 0.72 mmol, 99 %). 
Mp: 198-200 °C; 1H NMR (700 MHz, CDCl3): δH 8.15 (d, 2H, J = 8.1 Hz, 4), 7.76 (d, 2H, J = 7.6 Hz, 13), 
7.65 (d, 2H, J = 8.1 Hz, 5), 7.35 (app. t, 2H, J = 8.2 Hz, 15), 7.28 (d, 2H, J = 8.2 Hz, 16), 7.21 (app. t, 2H, 
J = 7.6 Hz, 14), 6.86 (br s, 2H, 9), 6.60 (br s, 2H, 10), 3.98 (s, 3H, 1), 2.31 (s, 6H, 18); 13C NMR (176 MHz, 
CDCl3): δC 166.9 (2), 153.9 (11), 142.3 (6), 140.7 (17), 138.6 (8), 131.2 (7), 131.1 (15), 130.5 (3), 130.2 
(4), 129.2 (13), 129.1 (16), 129.0 (9), 128.7 (5), 125.4 (14), 124.5 (10), 119.0 (12), 52.5 (1), 16.1 (18); IR 
(neat): υmax/cm-1 1716 (m); HRMS (TOF MS ASAP+) calcd for C31H26N2O2S2 [M+H]+ 523.1514, found 
523.1516.




5.2.2.3 (2-bromophenyl)(methoxymethyl)sulfane (3.4a) 
 
In a round bottomed flask under an inert atmosphere was added NaOtBu (961 mg, 10 mmol) and THF 
(25 mL). 2-bromobenzenethiol (1.2 mL, 10 mmol) was added to the resulting suspension, and the 
reaction mixture was stirred for 15 minutes. MOMCl (0.84 mL, 11 mmol) was then added and the 
reaction mixture stirred for a further 15 minutes. The reaction mixture was diluted with diethyl ether 
(50 mL) and washed with water (100 mL) and brine (100 mL). The organic layers were then combined 
and dried over MgSO4 and solvent removed under reduced pressure. The crude product was then 
purified by column chromatography (eluent system: 10:1 petrol 40-60:EtOAc) to give (2-
bromophenyl)(methoxymethyl)sulfane (2.33 g, 10 mmol, 100 %). 
Rf = 0.71 (10:1 petrol 40-60:EtOAc; UV light); 1H NMR (500 MHz, CDCl3): δH 7.60 (dd, 1H, J = 8.0, 1.6 Hz, 
3), 7.54 (dd, 1H, J = 8.0, 1.4, 6), 7.28 (td, 1H, J = 7.7, 1.4 Hz, 4), 7.06 (td, 1H, J = 7.7, 1.6 Hz, 5), 5.02 (s, 
2H, 7), 3.45 (s, 3H, 8); 13C NMR (126 MHz, CDCl3): δC 137.6 (1), 133.0 (3), 129.8 (6), 128.1 (5), 127.5 (4), 
123.9 (2), 76.6 (7), 56.4 (8); IR (neat): υmax/cm-1 3058 (w), 2981 (w), 2927 (w), 2893 (w), 282.0 (w); 
HRMS (TOF MS ASAP+) calcd for C8H979BrOS [M+H]+ 232.9458, found 232.9463.




5.2.2.4 1-(2-(2-((methoxymethyl)thio)phenyl)-1H-pyrrol-1-yl)-2,2-dimethylpropan-1-one (3.5a) 
 
To a Schlenk flask under an inert atmosphere was added (2-bromophenyl)(methoxymethyl)sulfane 
(500 mg, 2.14 mmol), N-Boc-2-pyrrole boronic acid (677 mg, 3.21 mmol), Pd(PPh3)4 (124 mg, 5 mol %) 
and potassium phosphate (681 mg, 3.21 mmol) in THF (7.5 mL) and water (3.5 mL).The reaction 
mixture was then stirred at 75°C for 24 hours. The reaction mixture was then diluted with DCM and 
washed with water. The organic layers were then combined and dried over MgSO4 and solvent 
removed under reduced pressure. The crude product was then purified by column chromatography 
(eluent system: 10:1 petrol 40-60:EtOAc) to give 1-(2-(2-((methoxymethyl)thio)phenyl)-1H-pyrrol-1-
yl)-2,2-dimethylpropan-1-one (499 mg, 1.64 mmol, 77%). 
Rf = 0.60 (10:1 petrol 40-60:EtOAc; UV light); 1H NMR (400 MHz, CDCl3): δH 7.60 (ddd, 1H, J = 7.8, 1.3, 
0.5 Hz, 6), 7.41 (dd, 1H, J = 3.3, 1.8 Hz, 12), 7.30 (ddd, 1H, J = 7.8, 6.8, 2.2 Hz, 5), 7.25-7.20 (m, 2H, 3,4), 
6.26 (app. t, 1H, J = 3.3 Hz, 11), 6.14 (dd, 1H, J = 3.3, 1.8 Hz, 10), 4.82 (s, 2H, 7), 3.32 (s, 3H, 8), 1.27 (s, 
9H, 15); 13C NMR (126 MHz, CDCl3): δC 149.3 (13), 137.5 (1), 136.1 (5), 132.5 (9), 130.6 (6), 129.4 (3), 
128.6 (4), 126.1 (2), 121.7 (12), 114.6 (10), 110.5 (11), 83.4 (7), 77.1 (8), 56.0 (14); IR (neat): υmax/cm-1 
2980 (w), 2932 (w), 2820 (w), 1736 (s).




5.2.2.5 1-(2-(2-((methoxymethyl)thio)phenyl)-1H-pyrrol-1-yl)-2,2-dimethylpropan-1-one (3.6a) 
 
1-(2-(2-((methoxymethyl)thio)phenyl)-1H-pyrrol-1-yl)-2,2-dimethylpropan-1-one was placed in a 100 
mL round bottomed flask under an inert atmosphere. Subsequently the flask was heated to 200 °C 
resulting in the evolution of gas (CO2, isobutene), and rapid colour change of the oil. After 30 minutes 
the flask was allowed to cool to room temperature. The dark purple oil was used immediately for the 
next reaction without purification. 
1H NMR (400 MHz, CDCl3): δH 9.63 (s, 1H, 13), 7.63 (dd, 1H, J = 7.7, 1.4 Hz, 6), 7.53 (dd, 1H, J = 7.7, 1.6 
Hz, 3), 7.29 (m, 1H, 4), 7.20 (m, 1H, 5), 6.90 (m, 1H, 12), 6.51 (ddd, 1H, J = 3.5, 2.7, 1.5 Hz, 10), 6.30 (m, 
1H, 11), 4.85 (s, 2H, 7), 3.38 (s, 3H, 8); 13C NMR (126 MHz, CDCl3): δC 135.0 (1), 134.2 (5), 131.1 (9), 
129.3 (3), 128.2 (4), 127.2 (12), 118.7 (2), 109.3 (11), 109.2 (10), 78.8 (7), 57.0 (8); IR (neat): υmax/cm-1 
3381 (br, w), 2981 (w), 2821 (w); HRMS (TOF MS ASAP+) calcd for C12H13NOS [M]+ 219.0718, found 
219.0713.







To a Schlenk flask under an inert atmosphere was added 1-(2-(2-((methoxymethyl)thio)phenyl)-1H-
pyrrol-1-yl)-2,2-dimethylpropan-1-one (161 mg, 0.74 mmol) and 4-methyl-4-formyl benzoate (61 mg, 
0.37 mmol). Dry DCM (6 mL) and TFA (ca. 0.1 mL) and the reaction mixure stirred for 3 hours 30 
minutes. Then, p-chloranil (181 mg, 0.74 mmol) was added as a solution in DCM (3 mL), and the 
reaction stirred for 10 minutes. The reaction mixture was then diluted with DCM and washed with 
water. The organic layers were then combined and dried over MgSO4 and solvent removed under 
reduced pressure to give methyl (Z)-4-((5-(2-((methoxymethyl)thio)phenyl)-1H-pyrrol-2-yl)(5-(2-
((methoxymethyl)thio)phenyl)-2H-pyrrol-2-ylidene)methyl)benzoate without the need for further 
purification (374 mg, 87%). 
Mp: 113-114 °C; Rf = 0.25 (10 :1 petrol 40-60:EtOAc); 1H NMR (300 MHz, CDCl3): δH 9.38 (br s, 1H, 20), 
8.14 (d, 2H, J = 8.3 Hz, 4), 7.74-7.68 (m, 4H, 13, 16), 7.65 (d, 2H, J = 8.3 Hz, 5), 7.35-7.24 (m, 4H, 14, 
15), 6.79 (d, 2H, J = 4.3 Hz, 9), 6.60 (d, 2H, J = 4.3 Hz, 10), 4.80 (s, 4H, 18), 3.99 (s, 3H, 1), 3.23 (s, 6H, 
19); 13C NMR (126 MHz, CDCl3): δC 166.8 (2), 154.1 (6), 143.3 (8), 142.1 (17), 136.3 (15), 132.9 (7), 131.0 
(4), 130.5 (11), 128.9 (5), 128.5 (3), 126.0 (16), 121.6 (13), 119.1 (14), 118.9 (12), 114.5 (9), 110.4 (10), 
55.9 (18), 52.3 (1), 27.5 (19); IR (neat): υmax/cm-1 2993 (w), 2948 (w), 2820 (w), 1720 (m); HRMS (TOF 
MS ASAP+) calcd for C33H30N2O4S2 [M+H]+ 583.1725, found 583.1734.




5.2.2.7 (2-((2-bromophenyl)thio)ethyl)trimethylsilane (3.4b) 
 
To a Schlenk flask under an inert atmosphere was added azobisisobutyronitrile (41 mg, 0.25 mmol), 
vinyltrimethylsilane (1.1 mL, 6 mmol) and 2-bromothiophenol (0.6 mL, 5 mmol). The reaction mixture 
was then stirred at 100 °C for 2 hours 30 minutes. The reaction mixture was diluted with petrol 40-60 
and passed through a short silica pad to give (2-((2-bromophenyl)thio)ethyl)trimethylsilane in a 
quantitative yield. 
Rf = 0.56 (petrol 40-60; UV light); 1H NMR (300 MHz, CDCl3): δH 7.54 (dd, 1H, J = 7.9, 1.3 Hz, 3), 7.30-
7.18 (m, 2H, 5,6), 7.01 (ddd, 1H, J = 7.9, 7.1, 1.8 Hz, 4), 3.00-2.92 (m, 2H, 7), 1.03-0.93 (m, 2H, 8), 0.07 
(s, 9H, 9); 13C NMR (96 MHz, CDCl3): δC 139.0 (1), 133.0 (3), 127.8 (5), 127.7 (4), 126.3 (6), 123.2 (2), 
28.9 (7), 16.2 (8), -1.6 (9); IR (neat): υmax/cm-1 3059 (w), 2951 (w); HRMS (TOF MS ASAP+) calcd for 
C11H1781BrSSi [M+H]+ 291.0061, found 291.0036.




5.2.2.8 2,2-dimethyl-1-(2-(2-((2-(trimethylsilyl)ethyl)thio)phenyl)-1H-pyrrol-1-yl)propan-1-one (3.5b) 
 
To a Schlenk flask under an inert atmosphere was added (2-((2-
bromophenyl)thio)ethyl)trimethylsilane (289 mg, 1 mmol), N-Boc-2-pyrrole boronic acid (317 mg, 1.5 
mmol), Pd(PPh3)4 (58 mg, 0.05 mmol) and K3PO4 (318 mg, 1.5 mmol). Solvent was added (THF : H2O, 
3.5 mL:1.5 mL) before heating to 75 °C and stirred for 24 hours. The reaction mixture was then diluted 
with DCM and washed with water. The organic layers were then combined and dried over MgSO4 and 
solvent removed under reduced pressure. The crude product was then purified by column 
chromatography (eluent system: 15:1 petrol 40-60:EtOAc) to give 2,2-dimethyl-1-(2-(2-((2-
(trimethylsilyl)ethyl)thio)phenyl)-1H-pyrrol-1-yl)propan-1-one (336 mg, 93%). 
Rf = 0.60 (10:1 petrol 40-60:EtOAc; UV light); 1H NMR (300 MHz, CDCl3): δH 7.37 (dd, 1H, J = 3.3, 1.8 Hz, 
13), 7.28-7.10 (m, 4H, 3, 4, 5, 6), 6.22 (app. t, 1H, 11), 6.09 (dd, 1H, J = 3.3, 1.8 Hz, 12), 2.76-2.68 (m, 
2H, 7), 1.23 (s, 9H, 16), 0.82-0.74 (m, 2H, 8), -0.05 (s, 9H, 9); 13C NMR (96 MHz, CDCl3): δC 149.3 (14), 
138.7 (1), 135.5 (5), 132.4 (10), 130.6 (6), 128.2 (3), 127.8 (4), 125.1 (2), 121.7 (13), 114.4 (11), 110.5 
(12), 83.1 (15), 28.7 (7), 27.6 (16), 16.8 (8), -1.7 (9); IR (neat): υmax/cm-1 2952 (w), 1737 (s); HRMS (TOF 
MS ASAP+) calcd for C20H29NO2SSi [M+H]+ 376.1767, found 376.1753.




5.2.2.9 2-(2-((2-(trimethylsilyl)ethyl)thio)phenyl)-1H-pyrrole (3.6b) 
 
2,2-dimethyl-1-(2-(2-((2-(trimethylsilyl)ethyl)thio)phenyl)-1H-pyrrol-1-yl)propan-1-one was placed in 
a 100 mL round bottomed flask under an inert atmosphere. Subsequently the flask was heated to 200 
°C resulting in the evolution of gas (CO2, isobutene), and rapid colour change of the oil. After 30 
minutes the flask was allowed to cool to room temperature. The dark purple oil was used immediately 
for the next reaction without purification. 
1H NMR (300 MHz, CDCl3): δH 9.92 (s, 1H, 14), 7.55 (dd, 1H, J = 7.8, 1.6 Hz, 3), 7.42 (dd, 1H, J = 7.8, 1.5 
Hz, 6), 7.27-7.21 (m, 1H, 5), 7.15 (app. td, 1H, 4), 6.90 (app. td, 1H, 13), 6.53 (ddd, 1H, J = 3.8, 2.6, 1.5 
Hz, 11), 6.29 (app. dt, 1H, 12), 2.81-2.71 (m, 2H, 7), 0.88-0.79 (m, 2H, 8), -0.03 (s, 9H, 9); 13C NMR (75 
MHz, CDCl3): δC 134.0 (1), 133.2 (5), 131.6 (10), 131.1 (6), 128.9 (3), 127.4 (4), 126.6 (13), 118.5 (2), 
109.2 (12), 108.8 (11), 30.8 (7), 17.0 (8), -1.7 (9); IR (neat): υmax/cm-1 3391 (br, w), 3057 (w), 2951 (w); 
HRMS (TOF MS ASAP+) calcd for C15H21NSSi [M+H]+ 276.1242, found 276.1240.







To a Schlenk flask under an inert atmosphere was added 2-(2-((2-(trimethylsilyl)ethyl)thio)phenyl)-1H-
pyrrole (120 mg, 0.44 mmol) and 4-methyl-4-formyl benzoate (36 mg, 0.22 mmol). Dry DCM (3.5 mL) 
and TFA (10 μL) and the reaction mixure stirred for 30 minutes. Then, p-chloranil (108 mg, 0.44 mmol) 
was added and the reaction stirred for 10 minutes. The reaction mixture was then diluted with DCM 
and washed with water. The organic layers were then combined and dried over MgSO4 and solvent 
removed under reduced pressure. The crude product was then purified by column chromatography 
(eluent system: 10:1 petrol 40-60:EtOAc) to give methyl (Z)-4-((5-(2-((2-
(trimethylsilyl)ethyl)thio)phenyl)-1H-pyrrol-2-yl)(5-(2-((2-(trimethylsilyl)ethyl)thio)phenyl)-2H-pyrrol-
2-ylidene)methyl)benzoate (96 mg, 64%). 
Mp: 99-101 °C; Rf = 0.50 (10:1 petrol 40-60:EtOAc); 1H NMR (300 MHz, CDCl3): δH 13.31 (s, 1H, 21), 8.14 
(d, 2H, J = 8.4 Hz, 4), 7.78 (d, 2H, J = 7.21 Hz, 13), 7.65 (d, 2H, J = 8.41 Hz, 5), 7.34-7.27 (m, 4H, 15, 16), 
7.23-7.16 (m, 2H, 14), 6.84 (d, 2H, J = 4.3 Hz, 9), 6.57 (d, 2H, J = 4.3 Hz, 10), 3.98 (s, 3H, 1), 2.84-2.75 
(m, 2H, 18), 0.71-0.62 (m, 2H, 19), -0.01 (s, 18H, 20); 13C NMR (75 MHz, CDCl3): δC 166.9 (2), 154.1 (11), 
142.4 (3), 141.0 (17), 140.8 (8), 138.4 (6), 137.8 (12), 132.1 (7), 131.0 (5), 130.3 (13), 129.0 (4), 128.9 
(15), 128.4 (10), 127.2 (16), 124.8 (14), 119.2 (9), 54.1 (1). 30.6 (18), 17.5 (19), 0.0 (20); IR (neat): 
υmax/cm-1 2951 (w), 1723 (m); HRMS (TOF ASAP+) calcd for C39H46N2O2S2Si2 [M+H]+ 695.2617, found 
695.2628.







To a Schlenk flask under an inert atmosphere was added methyl 4-(3,7-dibromo-5,5-difluoro-5H-
4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (200 mg, 0.41 mmol), 3-
methoxythiophene-2-boronic acid (394 mg, 1.64 mmol), Pd(PPh3)4 (24 mg, 5 mol %) and sodium 
carbonate (469 mg, 1.64 mmol) in toluene (2 mL) and 1,4-dioxane (2 mL).The reaction mixture was 
then refluxed at 90 °C for 23 hours. The reaction mixture was then diluted with DCM and washed with 
water. The organic layers were then combined and dried over MgSO4 and solvent removed under 
reduced pressure. The crude product was then purified by column chromatography (eluent system: 
4:1:1 petrol 40-60:EtOAc:toluene) to give methyl 4-(5,5-difluoro-3,7-bis(3-methoxythiophen-2-yl)-5H-
4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (190 mg, 0.35 mmol, 84%). 
Mp: 118-119 °C; Rf = 0.21 (3:1:1 petrol 40-60:EtOAc:toluene); 1H NMR (300 MHz, CDCl3): δH 8.16 (d, 
2H, J = 8.3 Hz, 4), 7.60 (d, 2H, J = 8.3 Hz, 5), 7.48 (d, 2H, J = 5.6 Hz, 15), 7.20 (d, 2H, J = 4.5 Hz, 9), 6.89 
(d, 2H, J = 5.6 Hz, 14), 6.69 (d, 2H, J = 4.5 Hz, 10), 3.98 (s, 3H, 1), 3.94 (s, 6H, 16); 13C NMR (75 MHz, 
CDCl3): δC 166.6 (2), 159.9 (13), 149.4 (11), 139.6 (6), 137.0 (7), 135.4 (3), 131.1 (8), 130.7 (4), 129.7 
(15), 129.4 (9), 128.4 (5), 122.0 (14), 115.1 (10), 111.5 (12), 59.0 (1), 52.5(16); 11B NMR (96 MHz, CDCl3): 
δB 1.51 (t, JB-F = 33.6 Hz); 19F NMR (282 MHz, CDCl3): δF -132.4 (q, JB-F = 33.6 Hz); IR (neat): υmax/cm-1 
1718 (m), 2991 (w), 3107 (w); HRMS (pNSI) calcd for C27H2111BF2N2O4S2 [M+H]+ 551.1082, found 
551.1068.







To a Schlenk flask under an inert atmosphere was added methyl 4-(3,7-dibromo-5,5-difluoro-5H-
4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (50 mg, 0.1 mmol), benzo[b]thien-2-
ylboronic acid (71 mg, 0.4 mmol), Pd(PPh3)4 (6 mg, 5 mol %) and sodium carbonate (114 mg, 0.4 mmol) 
in toluene (0.5 mL) and 1,4-dioxane (0.5 mL).The reaction mixture was then refluxed at 90 °C for 2 
hours. The reaction mixture was then diluted with DCM and washed with water. The organic layers 
were then combined and dried over MgSO4 and solvent removed under reduced pressure. The crude 
product was then purified by column chromatography (eluent system: 3:1 petrol 40-60:EtOAc) to give 
methyl 4-(3,7-bis(benzo[b]thiophen-2-yl)-5,5-difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-10-yl)benzoate (27 mg, 0.046 mmol, 46%). 
Mp: 296-297 °C; Rf = 0.35 (3:1 petrol 40-60:EtOAc); 1H NMR (300 MHz, CDCl3): δH 8.50 (s, 2H, 13), 8.21 
(d, 2H, J = 8.3 Hz, 4), 7.98-7.93 (m, 2H, 18), 7.87-7.81 (m, 2H, 15), 7.64 (d, 2H, J = 8.3 Hz, 5), 7.45-7.36 
(m, 4H, 16, 17), 6.94 (d, 2H, J = 4.4 Hz, 9), 6.81 (d, 2H, J = 4.4 Hz, 10), 4.00 (s, 3H, 1); 13C NMR (75 MHz, 
CDCl3): δC 166.5 (2), 151.2 (11), 141.2 (14), 140.9 (19), 140.4 (6), 138.7 (12), 137.3 (7), 133.4 (3), 131.8 
(8), 130.7 (17), 130.3 (5), 129.7 (16), 128.6 (18), 126.2 (15), 125.6 (4), 125.0 (9), 122.3 (10), 122.1 (13), 
52.7(1); 11B NMR (96 MHz, CDCl3): δB 1.80 (t, JB-F = 32.8 Hz); 19F NMR (282 MHz, CDCl3): δF -138.9 (q, JB-
F = 32.8 Hz); IR (neat): υmax/cm-1 1523 (s), 1722 (m), 2997 (w); HRMS (TOF MS ASAP+) calcd for 
C33H2111BF2N2O2S2 [M+H] 591.1190, found 591.1191; ε = 100 000 M-1 cm-1 (DCM); ɸF = 0.60 (DCM).







To a Schlenk flask under an inert atmosphere was added a mixture of methyl 4-(3,7-
bis(benzo[b]thiophen-2-yl)-5,5-difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-
yl)benzoate and methyl 4-(3-(benzo[b]thiophen-2-yl)-7-bromo-5,5-difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (31 mg), 2-hydroxybenzene boronic acid (17 mg, 0.12 
mmol), Pd(PPh3)4 (4 mg, 5 mol %) and sodium carbonate (34 mg, 0.12 mmol) in toluene (0.5 mL) and 
1,4-dioxane (0.5 mL).The reaction mixture was then refluxed at 90 °C for 24 hours. The reaction 
mixture was then diluted with DCM and washed with water. The organic layers were then combined 
and dried over MgSO4 and solvent removed under reduced pressure. The crude product was then 
purified by column chromatography (eluent system: 6:5:0.5 petrol 40-60:toluene:EtOAc) to give 
methyl 4-(10-(benzo[b]thiophen-2-yl)-10b-fluoro-10bH-11-oxa-4b1,10aλ4-diaza-10bλ4-
boracyclopenta[e]aceanthrylen-7-yl)benzoate (12.1 mg, 0.022 mmol, 17% over two steps). 
Mp: 267-269 °C; Rf = 0.26 (6:5:0.5 petrol 40-60:toluene:EtOAc); 1H NMR (300 MHz, CDCl3): δH 8.41 (s, 
1H, 13), 8.18 (d, 2H, J = 8.3 Hz, 4), 7.90-7.84 (m, 1H, 16), 7.82-7.78 (m, 1H, 17), 7.60 (d, 2H, J = 8.3 Hz, 
5), 7.49-7.41 (m, 2H, 25, 28), 7.38-7.28 (m, 4H, 15, 18, 26, 27), 6.84 (d, 1H, J = 4.3 Hz, 9), 6.77 (d, 1H, J 
= 4.7 Hz, 21), 6.69 (d, 1H, J = 4.3 Hz, 10), 5.80 (d, 1H, J = 4.7 Hz, 22), 3.98 (s, 3H, 1); 13C NMR (126 MHz, 
CDCl3): δC 167.1 (2), 166.5 (23), 154.3 (29), 147.6 (6), 141.1 (12), 140.5 (14), 139.5 (15), 138.3 (20), 
135.8 (21), 133.9 (22), 132.6 (27), 131.7 (7), 131.0 (11), 130.6 (25), 130.3 (4), 129.9 (5), 129.7 (3), 129.0 
(16), 127.9 (17), 126.8 (19), 125.6 (18), 125.2 (26), 124.7 (13), 122.1 (28), 121.9 (8), 120.9 (10), 120.0 
(24), 106.7 (9), 52.6 (1); 11B NMR (96 MHz, CDCl3): δB 1.19 (t, JB-F = 29.8 Hz); 19F NMR (282 MHz, CDCl3): 
δF -144.0 (q, JB-F = 29.8 Hz); IR (neat): υmax/cm-1 1523 (s), 1722 (m), 2997 (w); HRMS (TOF MS ASAP+) 
calcd for C31H2111BF2N2O3S [M+H]+ 551.1407, found 551.1401; ε = 52 000 M-1 cm-1 (DCM); ɸF = 0.85 
(DCM).




5.2.2.14 Methyl (Z)-4-((1H-pyrrol-2-yl)(2H-pyrrol-2-ylidene)methyl)benzoate (3.17) 
 
To a round bottomed flask, under an atmosphere of nitrogen, was added methyl 4-(di(1H-pyrrol-2-
yl)methyl)benzoate (1 g, 3.57 mmol) and p-chloranil (966 mg, 3.93 mmol) followed by DCM (40 mL). 
The resulting reaction mixture was stirred at room temperature for 18 hours. Subsequently, the 
reaction mixture was diluted with DCM and washed with brine and water. The organic layer was dried 
over Na2SO4, filtered, and the solvent removed under reduced pressure to give a dark solid. The crude 
product was used in subsequent reactions without further purification. 
Mp: = 128.4-129.8 °C [lit. 130-131 °C]; Rf = 0.42 (DCM; UV light); 1H NMR (300 MHz, CDCl3): δH 8.13 (d, 
2H, J = 8.4 Hz, 4), 7.68 (s, 2H, 11), 7.57 (d, 2H, J = 8.4 Hz, 5), 6.53 (d, 2H, J = 4.2 Hz, 9), 6.41 (d, 2H, J = 
4.2 Hz, 10), 3.97 (s, 3H, 1); 13C NMR (75 MHz, CDCl3): δC 166.7 (2), 144.1 (6), 141.8 (8), 141.0 (9), 139.8 
(7), 130.8 (4), 130.7 (5), 129.1 (3), 128.9 (10), 118.0 (11), 52.4 (1); IR(neat): υmax/cm-1 3143.9-2785.7 
(CH, w), 1718.3 (CO, s).




5.2.2.15 Methyl 4-(5,5-difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate 
(3.18) 
 
To a round bottom flask under an atmosphere of nitrogen was added methyl (Z)-4-((1H-pyrrol-2-
yl)(2H-pyrrol-2-ylidene)methyl)benzoate (0.5304 g, 1.91 mmol) and DCM (10 mL), followed by N,N-
diisopropylethylamine (0.92 mL, 5.27 mmol) and BF3.OEt2 (0.52 mL, 4.23 mmol). The resulting reaction 
mixture was stirred at room temperature for 1 hour, over which time the solution turned dark red. 
The reaction mixture was diluted with DCM (50 mL), washed with 0.1 M NaOH (100 mL), 0.1 M HCl 
(100 mL) and water (100 mL). The organic layer was dried over Na2SO4, filtered and the solvent 
removed under reduced pressure. The crude product was purified by silica gel column 
chromatography (DCM) to give methyl 4-(5,5-difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-10-yl)benzoate (0.2543 g, 0.78 mmol, 41% over two steps) as an orange solid. 
Rf 0.58 (DCM); Mp = 204.5-204.8 °C; 1H NMR (400 MHz, CDCl3): δH 8.20 (d, 1H, J = 8.6 Hz, 4), 7.97 (s, 
2H, 11), 7.65 (d, 1H, J = 8.6 Hz, 5), 6.89 (d, 2H, J = 4.3 Hz, 9), 6.57 (d, 1H, J = 4.1 Hz, 10), 3.99 (s, 3H, 1); 
13C NMR (75 MHz, CDCl3): δC 166.2 (2), 145.7 (6), 144.8 (8), 137.9 (9), 134.7 (7), 132.2 (4), 131.4 (5), 
130.4 (3), 129.6 (10), 119.0 (11), 52.5 (1); 11B NMR (96 MHz, CDCl3): δB 0.25 (t, JB-F = 28.5 Hz); 19F NMR 
(282MHz, CDCl3): δF -145.01 (q, JB-F = 28.5 Hz); IR(neat): υmax/cm-1 3142.9-2828.6 (CH, w), 1713.0 (CO, 
s). ε = 54 000 M-1 cm-1 (DCM).




5.2.2.16 Methyl 4-(3,7-dichloro-5,5-difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10 
yl)benzoate (3.19) 
 
Following a modified procedure from Jiao et al., to a round bottomed flask was added methyl 4-(5,5-
difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (86.5 mg, 0.27 mmol) 
and MeCN (2.2 mL). The resulting orange solution was heated to reflux and CuCl2.2H2O (0.45 g, 2.65 
mmol) was added. After 1 hour the reaction mixture was cooled to room temperature, diluted (DCM, 
50 mL) and washed with H2O (3x 30 mL). The organic layer was dried over Na2SO4, filtered, and the 
solvent removed under reduced pressure to a give a red solid. The crude product was purified by silica 
gel column chromatography (4:1 petrol 40-60:EtOAc) to give methyl 4-(3,7-dichloro-5,5-difluoro-5H-
4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (62.2 mg, 0.16 mmol, 59%) as a 
red/pink solid. 
Mp = 207-208 °C; Rf 0.65 (DCM); 1H NMR (300 MHz, CDCl3): δH 8.19 (d, 2H, J = 8.5 Hz, 4), 7.57 (d, 2H, J 
= 8.5 Hz, 5), 6.79 (d, 2H, J = 4.3 Hz, 9), 6.45 (d, 2H, J = 4.4 Hz, 10), 3.99 (s, 3H, 1); 13C NMR (176 MHz, 
CDCl3): δC 166.2 (2), 145.9 (6), 142.4 (7), 136.7 (4), 133.7 (5), 132.5 (3), 131.6 (8), 130.5 (9), 129.8 (11), 
119.5 (10), 52.7 (1); 11B NMR (96 MHz, CDCl3): δB 0.44 (t, JB-F = 27.9 Hz); 19F NMR (282MHz, CDCl3): δF -
148.14 (q, JB-F = 27.9 Hz); IR(neat): υmax/cm-1 3133-2800 (w), 1722 (m); HRMS (pNSI) calcd for 
C17H1210B35Cl2F2N2O2 [M+H]+: 394.0368, found 394.0361; ε = 39 000 M-1 cm-1 (DCM); ɸF = 0.18 (DCM).







To a round bottomed flask under an inert atmosphere was added methyl 4-(3,7-dichloro-5,5-difluoro-
5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10 yl)benzoate (21 mg, 0.05 mmol), 
trimethylamine (14 μL 0.1 mmol) and MeCN (1 mL). Subsequently, thiophenol (10 μL, 0.1 mmol) was 
added slowly. The reaction mixture was then stirred at room temperature for 30 minutes. The reaction 
mixture was then diluted with ethyl acetate and washed with HCl (1 M, 50 mL). The organic layers 
were then combined and dried over MgSO4 and solvent removed under reduced pressure. The crude 
product was then purified by column chromatography (eluent system: 4:1 petrol 40-60:EtOAc) to give 
methyl 4-(5,5-difluoro-3,7-bis(phenylthio)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-
yl)benzoate (25 mg, 0.046 mmol, 92%). 
Mp: 99-101 °C; Rf = 0.23 (4:1 petrol 40-60:EtOAc); 1H NMR (300 MHz, CDCl3): δH  8.11 (d, 2H, J = 8.3 Hz, 
4), 7.70 – 7.64 (m, 4H, 14, 16), 7.52 (d, 2H, J = 8.3 Hz, 5), 7.46 – 7.40 (m, 6H, 13, 15, 17), 6.54 (d, 2H, J 
= 4.4 Hz, 9), 5.88 (d, 2H, J = 4.4 Hz, 10), 3.94 (s, 3H,1); 13C NMR (176 MHz, CDCl3): δC 166.5 (2), 157.8 
(6), 138.3 (11), 136.9 (7), 135.9 (12), 135.0 (4), 131.5 (3), 130.4 (13), 130.2 (8), 129.8 (15), 129.8 (14), 
129.6 (5), 128.8 (9), 118.9 (10), 52.5 (1); 11B NMR (96 MHz, CDCl3): δB 1.02 (t, JB-F = 32.3 Hz); 19F NMR 
(282 MHz, CDCl3): δF -147.0 (q, JB-F = 32.3 Hz); IR (neat): υmax/cm-1 1542 (s), 1558 (m), 1712 (m), 2909 
(w), 3033 (w); HRMS (TOF MS ASAP+) calcd for C29H2111BF2N2O2S2 [M+H]+ 543.1189, found 543.1190; ε 
= 79 000 M-1 cm-1 (DCM); ɸF = 0.46 (DCM).







To a round bottomed flask under an inert atmosphere was added methyl 4-(3,7-dichloro-5,5-difluoro-
5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10 yl)benzoate (133 mg, 0.27 mmol), 
trimethylamine (20 μL 0.14 mmol) and THF (12 mL). The solution was then cooled to – 78 °C and 4-
(trifluoromethyl)thiophenol (37 μL, 0.27 mmol) added slowly. The reaction mixture was then stirred 
at – 78 °C for 1.5 hours. The reaction mixture was then allowed to warm to room temperature for 20 
minutes before it was diluted with ethyl acetate and washed with water. The organic layers were then 
combined and dried over MgSO4 and solvent removed under reduced pressure. The crude product 
was then purified by column chromatography (eluent system: 10:5:0.5  toluene:petrol 40-60:diethyl 
ether) to give methyl 4-(3-bromo-5,5-difluoro-7-((4-(trifluoromethyl)phenyl)thio)-5H-5λ4,6λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate (67 mg, 0.12 mmol, 43%). 
Mp: 167-169 °C; Rf = 0.28 (10:5:0.5  toluene:petrol 40-60:diethyl ether); 1H NMR (300 MHz, CDCl3): δH 
8.16 (d, 2H, J = 8.3 Hz, 4), 7.79 (d, 2H, J = 8.5 Hz, 14), 7.70 (d, 2H, J = 8.5 Hz, 13), 7.55 (d, 2H, J = 8.3 Hz, 
5), 6.71 (d, 1H, J = 4.6 Hz, 9), 6.62 (d, 1H, J = 4.2 Hz, 18), 6.49 (d, 1H, J = 4.2 Hz, 19), 5.98 (d, 1H, J = 4.6 
Hz, 10), 3.97 (s, 3H, 1); 13C NMR (75 MHz, CDCl3): δC 166.2 (2), 160.3 (15), 139.3 (6), 137.2 (16), 136.5 
(4), 134.8 (8), 134.7 (7), 134.2 (3), 133.8 (12), 132.0 (13), 131.5 (5), 130.3 (17), 129.6 (18), 129.0 (18), 
129.0 (19), 128.9 (9), 126.7 (q, JC-F = 3.7 Hz, 20), 121.5 (10), 120.4 (11), 52.5 (1); 11B NMR (96 MHz, 
CDCl3): δB 0.77 (t, JB-F = 30.6 Hz); 19F NMR (282 MHz, CDCl3): δF -62.9 (s), -146.7 (q, JB-F = 30.6 Hz); IR 
(neat): υmax/cm-1 3426 (w), 2954 (w), 1723 (m); HRMS (pNSI) calcd for C24H1510B81BrF5N2O232S [M+H] 
581.0134, found 581.0137.







To a Schlenk flask under an inert atmosphere was added methyl 4-(3-bromo-5,5-difluoro-7-((4-
(trifluoromethyl)phenyl)thio)-5H-5λ4,6λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate 
(97 mg, 0.17 mmol), 2-hydroxybenzene boronic acid (94 mg, 0.68 mmol), Pd(PPh3)4 (10 mg, 0.0083 
mmol), Na2CO3 (195 mg, 0.68 mmol), toluene (1 mL) and 1,4-dioxane (1 mL).The reaction mixture was 
then refluxed at 90 °C for 20 min. The reaction mixture was then diluted with DCM (50 mL) and washed 
with water (50 mL). The organic layers were then combined and dried over MgSO4 and solvent 
removed under reduced pressure. The crude product was then purified by column chromatography 
(eluent system: 10:5:0.5  toluene:petrol 40-60:diethyl ether) to give methyl 4-(5,5-difluoro-3-(2-
hydroxyphenyl)-7-((4-(trifluoromethyl)phenyl)thio)-5H-5λ4,6λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-10-yl)benzoate (20 mg, 0.034 mmol, 20%). This material was used immediately 
in the next step. 
Rf = 0.39 (5:1 petrol 40-60:EtOAc); 1H NMR (300 MHz, CDCl3): δH 8.19 (d, 2H, J = 8.5 Hz, 4), 7.73 (d, 2H, 
J = 8.4 Hz, 14), 7.67 (d, 2H, J = 8.4 Hz, 13), 7.63 (d, 2H, J = 8.5 Hz, 5), 7.57 (dd, 1H, J = 7.6, 1.7 Hz, 22), 
7.40-7.33 (m, 1H, 24), 7.09-7.02 (m, 2H, 25, 23), 6.83 (d, 1H, J = 4.2 Hz, 18), 6.73 (d, 1H, J = 4.5 Hz, 9), 
6.58 (d, 1H, J = 4.2 Hz, 19), 5.97 (d, 1H, J = 4.5 Hz, 10), 5.74 (br s, 1H, 26), 3.98 (s, 3H, 1); 11B NMR (96 
MHz, CDCl3): δB 0.97 (t, JB-F = 32.0 Hz); 19F NMR (282 MHz, CDCl3): δF -62.9 (s), -142.3 (dd, JB-F = 32.0 Hz).





10bl4-boracyclopenta[e]aceanthrylen-7-yl)benzoate (N,N,O,F-BODIPY 3.23) 
 
To a round bottomed flask under an inert atmosphere was added methyl 4-(5,5-difluoro-3-(2-
hydroxyphenyl)-7-((4-(trifluoromethyl)phenyl)thio)-5H-5λ4,6λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-10-yl)benzoate (20 mg, 0.034 mmol) and dry DCM (2 mL). N,N-
diisopropylethylamine (0.92 mL, 5.27 mmol) and BF3.OEt2 (0.52 mL, 4.23 mmol) were added, and the 
resulting reaction mixture was stirred at room temperature for 1 hour 15 minutes. The reaction 
mixture was diluted with DCM, and washed with water. The organic layer was dried over Na2SO4, 
filtered and the solvent removed under reduced pressure. The crude product was purified by silica gel 
column chromatography (5:1 petrol 40-60:EtOAc) to give methyl 4-(10b-fluoro-10-((4-
(trifluoromethyl)phenyl)thio)-10bH-11-oxa-4b1,10al4-diaza-10bl4-boracyclopenta[e]aceanthrylen-7-
yl)benzoate (2.6 mg, 0.005 mmol, 15%). 
Mp: 124-126 °C; Rf = 0.36 (5:1 petrol 40-60:EtOAc); 1H NMR (300 MHz, CDCl3): δH 8.19 (d, 2H, J = 8.5 
Hz, 4), 7.79-7.63 (m, 7H, 5, 24, 23, 16), 7.47 (ddd, 1H, J = 8.6, 7.2, 1.7 Hz, 15), 7.31-2.75 (m, 1H, 13), 
7.07 (m, 1H, 14), 7.00-6.95 (m, 2H, 19, 20), 6.83 (d, 1H, J = 4.3 Hz, 9), 6.17 (d, 1H, J = 4.3 Hz, 10), 4.00 
(s, 3H, 1); 13C NMR (176 MHz, CDCl3): δC 166.5 (2), 155.5 (21), 151.5 (17), 150.3 (6), 138.6 (22), 138.3 
(8), 137.0 (9), 136.9 (7), 133.6 (13), 133.4 (11), 133.1 (15), 131.9 (4), 131.1 (23), 130.9 (3), 130.6 (5), 
129.9 (25), 127.0 (24), 124.7 (26), 126.5 (14), 123.2 (18), 120.9 (12), 120.5 (10), 119.1 (16), 116.7 (20), 
116.2 (19), 52.6 (1); 11B NMR (96 MHz, CDCl3): δB 0.18 (d, JB-F = 46.5 Hz); 19F NMR (471 MHz, CDCl3): δF 
-62.75 (s), -141.68 (q, JB-F = 46.5 Hz); IR (neat): υmax/cm-1 2923 (w), 2852 (w), 1722 (m); HRMS (pAPCI) 
calcd for C30H1911BF4N2O332S [M+] 574.1145, found 574.1151; ε = 48 000 M-1 cm-1 (DCM); ɸF = 0.14 
(DCM).




5.2.3 Chapter 4 
5.2.3.1 5H-naphtho[1,2-e]pyrrolo[1,2-c][1,3]oxazin-5-one (4.5) 
 
To a Schlenk flask under an inert atmosphere was added 1-bromo-2-napthol (578 mg, 2 mmol), N-Boc-
2-pyrrole boronic acid (634 mg, 3 mmol), Pd(PPh3)4 (116 mg, 5 mol %) and K3PO4 (636 mg, 3 mmol). 
Solvent was added (THF:H2O, 7 mL:3.6 mL) before heating to 65 °C and stirring for 20 hours. The 
reaction mixture was then diluted with DCM and washed with water. The organic layers were then 
combined and dried over MgSO4 and solvent removed under reduced pressure. The crude product 
was then purified by column chromatography (eluent system: 15:1 petrol 40-60:EtOAc) to give 5H-
naphtho[1,2-e]pyrrolo[1,2-c][1,3]oxazin-5-one (298 mg, 64%). 
Mp: 153-154 °C; Rf = 0.40 (10:1 petrol 40-60:EtOAc; UV light); 1H NMR (300 MHz, CDCl3): δH 8.49 (d, 
1H, J = 8.6 Hz, 7), 7.88 (d, 1H, J = 8.1 Hz, 10), 7.77 (d, 1H, J = 8.9 Hz, 12), 7.70-7.64 (m, 2H, 1, 8), 7.55 
(ddd, 1H, J = 8.1, 6.9, 1.2 Hz, 9), 7.38 (d, 1H, J = 8.9 Hz, 13), 7.21 (dd, 1H, J = 3.7, 1.3 Hz, 3), 6.75 (t, 1H, 
J = 3.7 Hz, 2); 13C NMR (75 MHz, CDCl3): δC 146.3 (15), 144.1 (14), 131.4 (4), 129.7 (12), 129.3 (10), 
128.1 (8), 127.9 (6), 127.4 (11), 125.9 (9), 124.2 (7), 118.2 (1), 116.7 (13), 116.0 (2), 110.5 (3), 109.0 
(5); IR (neat): υmax/cm-1 1754 (s); HRMS (TOF MS ASAP+) calcd for C15H9NO2 [M+H]+ 236.0712, found 
236.0711.




5.2.3.2 1-(1H-pyrrol-2-yl)naphthalen-2-ol (4.4) 
 
To a round bottomed flask were added 5H-naphtho[1,2-e]pyrrolo[1,2-c][1,3]oxazin-5-one (815 mg, 
3.47 mmol), sodium hydroxide (27.76 g, 694 mmol), and ethanol (82 mL). The reaction mixture was 
stirred at room temperature for 1 hour. The reaction mixture was then neutralized with 2 M HCl, 
extracted with DCM and washed with water. The crude product was then purified by column 
chromatography (eluent system: 10:1 petrol 40-60:EtOAc) to give 1-(1H-pyrrol-2-yl)naphthalen-2-ol 
as a green oil (539 mg, 74%). 
Rf = 0.16 (10:1 petrol 40-60:EtOAc; UV light); 1H NMR (400 MHz, CDCl3): δH 8.31 (br s, 1H, 16), 7.82-
7.77 (m, 2H, 1, 12), 7.61 (d, 1H, J = 8.5 Hz, 7), 7.40 (ddd, 1H, J = 8.5, 6.8, 1.5 Hz, 8), 7.34 (ddd, 1H, J = 
8.1, 6.8, 1.3 Hz, 9), 7.25 (d, 1H, J = 8.9 Hz, 13), 7.07 (m, 1H, 3), 6.49-6.44 (m, 2H, 2, 10), 6.04 (br s, 1H, 
15); 13C NMR (101 MHz, CDCl3): δC 152.2 (14), 134.0 (6), 130.3 (12), 129.0 (4), 128.3 (1), 127.0 (8), 124.4 
(7), 123.6 (11), 123.3 (9), 120.1 (3), 117.3 (13), 112.6 (5), 110.4 (10), 110.0 (2); IR (neat): υmax/cm-1 3415 
(m), 3056 (w); HRMS (TOF MS ASAP+) calcd for C14H11NO [M+H]+ 210.0919, found 210.0914.




5.2.3.3 N,N,O,O-BODIPY 4.1 
 
To a Schlenk flask under an inert atmosphere was added 1-(1H-pyrrol-2-yl)naphthalen-2-ol (100 mg, 
0.36 mmol), 4-methyl-4-formyl benzoate (45 mg, 0.27 mmol) in DCM (2 mL). Then, TFA (5 µL) added 
dropwise, and the reaction mixture stirred for 1 hour at room temperature. Then p-chloranil (44 mg, 
0.18 mmol) was added, and reaction mixture stirred for 15 minutes. Then diisopropyl amine (0.15 mL, 
1.08 mmol) and boron triflouride diethyl etherate (0.16 mL, 1.26 mmol) were added and the reaction 
mixture stirred for 20 minutes. The reaction mixture was then diluted with DCM and washed with 
water. The organic layers were then combined and dried over MgSO4 and solvent removed under 
reduced pressure. The crude product was then purified by column chromatography (eluent system: 
4:1 toluene:DCM) to give N,N,O,O-BODIPY 4.1 (35 mg, 0.06 mmol, 16%). 
Mp: 350 °C (decomposed); Rf = 0.31 (4:1 toluene:DCM); 1H NMR (700 MHz, C6D6): δH 8.47 (d, 2H, J = 
8.3 Hz, 20), 8.10 (d, 2H, J = 8.3 Hz, 4), 7.53 (d, 2H, J = 7.9 Hz, 17), 7.42-7.37 (m, 4H, 19, 15), 7.34 (d, 2H, 
J = 8.3 Hz, 5), 7.22 (ddd, 2H, J = 7.9, 6.8, 1.2 Hz, 18), 7.05 (d, 2H, J = 4.4 Hz, 9), 6.76 (d, 2H, J = 4.4 Hz, 
10), 3.56 (s, 3H, 1); 13C NMR (176 MHz, C6D6): δC 166.2 (2), 155.0 (11), 149.8 (13), 138.9 (6), 135.5 (21), 
134.3 (7), 133.3 (15), 132.1 (3), 131.4 (8), 131.0 (5), 130.0 (16), 129.6 (4), 129.3 (10), 129.2 (17), 124.8 
(20), 124.2 (18), 121.6 (14), 119.0 (9), 114.5 (12), 51.9 (1); 11B NMR (128 MHz, C6D6): δB 0.07 (s); IR 
(neat): υmax/cm-1 1723 (m); HRMS (TOF MS ASAP+) calcd for C37H2311BN2O4 [M+H]+ 571.1835, found 
571.1827; ε = 43000 M-1 cm-1 (DCM); ɸF = 0.24 (DCM).





5.3 Photophysical and Chiroptical Measurements. 




Figure 5.1: Absorption and emission spectra of BODIPY 2.11, measured in DCM. Excitation 
wavelength used for emission: 510 nm. 
5.3.1.2 N,N,O,O-BODIPY 2.13 
 
Figure 5.2: Absorption and emission spectra of BODIPY 2.13, measured in DCM. Excitation 
wavelength for emission: 570 nm (DCM).





ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.18) 
 
Figure 5.3: Absorption and emission spectra of BODIPY 2.18, measured in DCM. Excitation 
wavelength for emission: 525 nm (DCM). 
5.3.1.4 Methyl 4-(9,14-dimethyl-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-borabenzo[5,6]indeno[3,4-
ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.32) 
 
Figure 5.4: Absorption and emission spectra of BODIPY 2.32, measured in DCM. Excitation 
wavelength for emission: 575 nm (DCM).





ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.33) 
 
Figure 5.5: Absorption and emission spectra of BODIPY 2.33, measured in DCM. Excitation 
wavelength for emission: 555 nm (DCM). 
5.3.1.6 Methyl 4-(7,12-dichloro-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-borabenzo[5,6]indeno[3,4-
ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.34) 
 
Figure 5.6: Absorption and emission spectra of BODIPY 2.34, measured in DCM. Excitation 
wavelength for emission: 575 nm (DCM).





ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.35) 
 
Figure 5.7: Absorption and emission spectra of BODIPY 2.35, measured in DCM. Excitation 




Figure 5.8: Absorption and emission spectra of BODIPY 3.2, measured in DCM. Excitation wavelength 
for emission: 520 nm (DCM).







Figure 5.9: Absorption and emission spectra of BODIPY 3.15, measured in DCM. Excitation 




Figure 5.10: Absorption and emission spectra of BODIPY 3.16, measured in DCM. Excitation 
wavelength for emission: 535 nm. (DCM).




5.3.1.11 Methyl 4-(5,5-difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate 
(3.18) 
 
Figure 5.11: Absorption and emission spectra of BODIPY 3.18, measured in DCM. Excitation 
wavelength for emission: 475 nm. (DCM). 
5.3.1.12 Methyl 4-(3,7-dichloro-5,5-difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10 
yl)benzoate (3.19) 
 
Figure 5.12: Absorption and emission spectra of BODIPY 3.19, measured in DCM. Excitation 
wavelength for emission: 507 nm. (DCM).







Figure 5.13: Absorption and emission spectra of BODIPY 3.21, measured in DCM. Excitation 




Figure 5.14: Absorption and emission spectra of BODIPY 3.24, measured in DCM. Excitation 
wavelength for emission: 510 nm (DCM).





10bl4-boracyclopenta[e]aceanthrylen-7-yl)benzoate (N,N,O,F-BODIPY 3.23) 
 
Figure 5.15: Absorption and emission spectra of BODIPY 3.23, measured in DCM. Excitation 
wavelength for emission: 545 nm (DCM). 
5.3.1.16 N,N,O,O-BODIPY 4.1 
 
Figure 5.16: Absorption and emission spectra of BODIPY 4.1, measured in DCM. Excitation 
wavelength for emission: 665 nm (DCM).




5.3.2 Molar Extinction Coefficients 
Molar extinction coefficients were obtained by measuring the absorbance at the absorptive λmax over 
a 4-10 point dilution series. The absorbance values for the series were then plotted against the molar 
concentrations of the series to calculate the molar extinction coefficient (ε) using the following 
equation: 
𝐴 =  𝜀𝑙𝑐 
Where 𝐴 is the absorbance ([au]), 𝜀 is the molar extinction coefficient (M-1 cm-1), 𝑙 is the path length 




Figure 5.17: Absorbance at the absorptive λmax plotted against molar concentration of a 8 point 
dilution series. Measured in DCM, ε = 84 000 M-1 cm-1.




5.3.2.2 N,N,O,O-BODIPY 2.13 
 
Figure 5.18: Absorbance at the absorptive λmax plotted against molar concentration of a 10 point 
dilution series. Measured in DCM, ε = 24 000 M-1 cm-1. 
5.3.2.3 Methyl 4-(9,14-dimethyl-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-borabenzo[5,6]indeno[3,4-
ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.18) 
 
Figure 5.19: Absorbance at the absorptive λmax plotted against molar concentration of a 4 point 
dilution series. Measured in hexane, ε = 30 000 M-1 cm-1.





ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.32) 
 
Figure 5.20: Absorbance at the absorptive λmax plotted against molar concentration of a 7 point 
dilution series. Measured in DCM, ε = 24 000 M-1 cm-1. 
5.3.2.5 Methyl 4-(7,12-dimethyl-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-borabenzo[5,6]indeno[3,4-
ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.33) 
 
Figure 5.21: Absorbance at the absorptive λmax plotted against molar concentration of a 7 point 
dilution series. Measured in DCM, ε = 39 000 M-1 cm-1.





ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.34) 
 
Figure 5.22: Absorbance at the absorptive λmax plotted against molar concentration of a 7 point 
dilution series. Measured in DCM, ε = 52 000 M-1 cm-1. 
5.3.2.7 Methyl 4-(7,12-difluoro-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-borabenzo[5,6]indeno[3,4-
ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.35) 
 
Figure 5.23: Absorbance at the absorptive λmax plotted against molar concentration of a 7 point 
dilution series. Measured in DCM, ε = 32 000 M-1 cm-1.







Figure 5.24: Absorbance at the absorptive λmax plotted against molar concentration of a 5 point 




Figure 5.25: Absorbance at the absorptive λmax plotted against molar concentration of a 5 point 
dilution series. Measured in DCM, ε = 100 000 M-1 cm-1.







Figure 5.26: Absorbance at the absorptive λmax plotted against molar concentration of a 6 point 
dilution series. Measured in DCM, ε = 57 000 M-1 cm-1. 
5.3.1.11 Methyl 4-(5,5-difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)benzoate 
(3.18) 
 
Figure 5.27: Absorbance at the absorptive λmax plotted against molar concentration of a 7 point 
dilution series. Measured in DCM, ε = 54 000 M-1 cm-1.




5.3.1.12 Methyl 4-(3,7-dichloro-5,5-difluoro-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10 
yl)benzoate (3.19) 
 
Figure 5.28: Absorbance at the absorptive λmax plotted against molar concentration of a 5 point 




Figure 5.29: Absorbance at the absorptive λmax plotted against molar concentration of a 5 point 
dilution series. Measured in DCM, ε = 79 000 M-1 cm-1.





10bl4-boracyclopenta[e]aceanthrylen-7-yl)benzoate (N,N,O,F-BODIPY 3.23) 
 
Figure 5.30: Absorbance at the absorptive λmax plotted against molar concentration of an 8 point 
dilution series. Measured in DCM, ε = 48 000 M-1 cm-1. 
5.3.2.15 N,N,O,O-BODIPY 4.1 
 
Figure 5.31: Absorbance at the absorptive λmax plotted against molar concentration of an 8 point 
dilution series. Measured in DCM, ε = 43 000 M-1 cm-1.




5.3.3 Fluorescence Quantum Yields 
Fluorescence quantum yields (ɸF) were obtained by recording emission spectra of a suitable reference 
compound and emission spectra of the BODIPY. It is important that the emission peak of the reference 
compound has the maximum overlap possible with the emission peak of the BODIPY to ensure an 
accurate measurement of the ɸF. Furthermore the absorbance at the excitation wavelength of the 
reference sample should be as similar as possible to the absorbance at the excitation wavelength of 
the BODIPY sample, and the same excitation wavelength should be used for both measurements. 
The fluorescence quantum yield was then calculated using the following equation: 





Where 𝜑𝐹 𝑟𝑒𝑓 is the fluorescence quantum yield of the reference compound, 𝐼 is the area under the 
emission peak, 𝜂 is the refractive index of the solvent, and 𝐴 is the absorbance at the excitation 
wavelength. 













A Aref I Iref ɸF 
2.13 Oxazine 1 0.11 (MeOH)174 DCM 1.4125 MeOH 1.3145 590 0.05080 0.05138 7555728 1659292 0.58 
2.18 Cresyl Violet 0.54 (MeOH)175 hexane 1.3741 MeOH 1.3145 520 0.0106 0.0106 8667874 10469931 0.49 
2.32 Cresyl Violet 0.54 (MeOH)175 DCM 1.4125 MeOH 1.3145 528 0.010 0.010 870533 1877058 0.41 
2.33 Cresyl Violet 0.54 (MeOH)175 DCM 1.4125 MeOH 1.3145 535 0.013 0.013 74234 1807890 0.25 
2.34 Cresyl Violet 0.54 (MeOH)175 DCM 1.4125 MeOH 1.3145 545 0.017 0.017 1930163 3165515 0.37 
2.35 Cresyl Violet 0.54 (MeOH)175 DCM 1.4125 MeOH 1.3145 535 0.013 0.013 1267511 1807890 0.43 
3.15 Oxazine 1 0.11 (MeOH)174 DCM 1.4125 MeOH 1.3145 590 0.05321 0.05138 8219872 1659292 0.60 
3.16 Cresyl Violet 0.54 (MeOH)175 DCM 1.4125 MeOH 1.3145 535 0.0207 0.0207 2163451 2053192 0.85 
3.19 Rhodamine 6G 0.92 (H2O)176 DCM 1.4125 H2O 1.333 507 0.0427 0.0427 1303785 7450201 0.18 
3.21 Cresyl Violet 0.54 (MeOH)175 DCM 1.4125 MeOH 1.3145 566 0.0408 0.0408 2360485 4141907 0.46 
3.23 Cresyl Violet 0.54 (MeOH)175 DCM 1.4125 MeOH 1.3145 545 0.0270 0.0270 480311 2753627 0.14 
4.1 Oxazine 1 0.11 (MeOH)174 DCM 1.4125 MeOH 1.3145 590 0.05138 0.05138 3222627 1659292 0.24 
Table 5.1: Data used to calculate the fluorescence quantum yields of final BODIPY products. 
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5.3.4 Experimental and Calculated Electronic Circular Dichroism Spectra  
5.3.4.1 3-(4-(methoxycarbonyl)phenyl)-10,15-dioxa-2a1,3a1-diaza-10a-borabenzo[5,6]indeno[1,7-
ef]aceanthrylen-2a1-ium-16-uide (N,N,O,C-BODIPY 2.18) 
Boltzmann-weighted UV-vis and ECD spectra for the postulated enantiomer (M)-(+)-2.18 were 
obtained from TD-DFT calculations at the cam-B3LYP/6-311++G(3df,2pd) level.177 First a low-energy 
conformation library was generated, followed by calculation of the individual ECD spectra for each of 
the low-energy conformations. The combined Boltzmann-weighted spectrum was blue-shift corrected 
by 10 nm, to compensate for the typical underestimation of transition energies by TD-DFT (Wouter 
Herrebout).178 
  
Figure 5.32: (a) Experimental ECD spectra for (P)-(-)-2.18 (blue), (M)-(+)-2.18 (red) and the 
experimental UV/Vis absorption spectra for (rac)-2.18; (b) Calculated ECD spectra for the postulated 
enantiomer (M)-(+)-2.18 (top) and the calculated UV/Vis absorption spectra for (rac)-2.18 (bottom); 
(c) Structure of the calculated lowest energy conformation of (M)-(+)-2.18.




ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.32) 
Boltzmann-weighted UV-vis and ECD spectra for the postulated enantiomer (P)-(-)-2.32 were obtained 
from TD-DFT calculations at the cam-B3LYP/6-311++G(3df,2pd) level.179 First a low-energy 
conformation library was generated, followed by calculation of the individual ECD spectra for each of 
the low-energy conformations (Jonathan Bogaerts). 
 
Figure 5.33: (a) Experimental ECD spectra for (P)-(-)-2.32 (orange), (M)-(+)-2.32 (blue) and the 
calculated ECD spectra for the postulated enantiomer (P)-(-)-2.32; (b) Structure of the calculated 
lowest energy conformation of (P)-(-)-2.32.




ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.33) 
Boltzmann-weighted UV-vis and ECD spectra for the postulated enantiomer (P)-(-)-2.33 were obtained 
from TD-DFT calculations at the cam-B3LYP/6-311++G(3df,2pd) level.179 First a low-energy 
conformation library was generated, followed by calculation of the individual ECD spectra for each of 
the low-energy conformations (Jonathan Bogaerts). 
 
Figure 5.34: (a) Experimental ECD spectra for (P)-(-)-2.33 (orange), (M)-(+)-2.33 (blue) and the 
calculated ECD spectra for the postulated enantiomer (P)-(-)-2.33; (b) Structure of the calculated 
lowest energy conformation of (P)-(-)-2.33.




ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.34) 
Boltzmann-weighted UV-vis and ECD spectra for the postulated enantiomer (P)-(-)-2.34 were obtained 
from TD-DFT calculations at the cam-B3LYP/6-311++G(3df,2pd) level.179 First a low-energy 
conformation library was generated, followed by calculation of the individual ECD spectra for each of 
the low-energy conformations (Jonathan Bogaerts). 
 
Figure 5.35: (a) Experimental ECD spectra for (P)-(-)-2.34 (orange), (M)-(+)-2.34 (blue) and the 
calculated ECD spectra for the postulated enantiomer (P)-(-)-2.34; (b) Structure of the calculated 
lowest energy conformation of (P)-(-)-2.34.




ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.35) 
Boltzmann-weighted UV-vis and ECD spectra for the postulated enantiomer (P)-(-)-2.35 were obtained 
from TD-DFT calculations at the cam-B3LYP/6-311++G(3df,2pd) level.179 First a low-energy 
conformation library was generated, followed by calculation of the individual ECD spectra for each of 
the low-energy conformations (Jonathan Bogaerts). 
 
Figure 5.36: (a) Experimental ECD spectra for (P)-(-)-2.35 (orange), (M)-(+)-2.35 (blue) and the 
calculated ECD spectra for the postulated enantiomer (P)-(-)-2.35; (b) Structure of the calculated 
lowest energy conformation of (P)-(-)-2.35.   
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5.3.4.6 N,N,O,O-BODIPY 4.1 
Boltzmann-weighted UV-vis and ECD spectra for the postulated enantiomer (M)-(+)-2.18 were 
obtained from TD-DFT calculations at the cam-B3LYP/6-311++G(3df,2pd) level.177 First a low-energy 
conformation library was generated, followed by calculation of the individual ECD spectra for each of 
the low-energy conformations. Due to unsatisfactory agreement between the calculated and 
experimental ECD spectra using the TD-DFT calculations at the cam-B3LYP/6-311++G(3df,2pd) level, 
calculations were repeated at the B3LYP and B3PW91 levels. It was found that the best agreement 
between the experimental and calculated ECD spectra was obtained using TD-DFT calculations at the 
B3LYP level (Jonathan Bogaerts and Wouter Herrebout). 
 
Figure 5.37: (a) Experimental ECD spectra for (P)-(-)-4.1 (blue), (M)-(+)-4.1 (orange) and the 
calculated ECD spectra for the postulated enantiomer (M)-(-)-4.1; (b) Structure of the calculated 
lowest energy conformation of (M)-(-)-4.1.
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5.3.5 Circularly Polarised Luminescence Spectra 
The CPL spectra were recorded on a custom built spectrometer 15 consisting of a laser driven light 
source (Energetiq EQ-99 LDLS, spectral range 170 to 2100 nm) coupled to an Acton SP2150 
monochromator (600 g/nm, 300 nm Blaze) that allows excitation wavelengths to be selected with a 6 
nm FWHM band-pass. The collection of the emitted light was facilitated (90° angle set up, 1 cm path 
length quartz cuvette) by a Lock-In Amplifier (Hinds Instruments Signaloc 2100) and Photoelastic 
Modulator (Hinds Instruments PEM-90). The differentiated light was focused onto an Acton SP2150 
monochromator (1200 g/nm, 500 nm Blaze) equipped with a high sensitivity cooled Photo Multiplier 
Tube (Hamamatsu 10723-20 red corrected). The detection of the CPL signal was achieved using the 
field modulation lockin technique. The electronic signal from the PMT was fed into the lock-in 
amplifier (Hinds Instruments Signaloc 2100). The reference signal for the lock-in detection was 
provided by the PEM control unit. The monochromators, PEM control unit and lockin amplifier were 
interfaced with a desktop PC and controlled by Labview2013 code. A correction factor for the 
wavelength dependence of the detection system was constructed using a calibrated lamp (Ocean 
Optics, CAL_200). The measured raw data was subsequently corrected using this correction factor. 
The validation of the CPL detection systems was achieved using a light emitting diodes (LEDs) at v650 
nm wavelength. The LED was mounted in the sample holder and the light from the LED was fed 
through a broad-band polarising filter and quarter wave plate (Thor Labs) to generate circularly 
polarised light. Prior to all measurements, this technique was used to set the phase of the lock-in 
amplifier correctly. Spectra were recorded using a 5 spectral average sequence in the range of 400-
800 nm, with 0.5 nm spectral intervals and using a 500 microsecond integration time. 
All CPL spectra were collected by either Dr Robert Pal (N,N,O,C-BODIPY 2.18) or Dr Lewis Mackenzie.




ef]aceanthrylen-2a1-ium-16-uide (N,N,O,C-BODIPY 2.18) 
 
Figure 5.38: Experimental CPL spectra of (M)-(+)-2.18. 
 
Figure 5.39: Experimental CPL spectra of (P)-(-)-2.18.




ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.32) 
 
Figure 5.40: Experimental CPL spectra of (M)-(+)-2.32. 
 
Figure 5.41: Experimental CPL spectra of (P)-(-)-2.32.




ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.33) 
 
Figure 5.42: Experimental CPL spectra of (P)-(-)-2.33. 
 
Figure 5.43: Experimental CPL spectra of (M)-(+)-2.33.




ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.34) 
 
Figure 5.44: Experimental CPL spectra of (P)-(-)-2.34. 
 
Figure 5.44: Experimental CPL spectra of (M)-(+)-2.34.




ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.35) 
 
Figure 5.45: Experimental CPL spectra of (M)-(+)-2.35. 
 
Figure 5.46: Experimental CPL spectra of (P)-(-)-2.35.




boracyclopenta[e]aceanthrylen-7-yl)benzoate (N,N,O,F-BODIPY 3.23) 
 
Figure 5.47: Experimental CPL spectra of (-)-3.23. 
 
Figure 5.48: Experimental CPL spectra of (+)-3.23.
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5.3.5.7 N,N,O,O-BODIPY 4.1 
 
Figure 5.49: Experimental CPL spectra of (-)-4.1. 
 
Figure 5.50: Experimental CPL spectra of (+)-4.1.
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5.3.6 Specific Optical Rotation Measurements 
The αobs was calculated according to the following equation: 
𝛼𝑜𝑏𝑠 = (𝑅 − 𝐵2) − (𝑆 − 𝐵1) 
Where R is the reading for the sample, S is the reading for the solvent, and B1 and B2 are blank 
recordings made before and after the measurement of the sample. Then [α]D was calculating using 





Where C is the concentration in g/mL, and d is the path length of the cell in dm. In all cases presented, 
the path length of the cell was 0.5 dm. 
Compound B1 S R B2 αobs C [α]D 
(M)-(+)-2.18 0.000 0.000 0.005 0.000 0.005 4.44×10-6 2252° 
(P)-(-)-2.18 0.000 0.002 -0.003 0.000 -0.005 4.76×10-6 -2100° 
(M)-(+)-2.32 0.005 0.005 0.024 0.010 0.014 5.56×10-6 5034° 
(P)-(-)-2.32 0.006 0.011 0.084 0.094 -0.015 6.19×10-6 -4847° 
(P)-(-)-2.33 0.000 -0.051 -0.072 -0.008 -0.013 4.60×10-6 -5652° 
(M)-(+)-2.33 -0.018 0.021 0.025 -0.028 0.014 6.43×10-6 4355° 
(P)-(-)-2.34 0.000 0.106 -0.020 -0.010 -0.116 1.88×10-6 -123404° 
(M)-(+)-2.34 0.000 -0.008 0.150 0.052 0.106 1.88×10-6 112766° 
(M)-(+)-2.35 -0.001 -0.011 0.050 -0.001 0.061 5.52×10-6 22101° 
(P)-(-)-2.35 -0.001 -0.018 -0.067 -0.009 -0.041 6.68×10-6 -12275° 
(-)-3.23 0.000 -0.037 -0.087 -0.019 -0.105 6.9×10-6 -30434° 
(+)-3.23 0.004 -0.020 0.023 -0.019 0.066 6.7×10-6 19701° 
(-)-4.1 0.054 0.079 0.045 0.110 -0.09 2.94×10-6 -61224° 
(+)-4.1 0.110 0.086 0.176 0.110 0.09 3.89×10-6 46272° 
Table 5.2: Measurements used to calculate the specific optical rotation ([α]D). 
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5.4 HPLC Methods and Chromatograms 
5.4.1 Chapter 2 
5.4.1.1 3-(4-(methoxycarbonyl)phenyl)-10,15-dioxa-2a1,3a1-diaza-10a-borabenzo[5,6]indeno[1,7-
ef]aceanthrylen-2a1-ium-16-uide (N,N,O,C-BODIPY 2.18) 
Resolution of the enantiomers of N,N,O,C-BODIPY 2.18 was performed on a Varian ProStar HPLC, fitted 
with: 
• Autosampler Model 410, 
• two Pumps Model 200, 
• Column Valve Module Model 500, 
• Diode Array Detector Model 335, 
• Daicel Chiralpak® IB column, 4.6×250 mm, 5 µm particle size. 
A 1 mg/mL solution of N,N,O,C-BODIPY 2.18 (in 80:20 hexane:ethyl acetate) was prepared. Runs were 
performed at a flow rate of 1 mL/minute using 85:15 hexane:ethyl acetate as eluent and a run length 
of 23 minutes. The detection wavelength used was 580 nm. We performed 12 runs of 20 µL injections 
and combined the fractions from each run. 
 
Figure 5.51: A typical chromatogram of the resolution of the enantiomers of N,N,O,C-BODIPY 2.18. 
After the runs were completed, we resubmitted the collected enantiomers to the same conditions to 
assess the enantiomeric excess (ee). 




Figure 5.52: Chromatogram of enantiomer 1 (M)-(+)-2.18 resubmitted to the separation conditions 
to assess the ee. 
 
Figure 5.53: Chromatogram of enantiomer 2 (P)-(-)-2.18 resubmitted to the separation conditions to 
assess the ee. 
5.4.1.2 Methyl 4-(9,14-dimethyl-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-borabenzo[5,6]indeno[3,4-
ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.32) 
Resolution of the enantiomers of N,N,O,C-BODIPY 2.32 was performed on a Perkin Elmer HPLC, fitted 
with: 
• Perkin Elmer Series 200 Autosampler, 
• Perkin Elmer Series 200 Pump, 
• Perkin Elmer Peltier Oven Selector Series 200, 
• Perkin Elmer Diode Array Detector Series 200, 
• Daicel Chiralpak® IA column, 4.6×250 mm, 5 µm particle size. 
A 1 mg/mL solution of N,N,O,C-BODIPY 2.32 (in 80:20 hexane:DCM) was prepared. Runs were 
performed at a flow rate of 1 mL/minute using 85:15 hexane:DCM as eluent and a run length of 20 
minutes. The detection wavelength used was 580 nm. We performed 6 runs of 20 µL injections and 
combined the fractions from each run. 
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Figure 5.54: A typical chromatogram of the resolution of the enantiomers of N,N,O,C-BODIPY 2.32. 
After the runs were completed, we resubmitted the collected enantiomers to the same conditions to 
assess the enantiomeric excess (ee). 
Figure 5.55: Chromatogram of enantiomer 1 (M)-(+)-2.32 resubmitted to the separation conditions 
to assess the ee. 




Figure 5.56: Chromatogram of enantiomer 2 (P)-(-)-2.32 resubmitted to the separation conditions to 
assess the ee. 
5.4.1.3 Methyl 4-(7,12-dimethyl-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-borabenzo[5,6]indeno[3,4-
ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.33) 
Resolution of the enantiomers of N,N,O,C-BODIPY 2.33 was performed on a Perkin Elmer HPLC, fitted 
with: 
• Perkin Elmer Series 200 Autosampler, 
• Perkin Elmer Series 200 Pump, 
• Perkin Elmer Peltier Oven Selector Series 200, 
• Perkin Elmer Diode Array Detector Series 200, 
• Daicel Chiralpak® IA column, 4.6×250 mm, 5 µm particle size. 
A 1 mg/mL solution of N,N,O,C-BODIPY 2.33 (in toluene) was prepared. Runs were performed at a flow 
rate of 1 mL/minute using toluene as eluent and a run length of 10 minutes. The detection wavelength 
used was 580 nm. We performed 6 runs of 20 µL injections and combined the fractions from each run. 
Figure 5.57: A typical chromatogram of the resolution of the enantiomers of N,N,O,C-BODIPY 2.33. 
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After the runs were completed, we resubmitted the collected enantiomers to the same conditions to 
assess the enantiomeric excess (ee). 
Figure 5.58: Chromatogram of enantiomer 1 (M)-(+)-2.33 resubmitted to the separation conditions 
to assess the ee. 
 
Figure 5.59: Chromatogram of enantiomer 2 (P)-(-)-2.33 resubmitted to the separation conditions to 
assess the ee. 
5.4.1.4 Methyl 4-(7,12-dichloro-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-borabenzo[5,6]indeno[3,4-
ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.34) 
Resolution of the enantiomers of N,N,O,C-BODIPY 2.34 was performed on a Perkin Elmer HPLC, fitted 
with: 
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• Perkin Elmer Series 200 Autosampler, 
• Perkin Elmer Series 200 Pump, 
• Perkin Elmer Peltier Oven Selector Series 200, 
• Perkin Elmer Diode Array Detector Series 200, 
• Daicel Chiralpak® IA column, 4.6×250 mm, 5 µm particle size. 
A 1 mg/mL solution of N,N,O,C-BODIPY 2.34 (in 80:20 toluene:hexane) was prepared. Runs were 
performed at a flow rate of 1 mL/minute using 80:20 toluene:hexane as eluent and a run length of 10 
minutes. The detection wavelength used was 580 nm. We performed 10 runs of 20 µL injections and 
combined the fractions from each run. 
 
Figure 5.60: A typical chromatogram of the resolution of the enantiomers of N,N,O,C-BODIPY 2.34. 
After the runs were completed, we resubmitted the collected enantiomers to the same conditions to 
assess the enantiomeric excess (ee). 
 
Figure 5.61: Chromatogram of enantiomer 1 (M)-(+)-2.34 resubmitted to the separation conditions 
to assess the ee. 




Figure 5.62: Chromatogram of enantiomer 2 (P)-(-)-2.34 resubmitted to the separation conditions to 
assess the ee. 
5.4.1.5 Methyl 4-(7,12-difluoro-10,15-dioxa-2a1λ4,3a1-diaza-10aλ4-borabenzo[5,6]indeno[3,4-
ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.35) 
Resolution of the enantiomers of N,N,O,C-BODIPY 2.35 was performed on a Perkin Elmer HPLC, fitted 
with: 
• Perkin Elmer Series 200 Autosampler, 
• Perkin Elmer Series 200 Pump, 
• Perkin Elmer Peltier Oven Selector Series 200, 
• Perkin Elmer Diode Array Detector Series 200, 
• Daicel Chiralpak® OD-H column, 4.6×250 mm, 5 µm particle size. 
A 1 mg/mL solution of N,N,O,C-BODIPY 2.35 (in 95:5 hexane:IPA) was prepared. Runs were performed 
at a flow rate of 1 mL/minute using toluene as eluent and a run length of 25 minutes. The detection 
wavelength used was 580 nm. We performed 11 runs of 20 µL injections and combined the fractions 
from each run. 
Figure 5.63: A typical chromatogram of the resolution of the enantiomers of N,N,O,C-BODIPY 2.35. 
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After the runs were completed, we resubmitted the collected enantiomers to the same conditions to 
assess the enantiomeric excess (ee). 
Figure 5.64: Chromatogram of enantiomer 1 (M)-(+)-2.35 resubmitted to the separation conditions 
to assess the ee. 
 
Figure 5.65: Chromatogram of enantiomer 2 (P)-(-)-2.35 resubmitted to the separation conditions to 
assess the ee. 
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5.4.2 Chapter 3 
5.4.2.1 Methyl 4-(10b-fluoro-10-((4-(trifluoromethyl)phenyl)thio)-10bH-11-oxa-4b1,10al4-diaza-10bl4-
boracyclopenta[e]aceanthrylen-7-yl)benzoate (N,N,O,F-BODIPY 3.23) 
Resolution of the enantiomers of N,N,O,F-BODIPY X was performed on a Perkin Elmer HPLC, fitted 
with: 
• Perkin Elmer Series 200 Autosampler, 
• Perkin Elmer Series 200 Pump, 
• Perkin Elmer Peltier Oven Selector Series 200, 
• Perkin Elmer Diode Array Detector Series 200, 
• Daicel Chiralpak® IA column, 4.6×250 mm, 5 µm particle size. 
A 1 mg/mL solution of N,N,O,F-BODIPY 3.23 (in toluene) was prepared. Runs were performed at a flow 
rate of 1 mL/minute using toluene as eluent and a run length of 20 minutes. The detection wavelength 
used was 604 nm. We performed 6 runs of 20 µL injections and combined the fractions from each run. 
 
Figure 5.66: A typical chromatogram of the resolution of the enantiomers of N,N,O,F-BODIPY 3.23. 
After the runs were completed, we resubmitted the collected enantiomers to the same conditions to 
assess the enantiomeric excess (ee). 




Figure 5.67: Chromatogram of enantiomer 1 (+)-3.23 resubmitted to the separation conditions to 
assess the ee. 
Figure 5.68: Chromatogram of enantiomer 2 (-)-3.23 resubmitted to the separation conditions to 
assess the ee. 
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5.4.3 Chapter 4 
5.4.3.1 N,N,O,O-BODIPY 4.1 
Resolution of the enantiomers of N,N,O,O-BODIPY X was performed on a Perkin Elmer HPLC, fitted 
with: 
• Perkin Elmer Series 200 Autosampler, 
• Perkin Elmer Series 200 Pump, 
• Perkin Elmer Peltier Oven Selector Series 200, 
• Perkin Elmer UV/Vis Detector Series 200, 
• Daicel Chiralpak® IA column, 4.6×250 mm, 5 µm particle size. 
A 1 mg/mL solution of N,N,O,C-BODIPY 4.1 (in toluene) was prepared. Runs were performed at a flow 
rate of 1 mL/minute using toluene as eluent and a run length of 20 minutes. The detection wavelength 
used was 360 nm. We performed 8 runs of 20 µL injections and combined the fractions from each run. 
 
Figure 5.69: A typical chromatogram of the resolution of the enantiomers of N,N,O,O-BODIPY 4.1. 
After the runs were completed, we resubmitted the collected enantiomers to the same conditions to 
assess the enantiomeric excess (ee). 




Figure 5.70: Chromatogram of enantiomer 1 (-)-4.1 resubmitted to the separation conditions to 
assess the ee. 
Figure 5.71: Chromatogram of enantiomer 2 (-)-4.1 resubmitted to the separation conditions to 
assess the ee. 
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5.5 X-Ray Crystallography Data. 
Crystal structure data for mjh150036, mjh150037 and mjh180018 were collected on a Xcalibur, Atlas, 
Gemini ultra diffractometer equipped with a sealed X-ray tube (λ CuKα = 1.54184 Å) and an Oxford 
Cryosystems CryostreamPlus open-flow N2 cooling device. Analysis and structural elucidation of 
compounds 2.10, 2.18 and 2.33 were performed by Dr Paul Waddell. 
5.5.1 Methyl (Z)-4-((5-bromo-1H-pyrrol-2-yl)(5-bromo-2H-pyrrol-2-ylidene)methyl)benzoate 
(2.10) 
 
Identification code mjh150036 
Empirical formula C17H12Br2N2O2 
Formula weight 436.11 
Temperature/K 150.0(2) 
Crystal system monoclinic 












Crystal size/mm3 0.4 × 0.22 × 0.18 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 7.854 to 133.902 
Index ranges -13≤h≤13, -14≤k≤15, -10≤l≤13 
Reflections collected 11955 
Independent reflections 2931 [Rint=0.0378, Rsigma=0.0272] 
Data/restraints/parameters 2931/1/215 
Goodness-of-fit on F2 1.097 
Final R indexes [I>=2σ (I)] R1 = 0.0298, wR2 = 0.0740 
Final R indexes [all data] R1 = 0.0326, wR2 = 0.0762 
Largest diff. peak/hole / e Å-3 0.45/-0.65 
Table 5.3: Crystal data and structure refinement for mjh150036 




borabenzo[5,6]indeno[1,7-ef]aceanthrylen-2a1-ium-16-uide (N,N,O,C-BODIPY 2.18) 
 
Identification code mjh150037 
Empirical formula C59H39B2Cl3N4O8.3 
Formula weight 1064.71 
Temperature/K 150.0(2) 
Crystal system orthorhombic 












Crystal size/mm3 0.39 × 0.26 × 0.15 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 5.436 to 133.648 
Index ranges -13≤h≤16, -36≤k≤38, -13≤l≤12 
Reflections collected 17923 
Independent reflections 4163 [Rint=0.0286, Rsigma=0.0191] 
Data/restraints/parameters 4163/351/361 
Goodness-of-fit on F2 1.081 
Final R indexes [I>=2σ (I)] R1 = 0.0450, wR2 = 0.1309 
Final R indexes [all data] R1 = 0.0467, wR2 = 0.1334 
Largest diff. peak/hole / e Å-3 0.54/-0.61 
Flack parameter 0.002(8) 
Table 5.4: Crystal data and structure refinement for mjh150037 




ef]aceanthrylen-3-yl)benzoate (N,N,O,C-BODIPY 2.33) 
 
Identification code mjh180018 
Empirical formula C31H23BN2O4 
Formula weight 498.32 
Temperature/K 150.0(2) 
Crystal system triclinic 












Crystal size/mm3 0.42 × 0.13 × 0.03 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 9.102 to 133.844 
Index ranges -9 ≤ h ≤ 8, -9 ≤ k ≤ 9, -23 ≤ l ≤ 23 
Reflections collected 17241 
Independent reflections 4319 [Rint=0.0368, Rsigma=0.0291] 
Data/restraints/parameters 4319/0/347 
Goodness-of-fit on F2 1.025 
Final R indexes [I>=2σ (I)] R1 = 0.0365, wR2 = 0.0879 
Final R indexes [all data] R1 = 0.0477, wR2 = 0.0951 
Largest diff. peak/hole / e Å-3 0.23/-0.18 
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DFT calculations of the HOMO, HOMO(-1) and LUMO N,N,O,C-BODIPY 2.18 
To aid in the assignment of the oxidative and reductive electrochemical processes highlighted by cyclic 
voltammetry analysis, a series of DFT calculations were made with the intention of identifying the 
HOMO and LUMO of N,N,O,C-BODIPY 2.18 (performed by Owen Woodford). The LUMO was found to 
be distributed over the dipyrrin core of the BODIPY, with a minor contribution from the meso-aryl ring 
(figure AP.1). Typically, when the LUMO is distributed mostly over the dipyrrin core of a BODIPY, the 
electrochemistry is reversible. Therefore we can assign the reduction wave at -1.17 V as the addition 
of a single electron to the dipyrrin unit. 
 
Figure AP.1: Kohn-Sham (isodensity 0.02) distribution pattern computed for the LUMO of N,N,O,C-
BODIPY 2.18. 
Calculations of the HOMO revealed that the electron density is distributed around the dipyrrin unit, 
with a sizeable contribution from the directly (ie. C-C) linked phenolic ring (figure AP.2). Neither the 
meso-aryl ring nor the other phenolic ring contribute to the HOMO. 
 
Figure AP.2: Kohn-Sham (isodensity 0.02) distribution pattern computed for the HOMO of N,N,O,C-
BODIPY 2.18. 
Contrarily, the HOMO(-1) has the electron density distributed mostly on the phenolic rings, with only 
a small contribution from the BODIPY core (figure AP.3). Similar to the electronic distribution observed 
in the HOMO, the majority of the electron density is associated with the directly linked phenol ring, 





Figure AP.3: Kohn-Sham (isodensity 0.02) distribution pattern computed for the HOMO(-1) of 
N,N,O,C-BODIPY 2.18. 
Based on this information, we can assign the first oxidation peak (0.84 V) in the cyclic voltammogram 
of N,N,O,C-BODIPY 2.18 to the preferential removal of an electron from the dipyrrin unit. There is 
some involvement of the directly-linked phenol ring, and this might be responsible for the poor 
reversibility of this oxidation. As is commonly observed in BODIPY dyes, we can conclude that the 
optical absorption transition is primarily a HOMO-LUMO transition localised on the BODIPY core. The 
second oxidation process can be assigned to the removal of an electron from the boron-chelated 
phenol rings. On this basis, we should expect to find a charge-transfer state located slightly above the 





Structural Assignment of N,N,O,C-BODIPY 2.35 
All NMR data was collected on a sample of N,N,O,C-BODIPY 2.35 in deuterated chloroform on a Bruker 
Avance III HD 700 MHz spectrometer by Professor William McFarlane. 
 




Multiplicity J (Hz) 
1 52.6 3.99 3 s - - 
2 166.4 - - - - 3.99 (1), 8.19 (4), 7.74 
(5) 
3 132.0 - - - - 3.99 (1), 8.19 (4), 7.74 
(5). 
4 130.0 8.19 2 d 8.6 7.74 (5) 
5 130.5 7.74 2 br s - 8.19 (4) 
6 137.8 - - - - 8.19 (4), 7.74 (5), 7.03 
(9) 
7 137.5 - - - - 7.74 (5), 7.03 (9) 
8 127.6 - - - - 7.03 (9), 108.5 (10) 
9 132.3 7.03 1 d 4.6 108.5 (10) 
10 108.5 6.44 1 d 4.6 7.03 (9) 
11 163.6 - - - - 7.03 (9), 108.5 (10) 
12 152.5 - - - - 7.28 (13), 6.89 (14), 
6.79 (16) 
13 118.5 7.28 1 dd 8.6, 4.0 6.89 (14), 6.79 (16) 
14 114.4 6.89 1 app. td 8.6, 3.1 7.28 (13), 6.79 (16) 
15 159.3 - - - - 7.28 (13), 6.89 (14), 
6.79 (16) 
16 115.2 6.79 1 dd 8.0, 3.1 7.28 (13), 6.89 (14) 
17 - - - - - - 
18 121.4 - - - - 7.00 (19) 




20 115.7 6.84 1 d 4.2 7.00 (19) 
21 132.3 - - - - 7.00 (19), 8.84 (20) 
22 146.8 - - - - 7.00 (19), 8.84 (20), 
7.42 (23), 6.72 (26) 
23 110.8 7.42 1 dd 8.5, 3.1 6.92 (25), 6.72 (26) 
24 156.8 - - - - 7.42 (23), 6.92 (25), 
6.72 (26) 
25 119.0 6.92 1 app. td 8.5, 3.9 7.42 (23), 6.72 (26) 
26 121.2 6.72 1 dd 9.0, 3.9 7.42 (23), 6.92 (25), 
27 150.3 - - - - 7.42 (23), 6.92 (25), 
6.72 (26) 
Atom δF 
28 -123.1 
29 -117.0 
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